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Early-stage drug discovery and chemical biology projects often use fluorescence-
based assays to obtain information about biological interactions and cellular processes. 
However, many of the best and brightest fluorophores suffer from major limitations such 
as very high cost and/or restrictive chemical properties that hinder their utility for studies 
of living biological systems. To create improved fluorescent molecular probes of 
receptor-ligand interactions and dynamic cellular processes, a major focus of this 
dissertation is on the bright coumarin-derived fluorophore Pacific Blue. Although Pacific 
Blue is commercially available, its high cost has restricted its utility as a building block 
for preparation of small molecule-derived and peptide-derived molecular probes. To 
overcome this limitation, we developed a new synthetic route that readily allows access 
to gram quantities of this fluorophore. This synthetic route is superior to previously 
published routes, and it can facilitate access to a wide variety of fluorescent ligands of 
receptors, biosensors, and related cellular probes. 
Quantification of receptor-ligand interactions is important for screening of both on-
target and off-target affinities of chemical probes and drug candidates. These assays 
must be cost-effective, efficient, and high-throughput to keep up with fast-paced needs 
of drug discovery projects. Toward this end, we characterized a new FRET pair, 
comprising the endogenous fluorescent amino acid tryptophan and Pacific Blue. We 
demonstrate that these fluorophores allow quantification of interactions between small 
molecules and tryptophan-containing proteins in vitro. We also synthesized and 
evaluated Pacific Blue derivatives of paclitaxel (Taxol) as tools to label microtubules, 
detect cellular efflux by P-glycoprotein (P-gp), and potentially explore some of the 
	 iv 
paradoxical clinical responses associated with the parent anticancer drug. We also 
characterized two other new FRET pairs, Pacific Blue-Pennsylvania Green and Pacific 
Blue-Oregon Green, and investigated the stability of disulfide linkers both in vitro and in 
living cells as models of drug delivery systems. Finally, using an alternative detection 
platform of fluorescence polarization, we describe the development of methods for the 
characterization of inhibitors of a protein-protein interaction involved in iron homeostasis 
in the pathogenic bacterium Pseudomonas aeruginosa. This research extends the utility 
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Fluorophores in Chemical Biology and Drug Discovery 
 
Unmet medical needs are often addressed by initiation of a drug discovery program. 
This program is generally designed to target a specific protein, pathway, or phenotype 
thought to be important for the etiology of a particular disease. This process is often 
very challenging and costly and can require 12–15 years from initiation to approval and 
cost over $1 billion.1 An integral part of this process can involve chemical biology, where 
small molecule probes are used to screen for new ‘hits’ using high throughput platforms, 
validate targets, and investigate potential off-target effects. Chemical biology, a field at 
the interface between chemistry and biology, focuses on the use of small molecules to 
study biology. This field utilizes interdisciplinary methods that draw from diverse areas 
including chemical synthesis, analytical chemistry, medicinal chemistry, and drug 
discovery. The use of small molecule probes in biochemical (in vitro) and cellular 
assays is often critical in the understanding of biological processes and quantification of 
biomolecular interactions that form the basis of unmet clinical needs.  
 
1.1. Fluorescence in biology and medicine 
Fluorescent biosensors are widely used to study molecular interactions in biology 
and medicine. These types of chemical probes have been vital for understanding 
complex biological processes in cells, tissues, and animals. Fluorescence has been 
particularly important in the development of live cell imaging and high throughput 
screening in drug discovery. Molecules that fluoresce are called fluorophores. In biology, 
	 2 
fluorophores are typically designed to localize in a particular region of a biological 
specimen (e.g. through interactions with a specific protein target) or respond to a 
stimulus (e.g. activation of enzymatic substrates). 2-4 
Fluorescence, a photophysical process first described in 1852,5 involves three 
stages: excitation, excited-state lifetime, and fluorescence emission (depicted in Figure 
1.1). The fluorophore first absorbs photons from an external source such as an 
incandescent lamp or laser.6 Following excitation, the molecule undergoes 
conformational changes and interacts readily with its environment until it relaxes to the 
singlet excited state (S1). A photon of energy is then emitted to return the fluorophore to 
its ground state through the release of energy. Not all molecules are returned to the 
ground state through fluorescence emission, as other processes such as Förster 
resonance energy transfer (FRET, discussed in Section 1.3.2) and collisional quenching 
can occur.7 Fluorophores have several specific properties, including defined 
absorbance, excitation, and emission spectra, extinction coefficient (ε), quantum yield 
(Φ), and fluorescence lifetime (τ). Examples of these properties are listed in Table 1.1 




Figure 1.1. Jablonski diagram illustrating the three-stage process of fluorescence, as 
well as the FRET process of energy transfer (described in Section 1.3.2). 
 
Table 1.1. Representative spectroscopic properties of fluorescent dyes as illustrated for 
fluorescein in 0.1 M NaOH. 
 
Property Description Value for fluorescein8, 9 
Absorbance spectra A plot of wavelength versus 
absorbance 
 




A plot of wavelength versus the 
number of photons excited for a 
given emission wavelength 
 











A plot of emission wavelength versus  
emitted photons 
 
λmax = 510 nm 






The average time between excitation 




1.2. Common fluorophores 
Small molecule fluorophores typically consist of polyaromatic hydrocarbons or 
heterocycles. Extended conjugation shifts the absorption and fluorescence emission 
spectra to longer wavelengths. Other types of fluorophores, including quantum dots10 
and fluorescent polymers11 and proteins12 are well known but will not be described in 
detail here.  Changes to the environment surrounding the fluorophore (i.e. solvents, the 
presence of quenchers, and pH) can have a large effect on spectroscopic properties. 
Some general classes of fluorophores, categorized by excitation wavelength, are 
described below.  
 
1.2.1. Fluorophores excited by UV light  
 Two of the most abundant fluorescent molecules commonly observed in nature 
are the natural amino acids tryptophan and tyrosine (Figure 1.2). Because these 
fluorophores absorb photons at ~280 nm,13 they have limited use in live cell imaging, as 
toxicity and autofluorescence arise when cells and tissue are exposed to the high 
energy UV radiation needed to excite these residues. Nonetheless, these fluorophores 
are useful for in vitro applications including studies of protein folding and dynamics, and 
small molecule-protein and peptide-protein interactions.14-18 Longer wavelength 
fluorophores excited by UV light include the coumarins and pyrenes. Coumarins are 
abundant in nature,19 and substitution at the 7-position gives rise to highly fluorescent 
molecules. These fluorophores are attractive, as they are smaller in size and often are 
spectrally orthogonal to other popular fluorophores with longer wavelength absorption 
and emission properties. Fluorophores such as the pyrene derivative Alexa Fluor 4052 
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and the coumarin derivative Pacific Blue20 (Figure 1.2) are valued since they are well 
matched to the 405 nm spectra line of violet diode lasers found on flow cytometry and 
fluorescence microscopy instrumentation. 
 
Figure 1.2. Fluorophores excited with ultraviolet light. 
 
 1.2.2. Fluorescein and its derivatives 
 Fluorophores that can be excited by blue and green light are generally more 
commonly used for chemical biology applications. This class of molecules includes 
fluoresceins, BODIPY, and rhodamines (Figure 1.3). Following its original synthesis in 
1871,21 fluorescein has now become the most widely used fluorophore in science due to 
its high absorptivity, quantum yield, and water solubility. Countless fluorescein 
derivatives have been made to date.22-29 Some derivatives, including Oregon Green23 
and Pennsylvania Green22 (Figure 1.3), have incorporated fluorine atoms on the 
xanthene core to increase photostability by reducing reactivity with photogenerated 
singlet oxygen.30 In addition, the fluorine groups decrease the pKa of the phenol of 
compounds such as Oregon Green and Pennsylvania Green to ~4.8, thus reducing the 
strong sensitivity of fluorescein to changes in pH in biological systems. Fluorescein and 
its derivatives have traditionally been attractive because their absorption and 
fluorescence emission properties closely match the 488 nm spectral line of the common 
























analogues of fluorescein. The rhodamine scaffold was first described in 1887,31 and this 
class of molecules is generally red-shifted in comparison to fluorescein, absorbing 
green light and emitting yellow light.32 These fluorophores are typically pH insensitive 
and possess high photostability. Numerous derivatives have been developed for use as 
fluorescent labels for diverse applications including dyes for imaging of biological 
processes of the nematode worm C. elegans33, 34 and mice.35, 36 
 
 
Figure 1.3. Fluorophores excited with blue and green light. 
 
1.3. Methods for quantifying receptor-ligand interactions 
Receptor-ligand interactions play a fundamental role in countless biological 
processes. Discovering and quantifying these interactions is vital for studying cellular 
pathways and finding new molecules of medical importance. In the early stages of drug 
discovery, compounds of interest are identified based on many factors, often starting 
with affinity for a biological target. Labeled compounds that show high affinity and 
specificity for a target can be used in high throughput screens to identify other 























example in competition binding assays, to quantify and categorize other compounds on 
the path to finding a clinical drug candidate. Approaches for quantifying these 
interactions can be categorized into fluorescence-based and non-fluorescence based 
methods. Fluorescence-based methods include fluorescence polarization (FP),37 
Förster resonance energy transfer (FRET),38 and fluorescence intensity,39 while non-
fluorescence based techniques include isothermal titration calorimetry (ITC),40 surface 
plasmon resonance (SPR),41 ligand-observed NMR,42 differential scanning fluorimetry 
(DSF),43 protein X-ray crystallography,44 UV/Vis spectroscopy,45 equilibrium dialysis,46 
and radiolabeling.47 The limitations of each technique are listed in Table 1.2, while 
Sections 1.3.1-2 focus on FP and FRET application. 
 
 
Table 1.2. Summary of biophysical techniques for detecting and/or quantifying small 
molecule-protein interactions.48, 49  
 
Technique Throughput Disadvantages 
Fluorescence-based 
methods (FP, FRET, 
Fl. intensity) 
High 
• Prone to false positives  
• Typically require a competition 
assay format 
Isothermal titration 
calorimetry (ITC) Low 
• Material intensive 
• Not applicable to all systems, as 
large heat changes are required 
Surface plasmon 
resonance (SPR) Intermediate 
• Prone to false positives  
• Target or ligand must be 
immobilized 
Differential scanning 
fluorimetry (DSF) High 
• Extensive optimization necessary 
• Prone to artifacts  
Ligand-observed NMR Intermediate 
• Material intensive 
• Expensive isotope labeling may be 
required 
• Generally, limited to small proteins 
X-ray crystallography Low 
• Protein target must crystallize 
• Expensive X-ray sources required 
	 8 
UV/VIS spectroscopy Medium 
• False negatives and positives 
• Low sensitivity requires high 
concentrations 
Equilibrium dialysis Low 
• A separation step is required 
• Lengthy experiment (48 h) 
Radiolabeling Low 
• Expensive and tedious process to 
develop radioligand 
• A separation step is required 
• Radioactive waste must be 
disposed 
 
1.3.1. Fluorescence polarization 
Fluorescence polarization (FP), first used in a biological system in 1952,50, 51 has 
found wide applicability in clinical and biomedical studies. FP assays are particularly 
useful because they are homogeneous, high throughput, and can be inexpensive. FP 
assays provide information on molecular mobility, as this method measures changes in 
the rotational rate of a fluorescent ligand when the free form binds a protein target.52 
Plane-polarized light is used to excite a fluorophore, and the fluorescence intensities in 
planes both in the parallel (FII) and perpendicular (F⊥) direction to the plane of excitation 
are measured. The polarization (P) of a sample can then be determined using the 
following equation:48 
! = !!! − !!!!! + !!
 
A free ligand in solution (i.e. one not bound to the protein target) is able to rapidly 
rotate, and is therefore not aligned with the source. As depicted in Figure 1.4, following 
excitation with polarized light, this low molecular weight complex leads to depolarization 
of the emitted light, and produces a low polarization signal. However, when a ligand is 
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bound to a protein target, the ligand tumbles more slowly and this high molecular weight 
complex is not able to rotate as freely as when unbound, leading to an increase in 
polarization.53  
 
Figure 1.4. Schematic representation of fluorescence polarization of two samples: 
protein-ligand complex (top) and free ligand in solution (bottom).  
 
 Polarization is measured using a fluorometer equipped with an excitation source 
(typically a Xe or Hg arc lamp), excitation polarizer, rotatable emission polarizer, 
excitation and emission monochromators or filters, detector, and sample platform (i.e. 
cuvette or multiwell plate).52 To measure the affinity of a fluorescent ligand for a protein, 
the protein of interest is titrated into a fixed concentration of fluorescent ligand (below Kd) 
and allowed to reach equilibrium. Generally, FP is used for competition-based assays, 
where an unlabeled small molecule of interest is titrated into a sample of a fixed 
concentration of ligand:protein complex, and a loss of polarization is measured as a 
function of the concentration of the unlabeled small molecule.37  
 Polarization assays are limited by the fluorescence lifetime of the fluorescent 
ligand, interference with unlabeled ligands, autofluorescence, shifts in quantum yield, 
and molecular weight and flexibility of the fluorescent ligand.54 The fluorescence lifetime 
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of a dye can be limiting in FP assays, and it is important to choose a dye with a 
fluorescence lifetime that closely matches its rate of rotation. The fluorescence 
polarization decreases as the fluorescence lifetime increases. A fluorophore with a short 
lifetime has high polarization, even when unbound, and therefore is limited to a small 
molecule-protein mass of ~100 kDa. Conversely, fluorophores with long lifetimes can be 
depolarized even when in complex with the protein, and therefore few changes in 
polarization can be detected over the free ligand.55-57 Fluorescence enhancement or 
quenching can occur based on changes in the microenvironment of the dye (i.e. when 
free in solution versus bound) and changes in the fluorescence lifetime of the dye. The 
fluorescence enhancement or quenching must be independently evaluated for accurate 
affinity measurements by FP.56 Finally, interference from the unlabeled ligands within a 
competition assay can cause false positives and negatives within a screen. This 
interference has been studied58, 59 and should be considered when developing assays.   
 
1.3.2. Förster resonance energy transfer 
Förster resonance energy transfer (FRET) is a well-established photophysical 
phenomenon that was first described in 1948.60 Through a non-radiative process, a 
donor molecule transfers energy to a nearby acceptor chromophore or fluorophore via 
dipole-dipole interactions. The amount of energy transfer that occurs is dependent on 
three criteria: the distance between the two fluorophores, spectral overlap between the 
emission spectrum of the donor and the absorbance spectrum of the acceptor, and the 
dipole-dipole moments of the two molecules.7 This phenomenon measures interactions 
between molecules in close proximity (~1–10 nm), making this a popular technique for 
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ratiometric studies in chemical biology.61 The FRET efficiency (E) is inversely 
proportional to the sixth power of distance between the two fluorophores (Figure 1.5, 






The Förster distance (R0) is the distance at which the transfer efficiency equals 
50% and can be calculated for a FRET pair by the following equation (in Å): 
!! = 0.211 !!!!!!!!!" !/!    
where η is the refractive index of the solvent, κ is the average squared orientational part 
of a dipole-dipole interaction, ΦD is the quantum yield of the donor, and J is spectral 
overlap of the FRET pair (overlap between the donor emission and acceptor absorption, 






Figure 1.5. Energy transfer is dependent on the distance between two fluorophores and 
their spectral overlap. A: Schematic of the FRET process. B: Dependence of FRET 
efficiency on the distance between the FRET pair. The donor and acceptor are 
represented as blue and red circles. C: Graphical representation of spectral overlap of 
an ideal FRET pair. The emission spectra of donor fluorophore is depicted as blue line, 
and absorption spectra of acceptor fluorophore as a red line, and spectral overlap J(λ) 
shaded grey.  
 
 
 FRET can be classified as two categories: intrinsic and extrinsic. Intrinsic FRET 
(iFRET) involves a fluorophore that occurs in nature, such as tryptophan and tyrosine 
residues within a protein of interest. Since tryptophan is excited by UV light, this 
application is limited to in vitro studies, but has been powerful in investigating changes 
in protein conformation and studies of macromolecule-ligand interactions.62-66 Because 
the quantum yield of tryptophan is low13 in comparison to other commonly used 
fluorophores for FRET applications, it is critical that a bright acceptor fluorophore is 
used to enable efficient and sensitive assays. Some homogenous Trp-FRET assays 
have been developed for quantification of receptor-ligand interactions,67-70 but the field 
is still limited by the need to use high probe concentrations to detect these signals. 
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 For cellular studies, FRET pairs than absorb and emit in the visible range (400-
600 nm) are commonly used. These FRET pairs have larger Förster distances than UV 
fluorophores, and therefore can examine somewhat longer-range interactions.71 
Commonly used FRET pairs include the Alexa fluorophores27 (i.e. Alexa 488/Alex 594) 
and fluorescent proteins, such as green fluorescent protein (GFP)/yellow fluorescent 
protein (YFP).72-74 Generally, these are limited by high cost (Alexa Fluors), which 
hinders synthesis of complex FRET based probes, and/or large molecular size (fused 
fluorescent proteins), which can affect the interactions under investigation.  
 FRET-based ligand binding assays are generally homogenous, can be 
inexpensive (dependent on the FRET pair), high throughput, and flexible.74 In assays 
that use small molecule FRET pairs, a protein is typically labeled with the fluorophore 
via covalent modification with lysine or cysteine residues and interactions with a 
fluorescent ligand are measured. In general, these applications can be limited by 
heterogeneous and poorly defined conjugation of the fluorescent molecule to the protein 
of interest. However, recent advances in this field using SNAP-Tag technology and 
unnatural fluorescent amino acids have been described to help overcome some of 
these limitations.75-78  
 
1.4. Outline of this dissertation 
In early stage drug discovery, fluorescence-based assays often play a vital role in 
understanding biological interactions and cellular processes. My research has focused 
on the development of new fluorescent probes and assays that advance our knowledge 
of these biological events. My research has centered on the Pacific Blue fluorophore, a 
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bright coumarin derivative used in fluorescence imaging and flow cytometry applications. 
In this dissertation, Chapter 2 describes a new synthetic route to access gram quantities 
of Pacific Blue and overcome the high cost of this commercial fluorophore. The chapter 
also investigates a new FRET pair, tryptophan-Pacific Blue, and its use in quantifying 
small molecule-protein interactions, both through direct binding and competition-based 
platforms. Chapter 3 describes the synthesis and biological evaluation of fluorescent 
derivatives of paclitaxel (Taxol) that we are investigating to create new probes of cellular 
efflux by P-glycoprotein (P-gp) and explore some of the paradoxical clinical responses 
associated with the parent anticancer drug. Chapter 4 characterizes other FRET pairs, 
Pacific Blue-Pennsylvania Green and Pacific Blue-Oregon Green, and describes studies 
directed towards better understanding a targeted drug delivery system under 
development in the Peterson group. Finally, Chapter 5 reports the development of a 
fluorescence polarization assay for studies of ligands that inhibit a protein-protein 
interaction involved in iron homeostasis in pathogenic bacteria.  
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Quantification of Small Molecule-Protein Interactions by FRET Between 
Tryptophan and the Pacific Blue Fluorophore 
 
2.1. Introduction 
To quantify the affinity of small molecules for proteins, a wide variety of 
biophysical techniques have been developed. Homogeneous methods include 
isothermal titration calorimetry (ITC),1, 2 fluorescence polarization (FP),3 and Förster 
resonance energy transfer (FRET).4 Although these techniques are powerful, each 
has limitations. ITC, considered the gold standard for affinity determination, is 
material intensive, low throughput, and requires an appreciable change in heat upon 
binding. In widely employed FP (or related fluorescence anisotropy),3, 5 small 
molecules linked to fluorophores report changes in the polarization of emitted 
photons when a rapidly rotating small molecule binds a slowly tumbling protein. 
However, probe size, solvent viscosity, fluorescence quenching, and linker flexibility 
can limit applicability.3  
FRET has the potential to overcome some of these limitations. This method 
involves non-radiative transfer of excitation (Ex.) energy from a donor fluorophore to 
a proximal acceptor fluorophore.4 This transfer is highly distance dependent, with an 
efficiency of 50% at the Förster distance (R0, typically < ~ 5 nm). FRET-based 
binding assays generally involve one fluorophore attached to a receptor of interest 
and another fluorophore conjugated to a ligand. However, this requirement for two 
exogenous fluorophores poses challenges, given that conjugation of fluorophores to 
proteins can result in heterogeneity, or require site-directed labeling reactions. 
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As an alternative method for detection of small molecule-protein interactions, 
FRET initiated by excitation of intrinsically fluorescent tryptophan (Trp, 1, Figure 1) 
residues is of increasing interest.6-8 Beneficially, these residues are commonly found 
in or near protein ligand binding sites, and at interfaces between proteins and other 
biomolecules.9, 10 Although maximally excited at 280 nm, Trp can be selectively 
excited over Tyr at 295 nm. Fluorescent photons emitted by Trp range from ~308 nm 
to ~355 nm, roughly correlated with exposure to aqueous solution,11 with modest 
quantum yield (Φ = 0.2). A previously reported11 comparison of 19 Trp residues from 
17 proteins with experimentally determined structures revealed an average Trp 
emission of 333 nm. Because the emission λmax and quantum yield of Trp are 
affected by the polarity of the local environment,12 its environmental sensitivity and 
quenching by exogenous factors has been widely used to study changes in protein 
conformation and binding of ligands.  The intrinsic emission of Trp can also 
participate in FRET with other fluorophores (termed Trp-FRET),7 and this approach 
has been extensively employed to study protein folding and dynamics.13-15 
Fluorophores known to participate in Trp-FRET include dansyl (2), 7-
hydroxycoumarin (7HC, 3), and dimethylaminocoumarin (DMACA, 4).4 Coumarins 3 
and 4 were recently reported6 by Chung to be the best Trp-FRET acceptors identified 
to date. However, environmental effects, limited brightness, small Stokes shifts, and 
low efficiency continues to hinder their sensitivity.13 A few noncompetitive and 
competitive binding assays using Trp-FRET have been reported,16-18 but generally 
require high concentrations of fluorescent probes for detection. These high 
concentrations can prevent quantitative measurements of the low dissociation 
constants (Kd) and competitive inhibition constants (Ki) that are frequently observed 
between small molecules and proteins.        
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To identify a more sensitive FRET acceptor for Trp, we examined overlap 
between the emission spectrum of this amino acid (Ex. 280 nm, Em. ~350 nm, ε = 
5,600 M-1 cm-1) and the absorbance spectrum of 6,8-difluoro-7-hydroxycoumarin, a 
fluorophore known as Pacific Blue (PB, 5).19 Because of its favorable photophysical 
properties (Ex. 400 nm, Em. 447 nm, ε = 29,500 M-1 cm-1, Φ = 0.75, pKa = 3.7), PB 
is of substantial interest for labeling of proteins and other biomolecules.20, 21 As 
shown in Figure 2.2, the large overlap between the emission of Trp and the 
absorption of PB suggested that this fluorophore might be a particularly sensitive 
FRET partner.  
 





Figure 2.2. Absorbance (Abs., solid lines) and emission (Em., dotted lines) spectra 
of Trp (1, black lines, 32 µM for Abs and 2 µM for Em.) and PB (5, blue lines, 32 µM 
for Abs and 50 nM for Em.) in PBS (pH 7.4). The spectral overlap integral (J(λ)) 
critical for FRET is shaded grey. 
 





























2.2. A Practical synthesis of the Pacific Blue fluorophore 
Pacific Blue (5, 6,8-difluoro-7-hydroxycoumarin 3-carboxylic acid) is a 
coumarin-based fluorophore that is becoming increasingly popular for chemical 
biology applications. These applications include labeling of antibodies for research 
and diagnostics,22 labeling of specific proteins inside living cells,20 and tagging of 
peptides for analysis by mass spectrometry.23 This derivative of umbelliferone is of 
particular interest due to its low phenol pKa of 3.7, resulting from difluorination.19 
This high acidity enables bright fluorescence in all compartments of cells, including 
acidic organelles such as endosomes and lysosomes, providing substantial 
advantages over other more pH-sensitive dyes. In addition, the high photostability 
and high quantum yield of Pacific Blue make this molecule useful for fluorescence 
microscopy, flow cytometry, and other applications. 
We found that the existing 7-step synthesis (Scheme 2.1) of Pacific Blue 
substantially limits access to this compound. The previously reported routes based 
on costly 2,4-difluororesorcinol (10, $24 / g, Matrix Scientific, PB 5 can be prepared 
in two steps with 41% yield19) or 2,3,4,5-tetrafluoronitrobenzene (6, $1.80 / g, 
Oakwood Chemicals, PB 5 can be prepared from this material in seven steps with 
29% yield24) are expensive and inefficient. In addition, the published24, 25 syntheses 
include difficult purifications, low yielding steps, and unstable intermediates. These 
issues prevented access to the gram quantities of Pacific Blue fluorophore desired 
for diverse studies of chemical biology by our group. To improve access to the 
fluorophore, we developed a new 5-step synthesis that achieves an overall yield of 
50%. Moreover, our new synthetic route utilizes inexpensive starting materials and 
reagents and avoids extensive column chromatography, greatly improving access to 
this valuable fluorophore.  
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To develop an improved synthesis of Pacific Blue (5, PB), we chose to start 
with the inexpensive fluorinated building block 2,3,4,5-tetrafluorobenzoic acid (16, 
Scheme 2.2, $0.4 / g, Oakwood Chemicals). This compound was converted into 
tetrafluorobenzonitrile 17 by reaction with oxalyl chloride, ammonium hydroxide, and 
catalytic DMF followed by dehydration with phosphoryl chloride. This approach 
produced the desired product with no column purification necessary (this product can 
also be purchased for $3 / g from Oakwood Chemicals). This tetrafluorobenzonitrile 
was transformed to nitrile 18 by nucleophilic aromatic substitution with two 
equivalents of benzyl alcohol. During optimization of this step, three bases: sodium 
hydride (NaH), potassium tert-butoxide (KOtBu), and potassium carbonate (K2CO3) 
were investigated for this SNAr reaction. Even at low temperatures, NaH and KOtBu 


























































































desired disubstituted product 18, in 87% yield. By using potassium carbonate, side 
reactions observed with stronger bases were suppressed, and no other products 
were isolated by column chromatography.  Reduction of 18 with DIBAL-H, followed 
by precipitation from ethanol, provided the tetrasubstituted benzaldehyde 19. 
Deprotection by hydrogenolysis of 19 yielded the difluororesorcinol aldehyde 11, a 
common intermediate also reported in the previously published syntheses of Pacific 
Blue. We found that relatively inexpensive 2,3,4,5-tetrafluorobenzoic acid (16, $0.4 / 
g, Oakwood Chemicals) can be converted to the common intermediate aldehyde 
1119, 24 in 66% overall yield in a four-pot process. Optimization of the final 
Knoevenagel condensation, utilizing meldum’s acid, resulted in 5, which was then 
efficiently converted to the amine-reactive Pacific Blue-NHS ester 15 using an 
improved route. Based on reagent costs alone, this new synthesis is approximately 
ten times less expensive than the previously published synthesis (Table 2.1) and 
requires three fewer synthetic steps.24 
 




































































Table 2.1: Comparison of the cost of reagents needed to make one gram of Pacific 
Blue-NHS ester (15). Costs were estimated based on yields published for each 
synthetic step and the least expensive reagents available for purchase from Sigma 





Lee and Peterson 
 (This work, starting 
with 16) 
Lee and Peterson 
(This work, using a 
commerical source 
of 17) 
Number of steps 9 6 5 
Starting Material 6 16 17 
Cost of reagents 
needed to make 
15 (1 g) 
$58.74 $5.65 $12.06 
 
2.3. Comparison of Trp-FRET acceptors  
To investigate the potential of Pacific Blue as a FRET acceptor for tryptophan 
residues in proteins, we investigated binding of the bacterial protein streptavidin (SA) 
to biotin and analogues. This tetrameric protein binds biotin with exceptionally high 
affinity (Kd = 10-14 M-1),26 and X-ray crystallography27 has revealed six Trp residues in 
close proximity to each of its four biotin-binding sites. Additionally, Trp79, Trp108, 
and Trp120 are critical for binding of SA to biotin via van der Waals and hydrophobic 
interactions.27, 28 Moreover, these Trp residues can initiate FRET with biotinylated 
fluorophores.16, 29, 30 Correspondingly, docking31 of this X-ray structure (Figure 2.3) to 
PB-biotin derivative 20 (Figure 2.4, panel B) supported the notion that binding of SA 
would favorably position the fluorophore in close proximity to endogenous Trp 
residues from the monomer that makes the majority of non-covalent contacts, as well 




Figure 2.3. A model of streptavidin (PDB 3RY2) docked to the PB-Biotin derivative 
20 (CPK model) with autodock vina. In each monomer, residues Trp79, Trp108, and 
Trp120 are shown as CPK models. The distance between the most proximal Trp120 
(marked) and the Pacific Blue moiety of 20 is ~ 11 Å. For clarity, only one bound 
ligand is shown.  
 
 
Figure 2.4. A: Normalized absorbance (Abs., solid lines) and fluorescence (Fluor.) 
emission (Em., dotted lines) spectra of 20-23 (32 µM for Abs., 50 nM for Fluor.) in 
PBS. 20-23 were excited at their λmax (405 nm (20), 330 nm (21), 375 nm (22), and 







Figure 2.5. Analysis of FRET upon binding of 20-23 (100 nM) to SA ([monomer] = 
400 nM). Ex. of SA (295 nm) results in maximal Em. at 340 nm. After binding of 20-
23, FRET Em. was observed at 457 nm (20), 532 nm (21), 467 nm (22), and 475 nm 
(23). Addition of biotin (10 µM) blocked FRET from 20. 
 
To compare PB (5) with known Trp-FRET acceptors (2–4), we synthesized 
biotin derivatives 20–23 (Figure 2.4, panel B). Comparison of normalized 
absorbance and emission spectra of these compounds (Figure 2.4, panel A) 
revealed that the PB-derived probe 20 was ~3-fold brighter than 22, ~17-fold brighter 
than 23, and > 100-fold brighter than 21 in aqueous phosphate buffered saline (PBS, 
pH 7.4).  
FRET can be measured as the relative fluorescence intensity of the donor in 
the absence (Id) and presence (Ida) of the acceptor.4 When probes 20-23 were added 
to SA, excitation of Trp revealed substantial differences in emission due to FRET 
(Figure 2.5). As listed in Table 2.2, values from these studies were used to analyze 
the sensitivity (Iad), efficiency (E), and other properties of these fluorophore pairs. 
Compared with PB (20), dansyl (21) was 33-fold less sensitive, 7HC (22) was 1.5-
fold less sensitive, and DMACA (23) was 6-fold less sensitive. Additionally, the blue-
shifted absorbance of 7HC (22) increased its excitation at 295 nm, reducing its FRET 
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fold effect by a factor of four. The specificity of the FRET signal of 20 upon binding to 
SA was confirmed by addition of biotin as a competitor (Figure 2.5). Consequently, 
PB proved to be the most efficient and sensitive FRET acceptor for Trp. 
 
Table 2.2. Photophysical properties of fluorescent probes. The intensity (Iad) of FRET 
acceptors (100 nM) was measured at Em. λmax when bound to SA (400 nM, Ex. 295 
nm)  and normalized to Id. The efficiency (E) of FRET with Trp when bound to SA 
was calculated as E = 1 – Ida/Id. The FRET fold effect (FF) was calculated as FF = 
Iad/Ia. R0 is the theoretical Förster distance calculated for each Trp-acceptor pair.  Ida 
= intensity of Em. of Trp (340 nm) in the presence of the acceptor. Id = intensity of 
Em. of Trp (340 nm) in the absence of acceptor. Iad and Ia  = intensity of Em. of the 
acceptor (457 nm (20), 532 nm (21), 467 nm (22), and 475 nm (23))  in the presence 
and absence of the donor (SA), respectively. 















21 0.1 0.13 6.8 2.1 0.068 3,500 
22 2.2 0.21 4.8 2.7 0.476 7,800 
23 0.6 0.35 8.0 2.8 0.066 11,600 
 
2.4. Ligand binding assay using Pacific Blue labeled biotin analogues 
Biotin binds SA with such high affinity that its association is essentially 
irreversible. To investigate fluorescent analogues with lower affinity that might be 
suitable for equilibrium binding measurements, we synthesized probes 24–26 
(Figure 2.6, panel A).32, 33 To generate equilibrium binding curves, SA was titrated 
into a low fixed concentration of the fluorescent probe (below the Kd), followed by 
excitation of Trp at 295 nm to trigger FRET (measured at 460 nm). Curve fitting was 
used to calculate direct binding Kd values of 11 ± 2 nM for thiobiotin-PB derivative 25, 
145 ± 19 nM for imidazolidinethione-PB 26, and 2,730 ± 340 nM for iminobiotin-PB 
24 in PBS (Figure 2.6). These values were in excellent agreement with independent 
assessments of Kd by ITC under the same conditions (12 ± 4 nM for 25 and 125 ± 45 
nM for 26, Figure 2.7). For these high affinity probes, attempts to measure affinities 
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by FP were unsuccessful due to fluorescence quenching, which dramatically affects 
the lifetime of the fluorophore.3 However, using higher concentrations of the lower 
affinity probe 24, FP yielded a comparable Kd value of 2,950 ± 270 nM, (Figure 2.8).  
 
Figure 2.6. A: Structures of analogues of biotin (24–26) used in direct binding 
assays. B: Quantification of the affinity (Kd) of SA for probes 24 (25 nM), 25 (5 nM), 
and 26 (25 nM) in PBS (pH 7.4) by Trp-FRET. Trp residues were excited at 295 nM 
and FRET was measured at 460 nm. Values were corrected to account for 
fluorescence quenching or enhancement upon binding. [SA] was based on 
monomeric protein. Dissociation constants (Kd) were calculated using a one-site 





Figure 2.7. A and B: Quantification of binding of 25 (A) and 26 (B) to SA in PBS (pH 
7.4) by ITC. Thermodynamic parameters and Kd were calculated with Origin 
software.  For 25: [SA in sample cell] = 4 µM, [25 in syringe] = 50 µM. For 26: [SA in 




Figure 2.8. Quantification of binding of 24 (25 nM) to SA in PBS (pH 7.4) by FP 
compared with Trp FRET. For Trp FRET, Trp residues were excited at 295 nm and 
FRET was measured at 460 nm. For FP, Pacific Blue was excited at 400 nm and 
polarization was measured at 460 nm. Values were corrected to account for 
fluorescence quenching or enhancement upon binding. [SA] was based on 
monomeric protein. Dissociation constants (Kd) were calculated using a one-site 




2.5. Competition-based assays with analogues of biotin 
We hypothesized that the high sensitivity of Trp-FRET with PB might be 
particularly valuable for quantifying small molecule-protein interactions in a 
competition assay format. To test this hypothesis, we quantified competitive inhibition 
constants (Ki) of the unlabeled biotin analogues 27–30 (Figure 2.9, panel A) using 
the PB-imidazolidinethione 26 as a fluorescent probe. The unlabeled ligands 27–30 
were added to SA (held at a concentration near the Kd) bound to 26 (held below Kd, 
25 nM). After incubation to achieve equilibrium, excitation of Trp at 295 nm was used 
to trigger FRET (measured at 460 nm). This approach allowed calculation of Ki 
values of 188 ± 25 nM for the benzyl ester imidazolidinethione derivative 30, 693 ± 
91 nM for the methyl ester imidazolidinethione 29, 1,350 ± 180 nM for 
imidazolidinethione 28, and 44,600 ± 5,800 nM for iminobiotin 27 in PBS (Figure 2.9, 
panel C) by non-linear curve fitting. Moreover, the affinity of the imidazolidinethione 
analogue 28 measured by ITC (Kd = 1,550 ± 270 nM) was in excellent agreement 
with the Ki quantified by Trp-FRET. Additionally, other previously published studies34, 




Figure 2.9. A: Structures of non-fluorescent analogues of biotin (27–30) used in 
competition binding assays. B: Quantification of competitive inhibitory constants (Ki) 
of 27–30 for SA complexed with 26 (175 nM for SA, 25 nM for 26) by Trp-FRET. Trp 
residues were excited at 295 nM and FRET was measured at 460 nm. Values were 
corrected to account for fluorescence quenching upon binding. [SA] was based on 
monomeric protein. Half maximal inhibitory concentrations (IC50) were calculated 
using a log(inhibitor) vs. response model in GraphPad Prism, and IC50 values were 
converted to Ki values. C: Evaluation of direct binding of 28 to SA by ITC. 28 was 
titrated into [SA] in PBS (pH 7.4) and thermodynamic parameters and Kd values were 







2.6. Comparison with fluoresence enhancement or quenching-based assays 
When PB-linked ligands bind to SA, their fluorescence is partially quenched 
(24, 25) or enhanced (26).  Hence, simple changes in fluorescence could potentially 
allow determination of their affinities for this protein. To examine the merits of this 
approach, we quantified the Kd of 24–25 for SA using only fluorescence quenching or 
enhancement, and we examined changes in fluorescence upon addition of the non-
fluorescent competitor 28 to SA-26. As shown in Figure 2.10, we found that simple 
fluorescence quenching or enhancement could be used to estimate the affinity of 
24–26 for SA, but Kd values obtained by this method differed by 2-fold (26) to 6-fold 
(25) from gold-standard measurements by ITC. Moreover, examination of 
competitive binding of 28 to SA-26 revealed substantial deviation from the binding 
model at high concentrations (Figure 2.10, panel D), which prevented accurate 
determination of Ki. This lower accuracy and precision associated with the sole use 
of fluorescence intensity presumably arises from its high sensitivity to aggregation of 
fluorophores and other environmental factors. In contrast, the dependence of FRET 
on the distance between fluorophores presumably reduces its susceptibility to these 
confounding factors. Based on these results, we conclude that Trp-FRET with PB is 
superior to fluorescence intensity measurements for quantifying equilibrium binding 




Figure 2.10. Analysis of interactions with SA by quenching or enhancement of 
fluorescence. PB was excited at 400 nm, and intensity of fluorescence emission at 
460 nm was measured.  A–C: Quantification of Kd values for direct binding. D: 
Fluorescence resulting from competition of 28 for SA bound to probe 26 (25 nM). In 
D, due to poor fit to the binding model, the Ki value was not calculated.  
 
 
2.7. Examination of Trp-FRET upon binding of a peptide to an antibody  
After characterizing Trp-FRET between small molecules and streptavidin, we 
sought to further examine the utility of this approach for quantifying peptide-protein 
interactions. In this case, we evaluated interactions between a monoclonal anti c-
Myc antibody 9E1036 and c-Myc tag peptide.37 The c-Myc tag peptide has been 
reported to interact with the Fab fragment of the antibody with Kd value of 250 nM to 
700 nM as measured by ITC.38 Important for this approach, X-ray crystallography of 
the Fab fragment of anti c-Myc antibody 9E10 bound to the c-Myc tag peptide38 
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revealed three Trp residues in close proximity to the bound peptide. We 
hypothesized that by attaching PB to the N-terminus of the peptide, the fluorophore 
would be favorably positioned in close proximity to endogenous Trp residues and 
enable FRET.  
 
Figure 2.11. A model of Fab fragment of Anti c-Myc (clone 9E10, PDB 2OR938) 
bound to the c-Myc tag peptide (EQKLISEEDLN, CPK model). Tryptophan residues 
of the Fab are shown as CPK models.  
 
We synthesized two fluorescent derivatives (32–33, Figure 2.12) of the Myc-
peptide using solid phase peptide synthesis (SPPS). These derivatives linked PB to 
the peptide N-terminus through glycine (32) or a miniature polyethylene glycol amino 
acid (mPEG, 33). When the antibody was added to peptide 32, excitation of Trp 
residues revealed changes in emission due to FRET (Figure 2.13). Values from this 
study were used to analyze a FRET efficiency (E) of 0.35, and a FRET fold effect 
(FF) of 6.1 for this system. The specificity of binding of 32 to the anti c-Myc antibody 




Figure 2.12. Structures of free and Pacific Blue-linked c-Myc tag peptides 31–33 
(Sequence of c-Myc tag: EQLISEEDLN).  
 
 
Figure 2.13. Analysis of FRET upon binding of 32 (100 nM) to anti c-Myc IgG (500 
nM). Excitation of Trp (295 nm) results in maximal emission at 340 nm. After binding 
of 32, emission due to FRET was observed at 455 nm (32). Addition of 31 (500 µM) 
blocked FRET from 32.  
 
To generate equilibrium binding curves, the anti c-Myc antibody was titrated 
into a low fixed concentration of 32 or 33, followed by excitation of Trp at 295 nm to 



























































































































binding Kd values of 270 ± 70 nM for 32 and 670 ± 190 nM for 33 (Figure 2.14). We 
further compared this FRET approach with the more commonly used method of 
fluorescence polarization. We found that Kd values measured by FP were ~1.5 fold 
higher (400 ± 60 nM for 32 and 1,250 ± 470 nM for 33) than those measured by Trp-
FRET. These studies revealed that Kd values measured by Trp-FRET match 
literature values reported for this protein-peptide interaction. It is likely that the higher 
values measured by FP could result from problems arising with quenching upon 
binding (which effects the lifetime of the fluorophore) or the flexible linker and the 
relatively large molecular weight of the peptides under investigation. Direct binding 
by ITC should be measured to confirm this hypothesis.  
 
 
Figure 2.14. Quantification of binding of 32 and 33 (100 nM) to anti c-Myc IgG in 
PBS (pH 7.4) by Trp FRET compared with FP. For FRET, Trp residues were excited 
at 295 nm and emission was measured at 460 nm. For FP, Pacific Blue was excited 
at 400 nm and polarization was measured at 460 nm. Dissociation constants (Kd) 
were calculated using a one-site binding model in GraphPad Prism. 
 
2.8. Examination of the cell permeability of Pacific Blue derivatives 
 Since Pacific Blue is more ‘drug-like’ than other common fluorophores (e.g. as 
compared to the much more polar fluorescein), and fluorescein and its derivatives 
are generally cell-impermeable, we sought to investigate the cell permeability of 
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conjugates of this fluorophore. For these studies, as shown in Figure 2.4 (panel A) 
we synthesized PB-Hexyl-Biotin (34, Figure 2.15, panel C), as a more hydrophobic 
(cLogDpH 7.4= -0.39 as calculated with ChemAxon MarvinView using the software 
default pKa of the PB phenol of 5.89) derivative of 20 (cLogDpH 7.4= -1.68 as 
calculated with ChemAxon MarvinView using the software default pKa of the PB 
phenol of 5.89). To assess cellular permeability, we transiently tranfected HeLa cells 
with pPA2-T7SA-WT-GTP-mRFP, a mammalian expression vector that expresses 
streptavidin fused at its C-terminus to a monomeric red fluorescent protein. If the 
small molecule is cell-permeable and binds to streptavidin, the biotin conjugate 
would be trapped inside the cell and visible by confocal laser scanning microscopy of 
living cells. We found that compound 34 (Figure 2.15, panel B) penetrates through 
the cell membrane, whereas 20 (Figure 2.15, panel A) did not enter cells. Based on a 
measured LogDpH 7.4 (20) = –1.4 ± 0.02 and LogDpH 7.4 (34) = –0.38 ± 0.08, we 
conclude that the 10-fold (measured) to 20-fold (calculated) greater hydrophobicity 
(differences in cLogD of 1 to 1.3) enables cellular permeability of this Pacific Blue 
derivative, and these results help establish thresholds of hydrophobicity that should 




Figure 2.15. Confocal and DIC micrographs of HeLa cells treated with PB-biotin 20 
(ethylenediamine linker, Figure 2.6) and PB-Hexyl-Biotin 34 (hexamethylenediamine 
linker). A: HeLa cells transiently transfected with pPA2-TS7A-WT-GTP-mRFP (false 
colored red) for 48 h and then treated with 20 (2 µM, false colored blue) for 30 min. 
B: HeLa cells transiently transfected with pPA2-TS7A-WT-GTP-mRFP (false colored 
red) for 48 h and then treated with 34 (2 µM, false colored blue) for 30 min. C: 
Structure of PB-Hexyl-Biotin, 34. 
 
 2.9. Conclusions 
In conclusion, we developed a new synthetic route that allows access to multi-
gram quantities of the Pacific Blue fluorophore. The previously published synthetic 
route posed several challenges including difficult purification of intermediates, low 
yields, unstable intermediates, and expensive reagents. Our new synthesis reduces 
both the issues listed, as well as the need for column purification. The new synthesis 
lowers the amount of steps by two and increases the overall yield to 50%. 




With large quantities of PB on hand, we prepared fluorescent molecular 
probes that bind the Trp-containing protein SA. Comparison with other SA-binding 
fluorescent probes revealed that PB is a highly sensitive and efficient FRET acceptor 
for Trp. This high sensitivity enabled quantification of Kd and competitive Ki values 
into the nM range. Moreover, these values were independently validated by ITC and 
FP methods, establishing the high accuracy and precision of this method. We further 
applied the Trp-FRET assay to a peptide-protein system to quantify binding affinities 
of this more complex system and established parameters for the design of cell-
permeable derivatives of PB. FRET between Trp and PB offers a new method for 
quantification of small molecule-protein interactions. 
 
2.10. Experimental 
2.10.1. General experimental section 
Chemicals were purchased from Sigma Aldrich, Acros Organics, Alfa Aesar, 
Oakwood Chemical, or Chem-Impex International. Streptavidin (SA) was purchased 
from Alfa Aesar. Monoclonal Anti c-Myc antibody, clone 9E10 (M4439, produced in 
mouse) was purchased from Sigma Aldrich. 1H NMR, 13C NMR and 19F NMR spectra 
were acquired on Bruker DRX-400 or Avance AVIII 500 MHz instruments. For 1H 
and 13C, chemical shifts (δ) are reported in ppm referenced to CDCl3 (7.26 ppm for 
1H and 77.2 ppm for 13C), CD3OD (3.31 ppm for 1H, 49.0 ppm for 13C), or DMSO-d6 
(2.50 ppm for 1H, 39.5 ppm for 13C). For 19F, chemical shifts (δ) are reported in ppm 
referenced to trifluoroethanol (-77.0 ppm for 19F). 1H coupling constants (JHH, Hz), 
13C coupling constants (JCF, Hz), and 19F coupling constants (JFF, Hz) are reported 
as: chemical shift, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, dt = doublet of triplets, dd = doublet of doublets, ddd = doublet 
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of doublet of doublets, dddd = doublet of doublet of doublet of doublets, td = triplet of 
doublets), coupling constant, and integration. High resolution mass spectra were 
obtained at the Mass Spectrometry Laboratory at the University of Kansas on a 
Micromass LCT Premier. Thin layer chromatography (TLC) was performed using 
EMD aluminum-backed (0.20 mm) silica plates (60 F-254), and flash 
chromatography used ICN silica gel (200-400 mesh). TLC plates were visualized 
with a UV lamp or by staining with I2. Preparative HPLC was performed with an 
Agilent 1200 instrument equipped with a Hamilton PRP-1 reverse phase column 
(250 mm length, 21.2 mm ID, 7 µm particle size) with detection by absorbance at 
215, 254, and 370 nm. All non-aqueous reactions were carried out using flame- or 
oven-dried glassware under an atmosphere of dry argon or nitrogen. 
Tetrahydrofuran (THF), dichloromethane (CH2Cl2), N,N-dimethylformamide (DMF), 
and methanol (CH3OH), were purified via filtration through two columns of activated 
basic alumina under an atmosphere of Ar using a solvent purification system from 
Pure Process Technology (GlassContour). Other commercial reagents were used as 
received unless otherwise noted. Absorbance spectra and measurements of molar 
extinction coefficients (ε) were generated using semimicro (1.4 mL) UV quartz 
cuvettes (Sigma-Aldrich, Z27667-7) on an Agilent 8452A diode array spectrometer. 
All optical spectroscopy and protein binding assays were conducted in PBS (10 mM 
Na2HPO4, 137 mM NaCl, 2.7 mM KCl, 1.8 mM KH2PO4,	pH 7.4), unless otherwise 
noted. Molar extinction coefficients were determined in PBS containing 0.5% DMSO 
and were calculated from Beer’s Law plots of absorbance λmax versus concentration 
as shown in Figure 2.16. Linear least squares fitting of the data (including a zero 
intercept) was used to determine the slope (corresponding to ε). Values (M-1 cm-1) 
were calculated as follows: Absorbance = ε [concentration (M)] L, where L = 1 cm. 
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Absorbance data for Streptavidin concentrations were quantified by UV absorbance 
at 280 nm based on its calculated molar extinction coefficient (εmonomer = 41,326 M-1 
cm-1) using a Thermo Scientific NanoDrop 1000 spectrophotometer. All fluorescence 
spectra were acquired using a SUPRASIL ultra-micro quartz cuvette (PerkinElmer, 
B0631079) on a Perkin-Elmer LS55 Fluorescence Spectrometer (10 nm excitation 
slit width). Relative quantum yields (Φ) in PBS were determined by the method of 
Williams.39 In brief, fluorophores were excited at 396 nm and the integrated 
fluorescence emission (415 nm to 700 nm) was quantified (concentrations of 5 nM to 
160 nM). Coumarin 102 (Φ = 0.66 in water) provided the standard.40 The integrated 
fluorescence emission at a given concentration was plotted against the maximum 
absorbance of the sample at that concentration determined by extrapolation based 
on absorbance measurements at higher concentrations. Linear least squares fitting 
of the data (including a zero intercept) was used to calculate the slope, which is 
proportional to the quantum yield. Quantum yields were calculated as follows: Φx = 
Φst(Gradx/Gradst), where Φst represents the quantum yield of the standard, Φx 
represents the quantum yield of the unknown, and Grad is the slope of the best 
linear fit. Theoretical Förster distances were calculated using a previously described 
protocol.41, 42 The following parameters and equations were used: ΦD is the quantum 
yield of the donor, η is the refractive index of the solvent, κ is the orientation factor, J 
is the degree of spectral overlap between the donor and acceptor, FD(λ) is the 
normalized donor fluorescence intensity, and εA(λ) is the absorbance spectrum of the 
acceptor normalized to its maximum molar extinction coefficient. 








Theoretical Förster distances were calculated using PhotoChemCAD software, the 
measured extinction coefficient for each probe, Φtryptophan = 0.2, ηphosphate buffer, pH 7.4 = 
1.33, and κ = 2/3. 
 
2.10.2. Biological assays and protocols 
Determination of Kd values by Förster Resonance Energy Transfer (FRET) from 
tryptophan to Pacific Blue 
Different concentrations of the SA protein, chosen to span a range of at least 20% to 
80% complexation, were incubated with fixed concentrations of 24 (25 nM), 25 (5 
nM), or 26 (25 nM) in PBS (pH 7.4) at room temperature with shaking for 1 h. These 
fixed probe concentrations were chosen to be substantially below the predicted Kd 
values to assure equilibrium binding measurements. Measurements of raw FRET 
values (I295, λex= 295 nm, λem= 460 nm) and fluorescence intensity values (I400, λex= 
400 nm, λem= 460 nm) were recorded for each sample. Averages of raw FRET (Id,295) 
values and fluorescence (Id,400) intensities of SA alone (background fluorescence) 
were calculated by averaging of three values for each concentration of SA. The 
fluorescence emission of the free ligand at 460 nm upon excitation at 295 nm (Ia,295) 
and 400 nm (Ia,400) were calculated by averaging three measurements of the Pacific 
Blue probe in PBS buffer. Background-subtracted FRET (IFRET) and fluorescence 
(Iad,400) signals were calculated as follows:  
!!"#$ =  !!"# − !!,!"# − !!,!"# 
!!",!"" =  !!"" − !!,!"" 
The quenching ratio (Qr) was calculated as follows: 






Background-subtracted FRET signals (IFRET) were processed to directly factor in 
quenching or enhancement of the fluorophore using the following equation, where Iad 
is the corrected FRET signal: 




To calculate the dissociation constant (Kd) using FRET data, the corrected FRET 
signal (Iad) was plotted against the concentration of streptavidin (monomer). The 
experiments were run in triplicate, and the one site - specific binding model of 
GraphPad Prism 6.0 was used for curve fitting. 
 
To calculate the dissociation constant (Kd) using fluorescence quenching data, the 
change in fluorescence (enhancement or quenching, Iad,400) was normalized and 
plotted against the concentration of streptavidin (monomer). The experiments were 
run in triplicate, and the one site - specific binding model of GraphPad Prism 6.0 was 
used for curve fitting. For 25, the fluorescence intensity values for the three highest 
concentrations SA monomer (64, 128, and 256 nM) were excluded from the analysis 
in order for the one site – specific binding model to fit. Note: for compound 32–33 
(Myc tag derivatives), the same procedure was followed with the exception of the 
following; Protein: Monoclonal Anti c-Myc antibody, ligand concentration: 100 nM, 
excitation and emission wavelengths were as follows: λex= 400 nm and λem= 460 nm. 
 
Determination of Ki values via competition assay (loss of Trp-PB FRET signal) 
The unlabeled ligand was added to a fixed concentration of pre-complexed SA and 
fluorescent probe 26 (SA = 175 nM, 26 = 25 nM) in PBS (pH 7.4) at room 
temperature with shaking for 1 h. The concentration of SA was chosen to be close to 
the Kd value measured for the fluorescent probe, and the concentration of 26 was 
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chosen to be substantially below Kd to assure equilibrium binding. Measurements of 
raw FRET values (I295, λex= 295 nm, λem= 460 nm) and fluorescence intensity values 
(I400, λex= 400 nm, λem= 460 nm) were recorded for each sample. Averages of raw 
FRET (Id,295) values and fluorescence (Id,400) intensities of SA alone (background 
fluorescence) were calculated by averaging of three values for each concentration of 
SA. The fluorescence emission of the free ligand at 460 nm upon excitation at 295 
nm (Ia,295) was calculated by averaging three measurements of 26 in PBS buffer. 
Background-subtracted FRET (IFRET) and fluorescence (Iad,400) signals were 
calculated as follows:  
!!!"# =  !!"# − !!,!"# − !!,!"# 
!!",!"" =  !!"" − !!,!"" 
The quenching ratio (Qr) was calculated as follows: 




Background-subtracted FRET signals (IFRET) were processed to directly factor in 
quenching or enhancement of the fluorophore using the following equation, where Iad 
is the corrected FRET signal: 




To calculate the IC50, the corrected FRET signal (Iad) was plotted against the 
concentration of unlabeled ligand. The experiments were run in triplicate, and the 
log(inhibitor) vs. response model of GraphPad Prism 6.0 was used for curve fitting. 









Isothermal titration calorimetry (ITC) 
 ITC experiments were performed using a MicroCal Auto-Isothermal Titration 
Calorimeter with protein and ligand solutions prepared in PBS. Titrations were 
performed at 25 °C and consisted of 25 injections (10 µL) of ligand (50–250 µM) into 
streptavidin (1.46 mL, 4–20 µM), with 6 min between injections. The experimental 
data were fit to a one-site binding model (Origin software) where ΔH (enthalpy 
change, kcal/mol), Ka (association constant, M–1), and n (number of binding sites) 
were variables. 
 
Determination of Kd values by fluorescence polarization (FP) of Pacific Blue 
FP is very sensitive to fluorescence quenching because of effects on the lifetime of 
the fluorophore. This quenching prevented attempts to use FP to independently 
quantify the affinity of ligands 25 and 26 for SA.3 However, quenching was less 
significant for the lower affinity ligand 24, and a previously described43 FP method 
was used to independently analyze this probe. Measurements of fluorescence 
intensity (I400, λex= 400 nm, λem= 460 nm) and fluorescence polarization (P, λex= 400 
nm, λem= 460 nm) were recorded for each sample. The change in polarization for 
each sample was calculated by subtracting the average (n=3) polarization of the free 
ligand (Pf). This change was plotted against the concentration of SA, and the 
maximum polarization of the fully bound complex was estimated (Bmax) based on a 
one-site specific binding model (GraphPad Prism 6.0). This polarization of the 








Background-subtracted fluorescence signals (Iad,400) were calculated as previously 
described. In order to correct for fluorescence enhancement or quenching, a 
fluorescence enhancement factor (Q) was calculated using the following equation, 
where Iad,400 and Ia,400 are the fluorescence intensity (λex= 400 nm, λem= 460 nm) of 
the sample and free ligand, respectively: 
! =  !!",!"" − !!,!""!!,!""
 
To incorporate fluorescence enhancement/quenching into the measurements, the 





To calculate the dissociation constant (Kd), the corrected fraction bound was plotted 
against the concentration of streptavidin, and a one site- specific binding equation of 
GraphPad Prism 6.0 was used for curve fitting.  
 
Cell culture: HeLa cells, obtained from ATCC (CCL-2), were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, Sigma D6429). All media was supplemented with 
fetal bovine serum (FBS, 10%), penicillin (100 units/mL), and streptomycin (100 
µg/mL) and incubated in a humidified 5% CO2 incubator at 37 °C unless otherwise 
noted.  
 
Transient transfection of HeLa cells: The plasmid pPA2-TS7A-WT-GTP-mRFP 
was studied previously by Drs. Laurie Mottram and Sonalee Athavankar of the 
Peterson group and are described in their PhD theses. Prior to transfection, HeLa 
cells in DMEM were seeded onto an 8-well cover glass slide (Ibidi µ-Slide, 300 µL, 
10,000 cells/well) and allowed to proliferate for 16 h at 37 °C. To form a DNA 
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complex, the plasmid DNA (2 µg) was incubated at 22 °C with the DNA transfection 
reagent X-tremeGENE HP (2 µL, Roche) in serum free DMEM medium (200 µL). 
After 30 min, the DNA complex (20 µL) was added to each well. The cells were 
further incubated at 37 °C for 48 h. After transfection, the cells were washed with 
medium, further treated with probes, and analyzed by confocal microscopy. 
 
Confocal microscopy: Compounds in DMSO stock solutions were serially diluted 
1,000-fold with complete media (final concentration of 0.1% DMSO) prior to addition 
to cells. Transiently transfected cells were treated with compounds at 37 °C for 30 
min before imaging by a Leica SPE2 confocal laser-scanning microscope with a 63X 
oil-immersion objective. 20 and 34 were excited with a 405 nm laser and emitted 
photons were collected from 425-475 nm. The mRFP was excited with a 532 nm 
laser and emitted photons were collected from 550-650 nm.  
 
LogD measurements: 5 mM solutions of 20 or 34 were made by dissolving the solid 
compounds in 1:1 octanol/phosphate buffer (4 mL total volume, 5 mM phosphate, pH 
7.4). Samples were shaken for 24 h at 22 °C to equilibrate. Following shaking, the 
samples were allowed to settle, and 1 mL from the top and bottom were removed and 
centrifuged at 14,000 rpm (no precipitate was observed for any of the samples). Aliquots 
of these fractions were diluted in octanol (derived from the top fraction) or 5 mM 
phosphate buffer (derived bottom fraction) to generate stock solutions that were then 
further diluted into a solvent mixture comprising ethanol (80%), octanol (10%), and 5 mM 
phosphate buffer (10%, pH 7.4) the for analysis by fluorescence spectroscopy. The ratio 





Figure 2.16. Analysis of compounds in PBS (pH 7.4) containing DMSO (0.5%). A: 
Determination of extinction coefficients of 20–23. B: Measurement of the quantum 
yield of 20 in PBS (pH 7.4) relative to coumarin 102. 
 
2.10.3 Synthetic procedures and compound characterization data 
General procedure 2A: Synthesis of fluorescent biotin derivatives 20 and 21. N-
Boc-ethylenediamine-D-biotin (64–87 mg, 1.5 eq), prepared as previously reported,44 
was treated with a solution of trifluoroacetic acid (TFA) / CH2Cl2 (2 mL, 30:70) for 20 
min. The mixture was concentrated under vacuum and washed with CH2Cl2 (5 mL) 
and ether (5 mL x 2) to remove excess TFA. The activated fluorophore (1 eq.), N,N-
diisopropylethylamine (DIEA, 5 eq.), and DMF (1–3 mL) were added, and the 
reaction was stirred at 22 °C for 16 h. The solvent was removed under vacuum, the 
residue was dissolved in DMSO (1.5 mL), and the product purified by preparative 
RP-HPLC (Gradient: H2O:CH3CN (9:1) to (0:100) with added TFA (0.1%) over 20 
min; elution time = 6–10 min). Pure fractions were collected, combined, and solvent 
was removed by lyophilization. 
General procedure 2B: Synthesis of fluorescent biotin derivatives 22 and 23. N-
Boc-ethylenediamine-D-biotin (92–120 mg, 1.5 eq), prepared as previously 
reported,44 was treated with a solution of TFA / CH2Cl2 (2 mL, 30:70) for 20 min. The 
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mixture was concentrated under vacuum and washed with CH2Cl2 (5 mL) and ether 
(5 mL x 2) to remove excess TFA. The fluorophore (1 eq.), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC, 1.1 eq.), 4-dimethylaminopyridine (DMAP, 
0.5 eq.), and DMF (2 mL), were added, and the reaction was stirred at 22 °C for 16 h. 
The solvent was removed under vacuum, the residue was dissolved in DMSO (1.5 
mL), and the product was purified by preparative RP-HPLC (Gradient: H2O:CH3CN 
(9:1) to (0:100) with added TFA (0.1%) over 20 min; elution time = 6–10 min). Pure 
fractions were collected, combined, and dried by lyophilization. 
General procedure 2C: Synthesis of biotin analogues linked to Pacific Blue (24–26). 
N-Boc-ethylenediamine-Pacific Blue (35, 23-29 mg, 1 eq.) was treated with a 
solution of TFA / CH2Cl2 (2 mL, 30:70) for 20 min. The mixture was concentrated and 
washed with CH2Cl2 (5 mL) and MeOH (5 mL x 2) to remove excess TFA. The biotin 
analogue (1.3 eq.), HBTU (1.5 eq.), hydroxybenzotriazole (HOBt, 1.5 eq.), DIEA (5 
eq.), and DMF (1 mL) were added. The reaction was stirred at 22 °C for 16 h. The 
solvent was removed under vacuum, the residue was dissolved in DMSO (1.5 mL), 
and the product was purified by preparative RP-HPLC (Gradient: H2O:CH3CN (9:1) 
to (0:100) with added TFA (0.1%) over 20 min; elution time = 6-10 min). Pure 
fractions were collected, combined, and dried by lyophilization. 
General procedure 2D: Solid phase peptide synthesis (SPPS) for compounds 31–
33 was performed on a Mettler Toledo Miniblock reactor (Model No: Bohdan 2080; 
12-well block with glass reaction vessels, 600 rpm) utilizing standard Fmoc chemistry 
employing Rink amide MBHA resin (0.36 mmol/g, 140 mg, 0.05 mmol). The resin 
was first swelled in DMF for 2 h and the Fmoc group was removed with deblocking 
solution (20% piperidine in DMF (2 mL), 2 x 4 min with shaking). The resin was 
washed with DMF (4x, 2 mL) to remove excess piperidine, and treated with Fmoc-
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amino acids (4 eq.), HATU coupling reagents (3.8 eq.), and DIEA (8 eq.) in DMF (2 
mL) with agitation until coupling was completed (3–12 h). The reaction solution was 
removed and resin was washed with DMF (4x, 2 mL). This coupling protocol was 
repeated for each additional amino acid. For 32–33, the final amine was capped by 
agitating with PB-NHS (15, 2 eq.) and DIEA (5 eq.) in DMF (2 mL) for 6 h. Cleavage 
from resin was done using a mixture of TFA:H2O:TIPS (95:2.5:2.5) with agitation for 
2 h. The resin was removed by filtration and washed with DCM (3x, 2 mL). The 
filtrates were combined and concentrated under vacuum to give crude products. 
Purification was done using preparative reverse-phase HPLC (Gradient: H2O:CH3CN 
(9:1) to (0:100) with added TFA (0.1%) over 20 min; elution time = 5-9 min). Pure 
fractions were collected, combined, and dried by lyophilization. 
 
 
2,3,4,5-Tetrafluorobenzonitrile (17). To a solution of 2,3,4,5-tetrafluorobenzoic acid 
(16, 10 g, 51 mmol), in CH2Cl2 (50 mL) was added oxalyl chloride (5.4 mL, 62.9 
mmol) and DMF (ca. 2 drops) and the reaction mixture was stirred at 22 °C for 16 h 
while vented to the atmosphere to allow escape of evolved gasses. The solvent was 
removed under reduced pressure, and the vessel was placed on high vacuum for 2 h 
to afford the acid chloride as a viscous oil. This oil was dissolved in chloroform (40 
mL) and cooled to 4 °C. Aqueous ammonia (28%, 55 mL) was slowly added and the 
reaction was stirred at 4 °C for 30 min. The mixture was extracted with chloroform, 
and the organic layer was dried, filtered, and concentrated under reduced pressure 
to afford a white solid. To the solid was added phosphoryl chloride (32 mL) and the 









mL) and ice water (100 mL), followed by sat. aqueous NaHCO3 (100 mL) for 1 h. The 
mixture was extracted with diethyl ether, and the organic layer was washed with sat. 
aqueous NaHCO3 (3 x 100 mL). The organic layer was dried, filtered, and 
concentrated under reduced pressure to afford 17 (7.9 g, 88%) as a colorless oil. 1H 
NMR (500 MHz, CDCl3) δ 7.33 (dddd, J = 8.8, 7.6, 5.3, 2.6 Hz, 1H); 13C NMR (126 
MHz, CDCl3) δ 149.5 (dddd, J = 269.0, 12.1, 4.0, 2.0 Hz), 147.4 (dddd, J = 259.0, 
10.8, 3.9, 2.2 Hz), 144.4 (dddd, J = 265.6, 15.9, 12.2, 3.2 Hz), 143.4 (ddd, J = 16.0, 
12.1, 3.2 Hz), 141.3 (dddd, J = 258.6, 15.0, 12.7, 4.0 Hz), 115.0 (dd, J = 21.9, 4.1 
Hz), 111.2 (m), 97.8 (dddd, J = 14.2, 9.3, 4.7, 1.7 Hz); 19F NMR (376 MHz, CDCl3) δ 
-129.99 (dddt, J = 31.8, 19.9, 11.9, 6.9 Hz), -134.49 (dddt, J = 32.4, 20.6, 11.8, 5.3 
Hz), -143.33 (tdd, J = 20.5, 12.9, 8.3 Hz), -150.62 (dddd, J = 39.3, 24.4, 17.3, 6.4 
Hz); HRMS (ESI-) m/z 173.9993 (M-H+, C7F4N requires 173.9967). Note: This 
compound is also commercially available (Oakwood Chemicals, 25 g / $75). 
 
  
2,4-Bis(benzyloxy)-3,5-difluorobenzonitrile (18). To a solution of 17 (7.8 g, 45 
mmol) in DMF (5 mL) was added benzyl alcohol (23 mL, 223 mmol) and potassium 
carbonate (37 g, 267 mmol). The reaction was heated to 105 °C for 16 h. The vessel 
was placed on high vacuum for 2 h to remove DMF followed by purification by 
column chromatography on silica gel (eluent: hexanes/ethyl acetate (17:1)) to afford 
18 (13.5 g, 86%) as a viscous colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.46-7.33 
(m, 11H), 7.04 (dd, J = 10.0, 2.3 Hz, 1H), 5.29 (s, 2H), 5.2251 (d, J = 1.0 Hz, 2H); 









Hz), 146.3 (dd, J = 11.9, 3.3 Hz), 140.7 (dd, J = 14.7, 12.1 Hz), 135.5, 135.2, 129.1, 
129.0, 128.84, 128.80, 128.77, 128.4, 114.9 (dd, J = 23.6, 3.7 Hz), 114.8 (d, J = 3.0 
Hz), 101.0 (dd, J = 10.5, 5.0 Hz), 76.8 (d, J = 5.6 Hz), 76.2 (t, J = 3.9 Hz); 19F NMR 
(376 MHz, CDCl3) δ -129.79 (d, J = 6.9 Hz), -138.96 (d, J = 6.9 Hz); HRMS (ESI+) 
m/z 374.0979 (M+Na+, C21H15F2NO2Na requires 374.0969). 
 
 
2,4-Bis(benzyloxy)-3,5-difluorobenzaldehyde (19). To a solution of 18 (13.4 g, 38 
mmol) in CH2Cl2 (20 mL) at -78 °C was added diisobutylaluminum hydride (Acros 
Organics, 1 M in cyclohexane, 45.9 mL). The reaction mixture was stirred at -78 °C 
for 3.5 h, and was then warmed to 22 °C. The reaction was quenched by stirring with 
aqueous HCl (0.5 M, 150 mL) for 1 h. The mixture was extracted with ethyl acetate, 
dried, filtered, and evaporated under reduced pressure. The resulting solid was 
recrystallized with ethanol to afford 18 (11.6 g, 87%) as a white solid. 1H NMR (500 
MHz, CDCl3) δ 10.01 (d, J = 3.3 Hz, 1H), 7.49 - 7.27 (m, 11H), 5.34 (s, 2H), 5.17 (d, 
J = 1.0 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 187.1 (dd, J = 3.2, 1.8 Hz), 151.8 (dd, 
J = 247.3, 4.0 Hz), 149.1 (dd, J = 250.8, 5.5 Hz), 146.6 (dd, J = 10.1, 2.9 Hz), 141.6 
(dd, J = 15.4, 12.2 Hz), 135.8, 135.3, 129.2, 128.94, 128.91, 128.90, 128.8, 128.4, 
124.1 (dd, J = 6.3, 1.6 Hz), 109.2 (dd, J = 21.2, 3.1 Hz), 77.4 (d, J = 6.5 Hz), 76.0 (t, 
J = 4.0 Hz); 19F NMR (376 MHz, CDCl3) δ -130.48 (d, J = 5.7 Hz), -140.71 (dd, J = 












3,5-Difluoro-2,4-dihydroxybenzaldehyde (11). To a solution of 19 (11.0 g, 31 
mmol) in CH3OH / THF (100 mL, 7:3) was added Pd/C (10%, 1.67 g), and the 
mixture was stirred under an atmosphere of hydrogen (1 atm) at 22 °C for 8 h. After 
removing the catalyst by filtration over celite, the filtrate was concentrated under 
reduced pressure and purified by column chromatography over silica gel (eluent: 
hexanes/ethyl acetate/acetic acid (82:18:1)) to afford 11 (4.6 g, 83%) as a light pink 
solid. 1H NMR (500 MHz, DMSO-d6) δ 11.58 (s, 1H), 10.86 (s, 1H), 10.0439 (d, J = 
2.4 Hz, 1H), 7.29 (dd, J = 10.8, 2.1 Hz, 1H); 13C NMR (126 MHz, DMSO-d6) δ 189.5, 
146.8 (d, J = 11.8 Hz), 145.6 (dd, J = 236.6, 4.5 Hz), 141.5 (dd, J = 18.0, 13.5 Hz), 
141.2 (dd, J = 238.9, 5.7 Hz), 113.9 (d, J = 5.8 Hz), 109. 4 (dd, J = 19.4, 2.9 Hz); 19F 
NMR (376 MHz, DMSO-d6) δ -144.25, -156.25 (d, J = 6.4 Hz); HRMS (ESI-) m/z 
173.0038 (M-H+, C7H3F2O3 requires 173.0050). Note: This product can be carried 
forward without further purification. Following simple filtration through celite and 
concentration, this crude material has yielded Pacific Blue (5) in high purity (79% 
yield over two steps, 8.5 mmol scale). 
 
  
6,8-Difluoro-7-hydroxy-2-oxo-2H-chromene-3-carboxylic acid (Pacific Blue, 5). 
To a suspension of 11 (4.2 g, 24.1 mmol) in water (110 mL) was added Meldrum’s 

















was stirred at 22 °C for 3.5 h. Aqueous HCl (2 M, 75 mL) was added and the 
reaction was placed at 4 °C for 1 h. A precipitate formed that was filtered, washed 
with cold water (2 x 25 mL), and dried under high vacuum to give Pacific Blue (5, 5.4 
g, 92%) as a light yellow solid. 1H NMR (500 MHz, DMSO-d6) δ 8.67 (d, J = 1.4 Hz, 
1H), 7.66 (dd, J = 10.5, 2.0 Hz, 1H); 13C NMR (126 MHz, DMSO-d6) δ 163.9, 155.6, 
148.6 (dd, J = 240.8, 4.7 Hz), 148.5 (t, J = 2.9 Hz), 141.3 (d, J = 9.6 Hz), 140.3 (dd, J 
= 18.1, 12.6 Hz), 138.7 (dd, J = 244.7, 6.4 Hz), 115.3, 110.5 (dd, J = 20.9, 3.0 Hz), 
109.0 (d, J = 10.2 Hz). 19F NMR (376 MHz, DMSO-d6) δ -137.33 (d, J = 9.3 Hz),        





carboxylate (Pacific Blue NHS ester, 15). To a solution of 5 (0.75 g, 3.1 mmol) in 
DMF (5 mL) was added N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC, 1.2 g, 6.2 mmol) and N-hydroxysuccinimide (0.89 g, 7.8 mmol). 
The reaction mixture was stirred at 22 °C for 16 h. This reaction mixture was added 
dropwise to cold 1 N HCl (75 mL). A precipitate formed that was filtered, washed with 
cold aq. HCl (1N, 25 mL), and dried under high vacuum to give 15 (920 mg, 87%) as 
a yellow solid. 1H NMR (500 MHz, DMSO-d6) δ 9.01 (d, J = 1.4 Hz, 1H), 7.78 (dd, J = 
10.2, 1.9 Hz, 1H), 2.89 (s, 4H); 13C NMR (126 MHz, DMSO-d6) δ 170.3, 158.4, 
154.4, 152.1 (t, J = 2.9 Hz), 148.8 (dd, J = 241.3, 4.9 Hz), 142.4 (d, J = 9.0 Hz), 












Hz), 25.6; 19F NMR (376 MHz, DMSO-d6) δ -136.84, -155.95 (d, J = 13.4 Hz); HRMS 





(Pacific Blue-Biotin, 20). Following general procedure 2A, Pacific Blue NHS ester 
(15, 50 mg, 0.15 mmol) yielded compound 20 (45 mg, 60%) as a pale yellow solid. 
1H NMR (500 MHz, DMSO-d6) δ 8.82 (d, J = 1.4 Hz, 1H), 8.67 (t, J = 5.8 Hz, 1H), 
7.93 (t, J = 5.6 Hz, 1H), 7.78 (dd, J = 10.5, 1.9 Hz, 1H), 6.44 (s, 1H), 6.36 (s, 1H), 
4.29 (dd, J = 7.7, 4.9 Hz, 1H), 4.11 (dd, J = 7.8, 4.4 Hz, 1H), 3.39 (q, J = 6.2 Hz, 2H), 
3.22 (q, J = 6.1 Hz, 2H), 3.07 (ddd, J = 8.5, 6.3, 4.4 Hz, 1H), 2.78 (dd, J = 12.4, 5.1 
Hz, 1H), 2.55 (d, J = 12.4 Hz, 1H), 2.06 (t, J = 7.4 Hz, 2H), 1.64-1.26 (m, 6H); 13C 
NMR (126 MHz, DMSO-d6) δ 172.3, 162.7, 161.3, 159.5, 148.8 (dd, J = 241.2, 4.6 
Hz), 147.3 (t, J = 2.9 Hz), 140.5 (d, J = 9.2 Hz), 140.0 (d, J = 13.2 Hz), 138.8 (dd, J = 
245.1, 6.6 Hz), 116.2, 110.6 (dd, J = 21.0, 3.0 Hz), 109.6 (d, J = 10.2 Hz), 61.0, 59.2, 
55.4, 40.1, 39.4, 38.5, 38.1, 35.2, 28.2, 28.1, 28.0, 25.3; HRMS (ESI-) m/z 509.1298 






























Following general procedure 2A, dansyl chloride (30 mg, 0.11 mmol) yielded 
compound 21 (25 mg, 42%) as a white solid. 1H NMR (500 MHz, DMSO-d6) δ 8.47 
(dt, J = 8.6, 1.1 Hz, 1H), 8.28 (dt, J = 8.8, 0.9 Hz, 1H), 8.10 (dd, J = 7.3, 1.2 Hz, 1H), 
7.99 (t, J = 5.9 Hz, 1H), 7.73 (t, J = 5.8 Hz, 1H), 7.62 (m, 2H), 7.28 (d, J = 7.4 Hz, 
1H), 6.42 (s, 1H), 4.30 (dd, J = 7.4, 4.7 Hz, 1H), 4.11 (dd, J = 7.7, 4.4 Hz, 1H), 3.13-
3.05 (m, 1H), 3.03 (dt, J = 7.5, 5.9 Hz, 2H), 2.85 (s, 6H), 2.83-2.75 (m, 3H), 2.57 (d, J 
= 12.5 Hz, 1H), 1.93 (t, J = 7.4 Hz, 2H), 1.66-1.15 (m, 6H).13C NMR (126 MHz, 
DMSO-d6) δ 172.2, 162.7, 158.3, 158.0, 151.2, 135.8, 129.5, 129.0, 128.4, 128.3, 
127.9, 123.7, 117.0, 115.2, 114.7, 61.0, 59.2, 55.4, 45.1, 42.0, 39.5, 35.1, 28.2, 25.1; 





Biotin, 7HC-Biotin, 22). 2-(7-Hydroxy-2-oxo-2H-chromen-4-yl)acetic acid was 
prepared as previously reported.45 Following general procedure 2B, 2-(7-hydroxy-2-
oxo-2H-chromen-4-yl)acetic acid (45 mg, 0.21 mmol) yielded compound 22 (57 mg, 
57%) as a yellow solid. 1H NMR (500 MHz, DMSO-d6) δ 10.57 (s, 1H), 8.27-8.15 (m, 
1H), 7.93-7.75 (m, 1H), 7.58 (d, J = 8.7 Hz, 1H), 6.79 (dd, J = 8.7, 2.4 Hz, 1H), 6.71 
(d, J = 2.4 Hz, 1H), 6.40 (d, J = 27.8 Hz, 2H), 6.16 (s, 1H), 4.30 (dd, J = 7.7, 5.0 Hz, 
1H), 4.12 (ddd, J = 7.7, 4.4, 1.8 Hz, 1H), 3.74-3.50 (m, 2H), 3.09 (m, 5H), 2.81 (dd, J 
= 12.4, 5.1 Hz, 1H), 2.57 (d, J = 12.5 Hz, 2H), 2.02 (t, J = 7.4 Hz, 2H), 1.67-1.18 (m, 
6H); 13C NMR (126 MHz, DMSO) δ 172.3, 167.8, 162.7, 161.2, 160.3, 155.0, 151.1, 















39.78, 39.69, 39.61, 39.5, 39.4, 39.2, 39.0, 38.9, 38.7, 38.1, 35.2, 28.2, 28.1, 25.2; 





(DMACA-Biotin, 23). 2-(7-(Dimethylamino)-2-oxo-2H-chromen-4-yl)acetic acid was 
prepared as previously reported.45 Following general procedure 2B, 2-(7-
(dimethylamino)-2-oxo-2H-chromen-4-yl)acetic acid (DMACA, 40 mg, 0.16 mmol) 
yielded compound 23 (36 mg, 43%) as a yellow solid. 1H NMR (500 MHz, DMSO-d6) 
δ 8.25- 8.18 (m, 1H), 7.82 (d, J = 5.4 Hz, 1H), 7.53 (d, J = 9.0 Hz, 1H), 6.73 (dd, J = 
9.0, 2.6 Hz, 1H), 6.56 (d, J = 2.5 Hz, 1H), 6.46-6.41 (m, 1H), 6.38 (s, 1H), 6.00 (s, 
1H), 4.30 (ddd, J = 7.7, 5.2, 1.0 Hz, 1H), 4.16-4.10 (m, 1H), 3.61-3.57 (m, 2H), 3.10 
(m, 5H), 3.02 (s, 6H), 2.82 (dd, J = 12.4, 5.1 Hz, 1H), 2.58 (d, J = 12.5 Hz, 1H), 2.03 
(t, J = 7.4 Hz, 2H), 1.69-1.18 (m, 6H); 13C NMR (126 MHz, DMSO) δ 172.7, 168.4, 
163.2, 161.2, 155.8, 153.2, 151.6, 126.5, 109.9, 109.5, 108.7, 97.9, 61.5, 59.6, 55.9, 
40.9, 39.3, 39.1, 38.6, 35.7, 28.7, 28.5, 25.6; HRMS (ESI+) m/z 516.2291 (M+H+, 




























solution of 15 (200 mg, 0.59 mmol) in DMF (5 mL) was added N-Boc-
ethylenediamine (114 mg, 0.71 mmol). The reaction mixture was stirred at 22 °C for 
16 h. The vessel was placed on high vacuum for 1 h to remove 4 mL of DMF. The 
remaining reaction mixture was added dropwise to cold 1 N HCl (40 mL). A 
precipitate formed that was filtered, washed with cold 1 N HCl (10 mL), and dried 
under high vacuum to give 35 (200 mg, 88%) as a yellow solid. 1H NMR (500 MHz, 
DMSO-d6) δ 8.81 (d, J = 1.4 Hz, 1H), 8.67 (t, J = 5.8 Hz, 1H), 7.77 (dd, J = 10.4, 1.9 
Hz, 1H), 6.95 (t, J = 5.6 Hz, 1H), 3.36 (q, J = 6.1 Hz, 2H), 3.10 (q, J = 6.0 Hz, 2H), 
1.37 (s, 11H), 1.45-1.39 (m, 1H); 13C NMR (126 MHz, DMSO-d6) δ 161.3, 159.5, 
155.7, 148.9 (dd, J = 240.9, 4.8 Hz), 147.3, 140.5 (d, J = 9.0 Hz), 140.1, 138.8 (dd, J 
= 245.0, 6.4 Hz), 116.2, 110.7, 110.5, 109.5, 109.5, 77.7, 28.2; HRMS (ESI-) m/z 





2(3H)-iminium (PB-iminobiotin, 24). Following general procedure 2C, 2-iminobiotin 
(19 mg, 0.077 mmol) yielded compound 24 (12 mg, 40%) as a pale yellow solid. 1H 
NMR (500 MHz, DMSO-d6) δ 8.80 (d, J = 1.4 Hz, 1H), 8.67 (t, J = 5.8 Hz, 1H), 8.22 
(d, J = 6.5 Hz, 1H), 8.11-8.01 (m, 1H), 7.94 (t, J = 5.6 Hz, 1H), 7.82-7.70 (m, 1H), 
7.62 (s, 2H), 6.55 (s, 1H), 4.63 (dd, J = 7.9, 4.8 Hz, 1H), 4.44 (ddd, J = 7.9, 4.5, 1.7 
Hz, 1H), 3.38 (d, J = 6.3 Hz, 2H), 3.22 (dd, J = 7.7, 3.7 Hz, 2H), 3.01-2.82 (m, 2H), 
2.77 (d, J = 12.9 Hz, 1H), 2.07 (t, J = 7.3 Hz, 2H), 1.75-1.23 (m, 6H); 13C NMR (126 















4.8 Hz), 147.4 (t, J = 3.0 Hz), 140.6 (d, J = 8.8 Hz), 140.2 (d, J = 17.4 Hz), 138.8 (dd, 
J = 245.3, 6.6 Hz), 116.1, 110. 6 (dd, J = 21.1, 2.9 Hz), 109.5 (d, J = 10.2 Hz), 64.4, 
63.0, 55.1, 40.1, 39.7, 38.1, 35.2, 28.2, 27.9, 25.2; HRMS (ESI-) m/z 508.1471 (M-




yl)pentanoate (36). d-Biotin methyl ester (387 mg, 1.50 mmol), prepared as 
previously reported,46 was dissolved in xylenes (6 mL). Lawesson’s reagent (607 mg, 
1.50 mmol) was then added and the reaction mixture was heated to 95 °C for 1 h. 
The solvent was removed under reduced pressure, and the resulting residue was 
extracted with ethyl acetate, dried, filtered, and evaporated under reduced pressure. 
The residue was purified by column chromatography over silica gel (eluent: CH2Cl2 / 
CH3OH (50:1)) to afford 36 (330 mg, 80%) as a white solid. 1H NMR (500 MHz, 
DMSO-d6) δ 8.24 (m, 1H), 8.17 (s, 1H), 4.54 (dd, J = 8.4, 5.0 Hz, 1H), 4.36 (ddd, J = 
8.4, 4.5, 1.5 Hz, 1H), 3.58 (s, 3H), 3.17 (ddd, J = 8.6, 6.0, 4.5 Hz, 1H), 2.86 (dd, J = 
12.6, 5.1 Hz, 1H), 2.67 (d, J = 12.7 Hz, 1H), 2.30 (t, J = 7.5 Hz, 2H), 1.77-1.24 (m, 
6H); 13C NMR (126 MHz, CDCl3) δ 182.4, 173.3, 66.0, 64.1, 55.7, 39.8, 33.1, 28.1, 



















acid (37). To a solution of 36 (125 mg, 0.46 mmol) in CH3OH (4 mL) was added aq. 
NaOH (1 N, 2 mL). The reaction mixture was heated to 35 °C for 0.5 h, followed by 
acidification with aq. HCl (1 N, 10 mL). A precipitate formed that was filtered, washed 
with cold aq. HCl (1 N, 5 mL), and dried under high vacuum to give 37 (90 mg, 76%) 
as a white solid. 1H NMR (500 MHz, DMSO-d6) δ 12.00 (s, 1H), 8.24 (s, 1H), 8.17 (s, 
1H), 4.54 (dd, J = 8.4, 4.9 Hz, 1H), 4.36 (ddd, J = 8.5, 4.7, 1.4 Hz, 1H), 3.17 (ddd, J 
= 8.8, 5.9, 4.4 Hz, 1H), 2.86 (dd, J = 12.6, 5.0 Hz, 1H), 2.67 (d, J = 12.6 Hz, 1H), 
2.20 (t, J = 7.4 Hz, 2H), 1.75-1.20 (m, 6H); 13C NMR (126 MHz, DMSO-d6) δ 182.4, 
174.5, 66.0, 64.1, 55.7, 40.1, 33.5, 28.2, 28.0, 24.6; HRMS (ESI-) m/z 259.0572 (M-





(PB-thiobiotin, 25). Following general procedure 2C, 37 (24 mg, 0.091 mmol) 
yielded compound 25 (18 mg, 49%) as a pale yellow solid. 1H NMR (500 MHz, 
DMSO-d6) δ 8.79 (d, J = 1.4 Hz, 1H), 8.66 (t, J = 5.8 Hz, 1H), 8.23 (s, 1H), 8.15 (s, 
1H), 7.92 (t, J = 5.6 Hz, 1H), 7.73 (d, J = 10.5 Hz 1H), 4.69-4.46 (m, 1H), 4.34 (ddd, 
J = 8.5, 4.6, 1.6 Hz, 1H), 3.54-3.28 (m, 10H), 3.28-3.10 (m, 4H), 2.82 (dd, J = 12.7, 
5.1 Hz, 1H), 2.65 (d, J = 12.7 Hz, 1H), 2.15-1.97 (m, 2H), 1.74-1.16 (m, 6H); 13C 
NMR (126 MHz, DMSO-d6) δ 182.4, 172.4, 161.5, 159.7, 149.3 (d, J = 239.7 Hz), 















108.8, 66.0, 64.2, 55.8, 40.4, 40.1, 38.9, 35.3, 30.8, 28.3, 28.0, 25.3; HRMS (ESI-) 
m/z 525.1050 (M-H+, C22H23F2N4O5S2 requires 525.1078). 
 
 
Methyl 6-((4R,5S)-5-methyl-2-oxoimidazolidin-4-yl)hexanoate (38). To a solution 
of d-Desthiobiotin (215 mg, 1.0 mmol) in CH3OH (5 mL), thionyl chloride (218 µL, 3.0 
mmol) was added dropwise. The reaction mixture was stirred at 22 °C for 3 h. The 
solvent was removed under reduced pressure followed by purification by column 
chromatography on silica gel (eluent: CH2Cl2 / CH3OH (20:1)) to afford 38 (217 mg, 
95%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 5.34 (s, 1H), 5.07 (s, 1H), 3.89-
3.78 (m, 1H), 3.70 (ddd, J = 9.2, 7.8, 4.9 Hz, 1H), 3.66 (s, 3H), 2.31 (t, J = 7.4 Hz, 
2H), 1.77 -1.17 (m, 8H), 1.12 (d, J = 6.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 
174.3, 164.0, 77.41, 77.36, 77.2, 76.9, 56.2, 51.7, 51.6, 34.0, 29.6, 29.1, 26.3, 24.8, 
15.8; HRMS (ESI+) m/z  251.1374 (M+H+, C11H20N2O3Na requires 251.1372). 
 
 
Methyl 6-((4R,5S)-5-methyl-2-thioxoimidazolidin-4-yl)hexanoate (29). To a 
solution of 38 (100 mg, 0.44 mmol) in xylenes (3 mL) was added Lawesson’s 
reagent (178 mg, 0.44 mmol). The reaction mixture was heated to 95 °C for 1 h. The 
solvent was removed under reduced pressure and the resulting residue was 
extracted with ethyl acetate, dried, filtered, and evaporated under reduced pressure. 
The residue was purified by column chromatography over silica gel (eluent: CH2Cl2 / 













CDCl3) δ 6.29 (br, 2H), 4.10 (t, J = 7.2 Hz, 1H), 4.01-3.87 (m, 1H), 3.67 (s, 3H), 2.32 
(t, J = 7.3 Hz, 2H), 1.81-1.23 (m, 8H), 1.18 (d, J = 6.1 Hz, 3H); 13C NMR (126 MHz, 
CDCl3) δ 182.8, 174.1, 60.5, 55.9, 51.7, 34.0, 29.0, 28.9, 26.4, 24.8, 15.2; HRMS 




(imidazolidinethione, 28). To a solution of 29 (63 mg, 0.26 mmol) in CH3OH (2 mL) 
was added aq. NaOH (1 N, 1 mL).  The reaction mixture was heated to 35 °C for 0.5 
h followed by acidification with aq. HCl (1 N, 5 mL). The resulting mixture was 
extracted with ethyl acetate, dried, filtered, and evaporated under reduced pressure. 
The residue was purified by column chromatography over silica gel (eluent: CH2Cl2 / 
CH3OH (25:1)) to afford 28 (55 mg, 93%) as an off-white solid. 1H NMR (500 MHz, 
CD3OD) δ 4.11-3.96 (m, 1H), 3.87 (dt, J = 8.8, 6.8 Hz, 1H), 2.30 (t, J = 7.4 Hz, 2H), 
1.71-1.25 (m, 8H), 1.13 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, CD3OD) δ 183.5, 
177.7, 61.4, 56.7, 34.8, 30.2, 30.0, 27.1, 25.9, 14.8; HRMS (ESI-) m/z 229.1006 (M-
























yielded compound 26 (26 mg, 68%) as a pale yellow solid. 1H NMR (500 MHz, 
DMSO-d6) δ 8.81 (br, 1H), 8.66 (t, J = 5.9 Hz, 1H), 8.18 (s, 1H), 8.02 (s, 1H), 7.91 (t, 
J = 5.7 Hz, 1H), 7.77 (dd, J = 10.6, 2.0 Hz, 1H), 3.92-3.77 (m, 1H), 3.68 (td, J = 8.2, 
4.7 Hz, 1H), 3.37 (m, 2H), 3.21 (q, J = 6.1 Hz, 2H), 2.05 (t, J = 7.4 Hz, 2H), 1.58-1.08 
(m, 8H), 0.96 (d, J = 6.4 Hz, 3H); 13C NMR (126 MHz, DMSO-d6) δ 181.8, 172.4, 
161.3, 159.5, 148.9 (dd, J = 240.1, 4.1 Hz), 147.3 (d, J = 3.3 Hz), 140.6 (d, J = 8.6 
Hz), 138.8 (dd, J = 245.1, 6.7 Hz), 116.1, 110.6 (dd, J = 21.6, 2.2 Hz), 109.4, 59.1, 
54.4, 38.1, 35.4, 28.7, 28.6 , 25.5, 25.2, 20.7, 14.6; HRMS (ESI-) m/z 495.1534 (M-
H+, C22H25F2N4O5S requires 495.1514). 
 
 
Benzyl 6-((5S)-5-methyl-2-oxoimidazolidin-4-yl)hexanoate (39). To a solution of 
d-Desthiobiotin (100 mg, 0.46 mmol) in DMF (2 mL) was added benzyl alcohol (95 
µL, 0.92 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 
56 mg, 0.6 mmol),  HOBt (92 mg, 0.6 mmol), DMAP (56 mg, 0.46 mmol),The 
reaction mixture was stirred at 22 °C for 16 h. . The solvent was removed under 
vacuum and the residue was purified by column chromatography over silica gel 
(eluent: CH2Cl2 / CH3OH (50:2)) to afford 39 (137 mg, 96%) as an off-white solid. 1H 
NMR (500 MHz, CDCl3) δ 7.34-7.22 (m, 5H), 5.05 (s, 2H), 3.87-3.76 (m, 1H), 3.65 (td, 
J = 8.3, 5.0 Hz, 1H), 2.30 (t, J = 7.4 Hz, 2H), 1.68-1.13 (m, 8H), 1.07 (d, J = 6.4 Hz, 
3H); 13C NMR (126 MHz, CDCl3) δ 173.6, 163.4, 136.1, 128.7, 128.4, 66.3, 56.4, 
51.8, 34.2, 29.5, 29.0, 26.3, 24.8, 15.8; HRMS (ESI+) m/z 305.1889 (M+H+, 










Benzyl 6-((5S)-5-methyl-2-thioxoimidazolidin-4-yl) hexanoate 
(imidazolidinethione-OBn, 30). To a solution of 39 (100 mg, 0.33 mmol) in xylenes 
(2.5 mL) was added Lawesson’s reagent (133 mg, 0.33 mmol). The reaction mixture 
was heated to 95 °C for 1.5 h. The solvent was removed under reduced pressure 
and the resulting residue was extracted with ethyl acetate, dried, filtered, and 
evaporated under reduced pressure. The residue was purified by column 
chromatography over silica gel (eluent: CH2Cl2 / CH3OH (50:1)) to afford 30 (86 mg, 
82%) as an off-white solid. 1H NMR (500 MHz, CDCl3) δ 7.45-7.27 (m, 5H), 5.11 (s, 
2H), 4.07 (dq, J = 8.8, 6.5 Hz, 1H), 3.90 (td, J = 9.0, 4.8 Hz, 1H), 2.36 (t, J = 7.4 Hz, 
2H), 1.73-1.21 (m, 8H), 1.16 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 182.5, 
173.4, 136.0, 128.6, 128.3, 66.2, 60.3, 55.8, 34.1, 28.8, 28.7, 26.2, 24.6, 15.0; 




Glutamyl-L-Aspartyl-L-Leucinamide (31). Using general procedure 2D, Rink 
amide MBHA resin (0.7 mmol/g, 71 mg, 0.05 mmol) was used to produce 31 (38 mg, 
0.032 mmol, 63% yield overall) as a white solid. LRMS (ESI+) m/z 1202.9 (M+H+, 











































Figure 2.17. Analytical HPLC profile of 31 after preparative HPLC. Retention time = 





Aspartyl-L-Leucinamide (32). Using general procedure 2D, Rink amide MBHA 
resin (0.7 mmol/g, 36 mg, 0.025 mmol) was used to produce 32 (21 mg, 0.014 mmol, 
57% yield overall) as a light yellow solid. LRMS (ESI-) m/z 1481.6 (M-H+, 
C63H91F2N14O25 requires 1481.6). 
 
Figure 2.18. Analytical HPLC profile of 32 after preparative HPLC. Retention time = 






























































Aspartyl-L-Leucinamide (33). Using general procedure 2D, Rink amide MBHA 
resin (0.7 mmol/g, 72 mg, 0.05 mmol) was used to produce 33 (22 mg, 0.022 mmol, 
10% yield overall) as a light yellow solid. LRMS (ESI-) m/z 1627.9 (M-H+, 
C70H105F2N14O28 requires 1627.7).  
 
Figure 2.19. Analytical HPLC profile of 33 after preparative HPLC. Retention time = 




carboxamido)hexyl)carbamate (40). To a solution of 15 (45 mg, 0.13 mmol) in 
DMF (1 mL) was added N-Boc-hexylenediamine (55 mg, 0.25 mmol) and DIEA (90 
µL, 0.52 mmol. The reaction mixture was stirred at 22 °C for 24 h. The vessel was 
placed on high vacuum for 1 h to remove 4 mL of DMF. The remaining reaction 




































































filtered, washed with cold 1 N HCl (10 mL), and dried under high vacuum to give 40 
(45 mg, 80%) as a yellow solid. 1H NMR (500 MHz, DMSO-d6) δ 8.78 (d, J = 1.4 Hz, 
1H), 8.58 (t, J = 5.8 Hz, 1H), 7.75 (dd, J = 10.5, 2.0 Hz, 1H), 6.78 (t, J = 5.6 Hz, 1H), 
3.29 (q, J = 6.7 Hz, 2H), 2.93–2.84 (m, 2H), 1.56–1.44 (m, 2H), 1.37–1.17 (m, 15H); 
 13C NMR (126 MHz, DMSO-d6) δ 160.9, 159.7, 155.6, 148.8 (dd, J = 240.8, 4.9 Hz), 
147.1 (d, J = 3.2 Hz), 140.5 (d, J = 8.7 Hz), 140.2–139.8 (m), 138.8 (dd, J = 245.0, 
6.5 Hz), 116.5, 110.5 (dd, J = 21.1, 3.0 Hz), 109.6 (d, J = 10.2 Hz), 77.3, 39.9, 39.8, 
29.4, 29.0, 28.3, 26.1, 26.0; HRMS (ESI-) m/z 439.1667 (M-H+, C17H17F2N2O6 






(PB-Hexyl-Biotin, 34). Compound 40 (40 mg, 0.09 mmol),  was treated with a 
solution of trifluoroacetic acid (TFA) / CH2Cl2 (2 mL, 30:70) for 20 min. The mixture 
was concentrated under vacuum and washed with CH2Cl2 (5 mL) and ether (5 mL x 
2) to remove excess TFA. Biotin-NHS ester (60 mg, 0.18 mmol), DIEA, (60 µL, 0.36 
mmol), and DMF (1 mL) were added, and the reaction was stirred at 22 °C for 16 h. 
The solvent was removed under vacuum, the residue was dissolved in DMSO (1.5 
mL), and the product purified by preparative RP-HPLC (Gradient: H2O:CH3CN (9:1) 
to (0:100) with added TFA (0.1%) over 20 min; elution time = 8 min). Pure fractions 
were collected, combined, and solvent was removed by lyophilization to yield 
compound 34 (19 mg, 50%) as a pale yellow solid. 1H NMR (400 MHz, DMSO) δ 


















3.72–3.63 (m, 1H), 3.49 (dd, J = 7.9, 4.4 Hz, 1H), 2.61 (q, J = 6.8 Hz, 2H), 2.38 (ddt, 
J = 11.7, 9.1, 5.7 Hz, 3H), 2.11 (dd, J = 12.8, 4.9 Hz, 1H), 1.99–1.81 (m, 1H), 1.39 (t, 
J = 7.3 Hz, 2H), 1.01–0.50 (m, 14H); 13C NMR (126 MHz, DMSO-d6) δ 173.8, 163.9, 
161.5, 159.4, 148.7 (dd, J = 242.4, 4.7 Hz), 146.6 (t, J = 3.0 Hz), 140.1 (d, J = 10.5 
Hz), 140.0 (d, J = 12.6 Hz), 138.3 (dd, J = 246.7, 6.3 Hz), 114.9, 109.0 (dd, J = 21.3, 
3.3 Hz), 108.9 (d, J = 10.3 Hz), 61.2, 59.4, 54.8, 38.8, 38.5, 38.0, 34.6, 28.09, 28.08, 
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Pacific Blue Derivatives of Paclitaxel Enable Selective Imaging of Microtubules 
and Assays of Efflux by P-glycoprotein in Living Cells 
 
 
3.1. Introduction  
	
Paclitaxel (Taxol, 41, Figure 3.1), a natural product first isolated from the bark of 
the yew tree Taxus brevifolia, has proven to be one of the most effective treatments for 
several types of cancer, including ovarian, breast, and lung cancers.1, 2 After entering 
the cytosol, this agent, and related compounds such as docetaxel,2 bind and stabilize β-
tubulin. This results in inhibition of microtubule polymerization dynamics and can induce 
mitotic arrest at the G2/M phase of the cell cycle (Figure 3.1).3 Engagement of this 
target protein by these cytotoxic drugs can trigger cellular death via apoptosis. For 
these reasons, paclitaxel and related compounds are considered mitotic poisons.2 
 
 
Figure 3.1. A and C: Effect of Taxol on dynamics of tubulin polymerization. B: Structure 
of paclitaxel (Taxol, 41).  
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Although they are widely used as therapeutics, the mechanisms underlying the 
selective cytotoxicity of microtubule stabilizers towards cancer cells compared to normal 
cells remain incompletely understood. In preclinical cancer models, such as cells in 
culture and tumor xenografts in mice, cancer cells double on average every 1–12 
days.4. Microtubule-stabilizing agents (MTAs), such as paclitaxel, exhibit antimitotic 
activity against these rapidly dividing cancer cell lines and models. These effects lead to 
the hypothesis that these agents preferentially affect rapidly proliferating cells and could 
exert selectivity in the clinic by targeting rapidly dividing cells within cancer tumors. 
However, these drugs also show major effects against slow growing tumors in human 
patients, while sparing more rapidly proliferating normal cells in bone marrow, gut, and 
other tissues, a phenomenon termed the “proliferation rate paradox”.5 At any given time, 
neutrophils of bone marrow are rapidly dividing, with ~60 billion cells / day undergoing 
the process of mitosis.6 In contrast, in a study of a large amount of clinical patient data 
involving many different cancer types, the median tumor-doubling time was found to be 
147 days.4 From this comparison alone, one would assume that neutropenia would be a 
dose-limiting side effect far before paclitaxel killed slow-dividing cancer cells, but this is 
not the case in most patients. Additionally, the anti-proliferative activities of these drugs 
do not correlate with cell-doubling time in some cancer preclinical models,7, 8 but do 
correlate well for others.9, 10 Furthermore, following the success of paclitaxel in the clinic, 
an enormous amount of effort and resources were dedicated to the development of 
more specific antimitotic agents, such as kinesin-5 inhibitors.5 However, although this 
new class of molecules showed efficacy against cancer cell culture models, they were 
removed from clinical trials due to extensive neutropenia. This indicated that kinesin-5 
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inhibitors have the desired clinical effect of killing rapidly dividing cells,11 but raised the 
question as to why paclitaxel would be superior in cancer patients. Additionally, reports 
of paclitaxel killing rarely dividing neuronal cells is known in the clinic, which does not 
track with the hypothesis that paclitaxel only effects rapidly dividing cells.12, 13 These 
results suggest that our knowledge of the therapeutic mechanisms of action of tubulin-
targeting chemotherapeutics is limited. Rational approaches for the design of improved 
cytotoxic chemotherapeutics will likely require a better understanding of the 
mechanisms of action of these clinically important agents.  
One approach to investigate the cellular effects of paclitaxel has involved the 
synthesis of fluorescent14-24 and other labeled25-27 analogues. The commercially 
available fluorescent Paclitaxel-Oregon Green (Flutax-2, 42, Figure 3.2), one of the 
most extensively investigated fluorescent derivatives, has been employed to investigate 
the mechanism of action of new cancer therapeutics,28-30 elucidate binding sites within 
tubulin,16-18 investigate the morphology of parasitic microorganisms,31-33 and develop 
new drug delivery34 and imaging platforms.35-37 Despite the utility of Flutax-2, we found 
that this probe lacks specificity toward microtubules in HeLa cells, is of relatively low 
affinity for microtubules,38 and is essentially non-toxic toward cells in culture, unlike the 
parent drug. We sought in the research described here to identify new fluorescent 




Figure 3.2. Structures of the known fluorescent taxoid Flutax-2 (42) and new Pacific 
Blue-linked derivatives of taxol (43–45).  
 
A hallmark of cellular responses to Taxol is the development of resistance to its 
antiproliferative effects. A major mechanism of this resistance is overexpression of the 
efflux transporter P-glycoprotein (P-gp, MDR1, ABCB1).39 Other mechanisms of 
resistance include mutations in the protein target β-tubulin, alterations in regulators of 
apoptosis, and effects on mitosis checkpoint proteins.40 Multidrug resistance (MDR) is a 
great challenge for clinical treatment of cancer, and efforts to circumvent MDR are of 
substantial interest. Many of these efforts focus on eliminating efflux by P-gp, either by 
modifications to the Taxol core to limit binding to P-gp41, 42 or through co-administration 
with P-gp inhibitors.43 To detect P-gp activity in cancer cells, assays of P-gp-mediated 
efflux generally use fluorescent substrates,44 both in preclinical drug development,45 and 
for the discovery of new P-gp inhibitors.46 Recent studies have used Flutax-247-49 and 
BODIPY FL Taxol50, 51 to detect small changes in cellular accumulation based on 
differences in P-gp activity. Here, we investigated novel fluorescent derivatives of Taxol 
in an effort to identify compounds that more closely mimic its binding to tubulin and its 
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Taxol at the 7-position through amino acid-derived linkers. We describe their cytotoxic 
activity toward rapidly dividing cells in culture, and their specificity for microtubules in 
living cells compared with a previously reported Taxol derivative. In these studies, many 
of the cell-based assays were conducted by Zhe Gao, a graduate student in the 
Peterson group. Finally, we describe efflux by P-gp, and the development of an assay of 
P-gp-mediated efflux using a PB-Taxol derivative.  
 
3.2. Synthesis of Pacific Blue-Taxol derivatives 
 As described in Chapter 2, Pacific Blue is a small coumarin-derived fluorophore 
with excellent spectral and physical properties. To further explore its utility in cell-based 
assays, we used PB to synthesize three new fluorescent derivatives of Taxol (PB-
Taxols).  Because modifications at the C-7 position of Taxol are known to retain high 
affinity for microtubules,52 PB was coupled at this position through amino acid-derived 
linkers that differ subtly and systematically in the number of methylenes between the 
amine and the carbonyl. These derivatives of Taxol (43–45) were synthesized as shown 
in Figure 3.3. To install the fluorophore regioselectively, the 2’-OH group, the most 
reactive alcohol within Taxol, was first protected with t-butyldimethylchlorosilane (TBS) 
to yield 46. Coupling reactions with Fmoc-protected amino acids and EDC/DMAP 
subsequently provided compounds 47–49. Deprotection of the Fmoc group and 
coupling with PB-NHS ester 15, followed by treatment with TBAF to remove the silyl 





Figure 3.3. Synthesis of PB-linked Taxol derivatives 43–45. Reagents and conditions: 
a) tert-butyldimethylchlorosilane, imidazole; b) Fmoc-Gly-OH (47), Fmoc-βAla-OH (48), 
or Fmoc-GABA-OH (49), EDC, DMAP; c) piperidine (20%) in DMF; d) 15, DIEA; e) 
TBAF (1.0 M) in THF.  
 
3.3. Quantification of affinities of PB-Taxols for microtubules 
 To examine the photophysical properties of 42–45, we obtained absorbance and 
emission spectra in PBS (containing 0.5% triton X-100 to prevent aggregation). As 
shown in Figure 3.4, 43–45 exhibited spectra properties (Abs., λmax = 415 nm, ε = 
23,300–24,300 M-1cm-1; Em., λmax = 460 nm) similar to Pacific Blue (Abs., λmax = 400 
nm; ε = 29,500 M-1cm-1; Em., λmax = 447 nm)53 whereas 42 (Abs., λmax = 505 nm; Em., 
λmax = 540 nm) exhibited spectral properties similar to Oregon Green (Abs., λmax = 501 
nm; Em., λmax = 526 nm).54 Consequently, the green and blue fluorophores of 42 and 
43–45 are sufficiently distinct to enable orthogonal excitation with the 405 nm (43–45) 
and 488 nm (42) laser lines commonly found on many confocal laser scanning 


















































Figure 3.4. Absorbance (Abs., solid lines, 10 µM) and emission (Em., dotted lines, 10 
nM) spectra of 44 (blue lines) and Flutax-2 (42, green lines) in PBS (pH 7.4) with  
DMSO (10%) and triton X-100 (0.5%) added to prevent aggregation. 
 
 To investigate the affinities of PB-Taxols, we quantified the fluorescence (fl.) 
enhancement upon binding to microtubules, which is a method used previously for 
Flutax-2 (Kd ~ 50–100 nM)18 and other fluorescent taxoids.55 To generate equilibrium 
binding curves, freshly prepared crosslinked microtubules18 were titrated into a low fixed 
concentration of the fluorescent probe (25 nM), followed by excitation of PB (405/30 nm 
excitation filter). Fluorescence emission of PB was then measured (LP 450 nm emission 
filter). Curve fitting was used to calculate Kd values of 34 ± 6 nM for PB-Gly-Taxol 43, 63 




Figure 3.5. Quantification of the affinity (Kd) of cross-linked microtubules for probes 43–
45 (25 nM) in GAB buffer (10 mM phosphate, 1 mM EDTA, 1 mM GTP, 3.4 M glycerol, 
pH 6.5) by enhancement of fluorescence upon binding. Protein concentration was 
based on monomeric tubulin. Dissociation constants (Kd) were calculated using a one-
site binding model in GraphPad Prism. Addition of Taxol (10 µM) blocked the increase in 
fluorescence of 43–45 upon binding to cross-linked microtubules, suggesting the 
increase in fluorescent signal was due to a specific interaction of 43–45 at the Taxol-
binding site. 
 
To attempt to rationalize differences in affinity, Flutax-2 and 43–45 were docked 
to the tubulin-binding site of a structure of beta tubulin56 (PDB 3J6G) using Autodock 
vina.57 These docking studies revealed that 7-substituted Taxols may bind this protein 
with a favorable insertion of the linked fluorophores (Figure 3.6) into a pocket near the 
Taxol-binding site. Whereas the reported affinity of Flutax-2 (Kd ~ 50–100 nM)18  for 
tubulin is quite similar to 44, the higher affinity of 43 was correlated with decreased 
linker length and flexibility. Although it was not possible to quantitatively support this 
computationally using Autodock vina, these results could be consistent with a reduction 
in affinity associated with conformational restriction of longer and more flexible linkers 
upon binding of PB to the same pocket. Compared to highly polar fluorophores such as 
Oregon Green, we hypothesized that the greater ‘drug-like’ properties of Pacific Blue, 
such as its low molecular weight, modest polarity, and limited number of H-bond donors 
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and acceptors, might further enhance the association of PB-Taxols with tubulin in living 
cells. 
 
Figure 3.6. Comparison of a cryo-EM structure of paclitaxel (41) bound to beta tubulin 
(PDB 3J6G,56 panel A) with models of 42 (panel B) and 44 (panel C) generated by 
docking with Autodock vina. Low energy poses of 42 and 44 with high similarity to the 





3.4. Confocal laser scanning microscopy of HeLa cells treated with fluorescent 
Taxol derivatives 
 To examine the subcellular distribution of PB-Taxols, we first treated HeLa cells 
with 44 (1 µM) and increasing concentrations of the P-gp inhibitor verapamil (Figure 3.7, 
panel C),58 since paclitaxel is a known substrate of this efflux pump.59 Confocal 
microscopy (Figure 3.7, panel A) revealed that verapamil increased the intracellular 
concentration of 44 in a dose dependent manner, and when verapamil was present in 
concentrations above 1 µM, the microtubules of HeLa cells were readily stained blue 
fluorescent. Flow cytometry was further used to quantify the effect of verapamil on the 
accumulation of 44. When treated with 44 (1 µM) and verapamil (25 µM), HeLa cells 
accumulated ~ 8-fold more blue fluorescence than those treated with 44 (1 µM) alone. 
Additionally, when HeLa cells were treated with 43 (1 µM, Figure 3.8, panels A and B), 
44 (Figure 3.8, panels C and D), and 45 (Figure 3.8, panels E and F) in the presence 
and absence of verapamil (25 µM), similar staining patterns were observed, indicating 
that each of the PB-Taxols strongly bind to tubulin in living HeLa cells. All three PB-
Taxols were readily effluxed from cells in the absence of verapamil, suggesting that they 
are all substrates of P-gp.  
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Figure 3.7. Verapamil enhances specific staining of microtubules by 44 in a dose 
dependent manner in HeLa cells. A: Confocal laser scanning (Ex. 405 nm, Em. 425-500 
nm) and DIC micrographs of living HeLa cells treated with 44 (1 µM) and verapamil for 1 
h at 37 °C.  The concentrations of verapamil are increased from left to right (from 0, 0.1, 
1, 10, 25 µM). B: Quantification of the intensity of blue fluorescence of HeLa cells by 
flow cytometry (Ex. 405 nm, Pacific Blue emission channel, 450/40 nm) after treatment 
with 44 (1 µM) in the presence (shaded blue) and absence (shaded grey) of 25 µM 
verapamil. An 8-fold increase was observed upon treatment with verapamil. C: Structure 




Figure 3.8. Confocal laser scanning and DIC micrographs of living HeLa cells treated 
with 43-45 (1 µM) in the presence (Panels B, D, F) or absence (Panels A, C, E) of 
verapamil (25 µM) for 1 h at 37 °C.   
 
 
3.5. Cellular toxicity of PB-Taxols in the presence and absence of verapamil  
  To compare the cytotoxicity profile of the blue fluorescent PB-Taxols with 
paclitaxel (41) and the green fluorescent Flutax-2 (42), HeLa cervical carcinoma cells 
(Figure 3.9, panel A), PC-3 prostate cancer cells (Figure 3.9, panel B), and Jurkat 
lymphocytes (Figure 3.9, panel C) were treated with paclitaxel (41) and compounds 42–
45 for 48 h. The cells were treated with or without verapamil (25 µM) to evaluate the 
effect of inhibition of P-gp. Among the fluorescent probes, compound 43, bearing a 
glycine-derived linker, proved to be the most toxic in the presence and absence of 
verapamil (e.g. IC50 = 31 nM against Jurkat cells), which was consistent with its superior 
affinity in vitro. Additionally, this glycine derivative (43) most closely paralleled the 
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activity of paclitaxel when P-gp was inhibited, such as a ~2-fold change in toxicity 
towards HeLa cells. As additional controls, verapamil did not appreciably affect the 
toxicity of paclitaxel or 43 towards PC-3 cells60 and Jurkat lymphocytes,61 which do not 
express high levels of P-gp. Interestingly, 44 and 45 appear to be better substrates for 
P-gp than the other compounds tested, with 4–10 fold changes observed in the 
presence and absence of verapamil. However, it should be noted that this increase 
could be due to other non-P-gp mediated effects of verapamil. From these studies, 43 
and 44 were shown to be substantially more toxic derivatives of paclitaxel than the more 
polar Flutax-2. Consequently, 43 may provide a more useful fluorescent tool to study the 




Figure 3.9. Analysis of cytotoxicity by flow cytometry. The cancer cell lines HeLa (A), 
PC-3 (B), and Jurkat (C) were treated with Taxol (41), Flutax-2 (42), Taxol-Gly-PB (43), 
Taxol-βAla-PB (44) and Taxol-GABA-PB (45) for 48 h in the absence (left) or presence 
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(right) of verapamil (25 µM). Of the three lines, HeLa cells are reported to express P-gp. 
Under these conditions, verapamil was non-toxic below 1 mM.  
 
 
3.6. PB-taxols label microtubules with greater specificity than Flutax-2 in live cells 
Given the substantial difference in toxicity between the PB-Taxols and Flutax-2, 
especially in the presence of verapamil, we sought to examine whether these probes 
exhibit differences in specificity in binding to microtubules. Upon treatment of HeLa cells 
with verapamil (25 µM), 42 (5 µM), and 44 (1 µM), co-localization studies revealed that 
PB-Taxol (44, Figure 3.10, panel A, false colored red) specifically binds microtubules in 
HeLa cells while the commercially available Flutax-2 (42, Figure 3.10, panel A, false 
colored green) stains particular organelles that did not co-localize with PB-Taxol in 
addition to staining microtubules. Further co-localization studies with dyes that traffic to 
particular organelles within the cell found that some of the green fluorescence of Flutax-
2 that does not co-localize well with 44 co-localizes with Nile Red (Figure 3.10, panel B, 
false colored red), a dye known to stain lipid droplets.62 The lower specificity of Flutax-2 
for microtubules, and its high polarity, which likely limits cellular permeability, likely 




Figure 3.10. Confocal laser scanning and DIC micrographs of HeLa cells treated with A: 
44 (1 µM) and Flutax-2 (5 µM) or B: Flutax-2 (42, 5 µM) and Nile Red (0.5 µM) for 1 h at 
37 °C in the presence of verapamil (25 µM). 
 
3.7. PB-Taxol 44 is a substrate of P-glycoprotein  
 We sought to investigate the mechanism underlying the profound effect of 
verapamil on the cellular fluorescence and cellular toxicity of 44 in HeLa cells. Given 
that P-glycoprotein is known to be inhibited by verapamil, we further studied PC-3 cells, 
which have low levels of expression60 of this transporter. To specifically introduce P-gp, 
PC-3 cells were transiently transfected with a plasmid expressing this protein fused to 
the green fluorescent protein EGFP (pHaMDR-EGFP, Figure 3.11, panel B). In the 
absence of P-gp (Figure 3.11, panel A) microtubules were strongly stained by treatment 
with 44 (1 µM). However, in transfected PC-3 cells (Figure 3.11, panel B, false colored 
green), a decrease in fluorescence was only present in cells that express the green 
fluorescent P-gp, consistent with high specificity of efflux by this transporter. Staining of 
microtubules in these transfected cells was rescued by treatment with verapamil (Figure 
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3.11, panel C), providing strong evidence that 44 is a substrate of P-gp-mediated efflux, 
and verapamil blocks this transporter activity.  
 
 
Figure 3.11. Confocal and DIC micrographs of PC-3 cells treated with PB-Taxol 44. A: 
PC-3 cells treated with 44 (1 µM) for 1 h. B: PC-3 cells transiently transfected with 
pHaMDR-EGFP plasmid for 48 h and then treated with 44 (1 µM) for 1 h. C: PC-3 cells 
transiently transfected with pHaMDR-EGFP plasmid for 48 h and treated with 44 (1 µM) 
and verapamil (25 µM) for 1 h.  
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 To further investigate the potential of 44 in MDR assays relevant to drug 
discovery, we utilized HCT-15 cells, which are reported to express high levels of P-gp.44, 
63 Efflux by P-gp was studied with three commonly used assay platforms: confocal 
microscopy,64, 65 flow cytometry,63, 66, 67 and with a fluorescence microplate reader.45, 46 
We additionally compared 44 with two commonly used substrates of drug efflux, 




Figure 3.12. Comparison of 44 with commercial fluorescent probes of efflux by P-gp. 
HCT-15 cells that overexpress P-gp were treated with 44 (5 µM, top row), Rho123 (1 
µM, middle row), and DiOC2(3) (1 µM, bottom row) in the presence and absence of 
verapamil (25 µM) for 1 h at 37 °C. A and B: Confocal micrographs in the absence and 
presence of verapamil, respectively. C: Quantification of the intensity of blue 
fluorescence (44, Pacific Blue emission channel, 450/40 nm) or green fluorescence 
(Rho123, DiOC2(3), FITC emission channel, 530/30) by flow cytometry. D: Structures of 
Rhodamine 123 and DiOC2(3).  
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 HCT-15 cells were treated with 44 (5 µM), Rho123 (1 µM), and DiOC2(3) in the 
presence (Figure 3.12, panel B) and absence (Figure 3.12, panel A) of verapamil (25 
µM) and imaged by confocal laser scanning microscopy. For all three efflux substrates, 
a significant decrease in the amount of probe taken up by the cells was observed when 
verapamil was not present. Upon further inspection, staining with Pacific Blue was less 
intense and more uniform than the other two dyes in cells not treated with verapamil. 
This effect is also seen by flow cytometry, which shows a major fluorescent side 
population in cells treated with DiOC2(3) (Figure 3.12, panel C, bottom row), and a 
broad fluorescence profile in cells treated with Rho123 (Figure 3.12, panel C, middle 
row). In contrast, 44 shows a more uniform fluorescence profile, and a large shift 
between cells treated with or without verapamil (Figure 3.12, panel C, top row). 
Additionally, Table 3.1 shows the calculated MDR Activity Factor (MAF) and MDR 
Activity Ratio (MAR) for each efflux substrate. 44 has higher MAF and MAR values than 




Table 3.1. Efflux assay parameters, measured by flow cytometry. HCT-15 cells were 
treated with 44 (5 µM), Rho123 (1 µM), and DiOC2(3) (1 µM) in the presence and 
absence of verapamil (25 µM) for 1 h at 37 °C. The MDR Activity Factor (MAF) was 
calculated using the following formula: MAF = 100 x ((MFI1 – MFI0)/MFI1), where MFI1 is 
the mean fl. intensity measured in the presence of verapamil, while MFI0 is the mean fl. 
intensity measured in the absence of verapamil.69 The MDR Activity Ratio (MAR) was 
calculated using the following formula: MAR = MFI1/ MFI0. 
 
  
MDR Activity  
Factor (MAF) MDR Activity Ratio  
PB-βAla-Taxol (44) 82 ± 3 5.5 ± 0.4 
Rho123 75 ± 2 4.0 ± 0.1 
DiOC2(3) 77 ± 1 4.3 ± 0.2 
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We further tested the utility of these assays in a 96-well plate format on a 
Packard Fusion Microplate Reader. To investigate this approach, we treated HeLa cells 
(trypsinized prior to assay), HCT-15 cells (trypsinized prior to assay), and Jurkat cells 
with 44 in the presence or absence verapamil for 30 min. The cells were centrifuged, 
washed with cold PBS to remove any remaining fluorophore not accumulated by cells, 
and resuspended in cold PBS for detection of fluorescence on the microplate reader 
(Ex. filter: 405/30 nm, Em. filter: LP 450 nm). Although changes in fluorescence were 
subtle in comparison to those measured by flow cytometry or confocal microscopy in the 
presence (Figure 3.13, shaded blue) and absence (Figure 3.13, shaded grey) of 
verapamil, MAF values of 28 ± 3 for HeLa cells, 30 ± 11 for HCT-15 cells, and 0 for 
Jurkat cells parallels observed differences in cellular toxicity and reported expression 
levels of P-gp for HCT-15 cells44 and Jurkat lymphocytes.61 These results suggest that 
44 could be used in high-throughput P-gp efflux assays in a microplate reader format.  
	
Figure 3.13. Fluorescence intensity measurements of probe 44 detect efflux by P-gp on 
96-well plates. HeLa, HCT-15, and Jurkat cells were treated with 44 (1 µM for HeLa and 
Jurkat, 5 µM for HCT-15) in the presence (shaded blue) and absence (shaded grey) of 
verapamil (25 µM) for 30 min at 37 °C. Jurkat cells provide a negative control line that 
does not express P-gp. p-Values for HeLa: <0.0001 (****) and HCT-15: p < 0.02 (**) 
were calculated using a t test in GraphPad Prism. 	
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3.8. Conclusions 
 We designed and synthesized derivatives of paclitaxel (Taxol) linked to the small 
coumarin-derived fluorophore Pacific Blue (Taxol-PBs). Imaging by confocal microscopy 
in the presence of the P-gp inhibitor verapamil revealed that Taxol-PBs bind 
microtubules in HeLa cells with substantially higher specificity than the commercially 
available green fluorescent taxoid Flutax-2. Moreover, whereas Taxol exhibits anti-
cancer activity at low nanomolar concentrations against many cell lines, and Flutax-2 is 
of low toxicity towards cells in culture, Taxol-PBs show substantially higher cytotoxicity 
in the absence of P-gp, making them potentially better probes of the anticancer 
mechanisms of this drug. In particular, 43, the glycine-linked derivative showed high 
toxicity and similar efflux properties when compared to the parent drug, making it one of 
the best fluorescent mimics described to date.  
 Efflux of PB-Taxols mediated by P-gp was examined in detail. Using verapamil, a 
known inhibitor of P-gp, a dose-dependent increase in accumulation of blue 
fluorescence in cells expressing P-gp was observed. To confirm the specificity of these 
compounds as substrates of P-gp, PC-3 cells were transfected with a plasmid encoding 
this transporter protein. Consistent with high specificity, efflux of the fluorescent taxoid 
was only observed in transfected cells as imaged by confocal microscopy. Furthermore, 
44 proved to be more sensitive than two commonly used efflux substrates in both 
confocal microscopy and flow cytometery efflux assays. Collectively, these studies 
revealed that the biological properties of Taxol-PBs are more similar to Taxol than other 
widely used fluorescent taxoids, and these probes may be useful tools for studies of the 
proliferation rate paradox associated with paclitaxel and efflux by P-gp.  
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3.9. Experimental 
3.9.1. General experimental section 
Chemicals were purchased from Sigma Aldrich, Acros Organics, Alfa Aesar, Oakwood 
Chemical, or Chem-Impex International. 1H NMR and 13C NMR were acquired on an 
Avance AVIII 500 MHz instrument. For 1H and 13C, chemical shifts (δ) are reported in 
ppm referenced to CDCl3 (7.26 ppm for 1H and 77.2 ppm for 13C) or DMSO-d6 (2.50 
ppm for 1H, 39.5 ppm for 13C). 1H coupling constants (JHH, Hz) and 13C coupling 
constants (JCF, Hz) are reported as: chemical shift, multiplicity (s = singlet, d = doublet, t 
= triplet, m = multiplet, dd = doublet of doublets, ddd = doublet of doublet of doublets, dq 
= doublet of quartets, dt = doublet of triplets, ddt = doublet of doublet of triplets), 
coupling constant, and integration. High Resolution Mass Spectra (HRMS) were 
obtained at the Mass Spectrometry Laboratory at the University of Kansas on a 
Micromass LCT Premier. Thin layer chromatography (TLC) was performed using EMD 
aluminum-backed (0.20 mm) silica plates (60 F-254), and flash chromatography used 
ICN silica gel (200-400 mesh). TLC plates were visualized with a UV lamp. Preparative 
HPLC was performed with an Agilent 1200 instrument equipped with a Hamilton PRP-1 
reverse phase column (250 mm length, 21.2 mm ID, 7 µm particle size) with detection 
by absorbance at 215, 254, 370, and 488 nm. All non-aqueous reactions were carried 
out using flame- or oven-dried glassware under an atmosphere of dry argon or nitrogen. 
Tetrahydrofuran (THF), dichloromethane (CH2Cl2), and N,N-dimethylformamide (DMF) 
were purified via filtration through two columns of activated basic alumina under an 
atmosphere of Ar using a solvent purification system from Pure Process Technology 
(GlassContour). Other commercial reagents were used as received unless otherwise 
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noted. Absorbance spectra were obtained using semimicro (1.4 mL) UV quartz cuvette 
(Sigma-Aldrich, Z27667-7) on an Agilent 8452A diode array spectrometer. 
Measurements for molar extinction coefficients were preformed using semimicro (1.4 
mL) UV quartz cuvette (Sigma-Aldrich, Z27667-7). Molar extinction coefficients (ε) in 
PBS (10 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl, 1.8 mM KH2PO4,	 pH 7.4) 
containing 10% DMSO and 0.5% triton X-100 were calculated from Beer’s Law plots of 
absorbance λmax versus concentration as shown in Figure 3.14. Linear least squares 
fitting of the data (including a zero intercept) was used to determine the slope 
(corresponding to ε). Values (M-1 cm-1) were calculated as follows: Absorbance = ε 
[concentration (M)] L, where L = 1 cm. Fluorescence spectra were acquired using a 
SUPRASIL ultra-micro quartz cuvette (PerkinElmer, B0631079) on a Perkin-Elmer LS55 
Fluorescence Spectrometer (10 nm excitation slit width).  
 
3.9.2. Biological assays and protocols 
Cell culture: HeLa cells, obtained from ATCC (CCL-2), were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, Sigma D6429). PC-3 cells were a gift from Dr. 
Matthew Levy (Albert Einstein College of Medicine) and were cultured in DMEM/Ham’s 
F-12 medium (Sigma 8437). Jurkat lymphocytes (human acute leukemia, ATCC #TIB-
152) and HCT-15 cells (ATCC CCL-225, gift from Dr. Liang Xu, University of Kansas) 
were cultured in RPMI-1640 medium (Sigma R8758). All media was supplemented with 
fetal bovine serum (FBS, 10%), penicillin (100 units/mL), and streptomycin (100 µg/mL) 
and incubated in a humidified 5% CO2 incubator at 37 °C unless otherwise noted.  
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Transient transfection of PC-3 cells: The plasmid pHaMDR-EGFP was a gift from Dr. 
Michael M. Gottesman (National Cancer Institute). Prior to transfection, PC-3 cells in 
DMEM/Ham’s F-12 were seeded onto an 8-well cover glass slide (Ibidi µ-Slide, 300 µL, 
10,000 cells/well) and allowed to proliferate for 16 h at 37 °C. To form a DNA complex, 
the plasmid DNA (2 µg) was incubated at 22 °C with the DNA transfection reagent X-
tremeGENE HP (2 µL, Roche) in serum free DMEM medium (200 µL). After 30 min, the 
DNA complex (20 µL) was added to each well. The cells were further incubated at 37 °C 
for 48 h. After transfection, the cells were washed with medium, further treated with 
probes, and analyzed by confocal microscopy. 
 
Confocal microscopy: Cells were added to an 8-well cover glass slide (Ibidi µ-Slide, 
300 µL, 20,000 cells/well) and allowed to proliferate for 24 h prior to addition of 
compounds. Compounds in DMSO stock solutions were serially diluted 1,000-fold with 
complete media (final concentration of 0.1% DMSO) prior to addition to cells. Cells were 
treated with compounds at 37 °C for a specified time before imaging by a Leica SPE2 
confocal laser-scanning microscope with a 63X oil-immersion objective. Taxol-PB 
analogues 43–45 were excited with a 405 nm laser and emitted photons were collected 
from 425-500 nm. Flutax-2 (42) was excited with a 488 nm laser and emitted photons 
were collected from 500-600 nm. Nile Red (Sigma, 72485) was excited with a 532 nm 
laser and emitted photons were collected from 600-700 nm. Identical laser power and 
PMT gain settings were used for all samples in a given figure to accurately assess 
differences in cellular fluorescence between the samples.  
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Cellular toxicity: HeLa cells were seeded on a 48-well plate in complete DMEM at 
20,000 cells / 500 µL per well 16 h prior to treatment. All compounds were serial diluted 
in DMSO and added to media to achieve a 1:1000 dilution factor (0.1% DMSO in each 
well). The original media was removed from all wells by aspiration and replaced with 
treatment media (330 µL) at the concentrations indicated. Plates were incubated for 48 
h at 37 °C and cells were analyzed in triplicate. Following this incubation period, the 
media was aspirated and wells were washed with PBS (phosphate-buffered saline, pH 
7.4). Wells were further treated with trypsin EDTA solution (50 µL) at 37 °C for 5 min 
followed by complete DMEM (100 µL) containing propidium iodide (PI, 4.5 µM). The 
total cell count for each well was determined by flow cytometry (Accuri C6) using light 
scattering and PI staining to identify populations of live cells. Counts of viable cells for 
each treatment were used to generate dose-response curves that were fitted by non-
linear regression inhibitor vs. response variable slope 4-parameter model (GraphPad 
Prism 6) to determine IC50 values. PC-3 cells were seeded as described previously with 
HeLa cells with the exception that DMEM/Ham’s F-12 medium was used. Jurkat 
lymphocytes were seeded in RPMI at 50,000 cells / 330 µL per well 16 h prior to 
treatment. The compounds were spiked into each well without replacing the medium. 
After 48 h incubation at 37 °C, PI (0.33µL of 3mM solution in PBS) was added to each 
well, and the cells were analyzed by flow cytometry as described previously. 
 
Efflux assay measured By flow cytometry:  Trypsinized HCT-15 or HeLa cells (1 x 
106 cells/mL) were incubated in suspension with 44 (HeLa, 1 µM; HCT-15, 5 µM), 
Rho123 (HCT-15, 1 µM), or DiOC2(3) (HCT-15, 1 µM) and either DMSO (0.2%) or 
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verapamil (25 µM) for 1 h at  37 °C. After incubation, cells were centrifuged at 2000 rpm 
for 2 min. The supernantent was removed and cells were resuspended in PBS (2% 
BSA) and placed on ice until FACS analysis. FACS analysis was preformed on a BD 
FACS Aria Fusion instrument equipped with 405 and 488 nm lasers. 10,000 cells were 
counted for each sample and each condition was tested in triplicate. Data for 44 was 
collected under a Pacific Blue filter (450/40 nm) and Rho123 and DiOC2(3) data was 
collected under a FITC filter (530/30 nm). FACS data was analyzed by gating cell 
populations based on untreated cells. The MDR Activity Factor (MAF) was calculated 
using the following formula: MAF = 100 x ((MFI1 – MFI0)/MFI1), where MFI1 is the mean 
fl. intensity measured in the presence of verapamil, while MFI0 is the mean fl. intensity 
measured in the absence of verapamil.69 The MDR Activity Ratio (MAR) was calculated 
using the following formula: MAR = MFI1/ MFI0. 
 
Efflux assay measured using a microplate reader:  Trypsinized HCT-15 or HeLa 
cells (2 x 106 cells/mL) were incubated in a Corning 96-well solid black polystyrene 
microplate in suspension with 44 (HeLa and Jurkat, 1 µM; HCT-15, 5 µM) and either 
DMSO (0.2%) or verapamil (25 µM) for 30 min at  37 °C. After incubation, cells were 
centrifuged at 800 rpm for 4 min. The supernatant was removed and cells were 
resuspended in cold PBS (2% BSA) and centrifuged at 800 rpm for 4 min again (wash 
step). The cells were resuspended in cold PBS (2% BSA) and fl. intensity data was 
acquired on a Packard Fusion Microplate Reader equipped with Pacific Blue excitation 
(405/30 nm) and emission filters (LP 450 nm). Each condition was run in quadruplicate. 
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Background fl. of untreated cells was subtracted from each sample before analysis. The 
MDR Activity Factor (MAF) was calculated as described above. 
 
Preparation of cross-linked microtubules: Following a previously published18 
protocol, microtubules were stabilized against disassembly for use in binding studies. 50 
mM tubulin in GAB buffer (10 mM phosphate, 1 mM EDTA, 1 mM GTP, 3.4 M glycerol, 
pH 6.5) was incubated at 37 °C for 30 min to allow assembly to occur, and then 20 mM 
glutaraldehyde was added and the solution was incubated at 37 °C for 10 min more to 
complete the cross-linking event. The reaction was quenched by the addition of 60 mM 
NaBH4 on ice.  
 
Determination of Kd values by fluorescence enhancement of Pacific Blue: 
Fluorescence (fl.) intensity data was acquired using a Corning 96-well solid black 
polystyrene microplate on a Packard Fusion Microplate Reader equipped with excitation 
(405 nm) and emission filters (450 nm). Different concentrations of the cross-linked 
microtubules, chosen to span a range of at least 20% to 80% complexation, were 
incubated with fixed concentrations of 43–45 (25 nM) in GAB (10 mM phosphate, 1 mM 
EDTA, 1 mM GTP, 3.4 M glycerol, pH 6.5) at 22 °C with shaking for 1 h. These fixed 
probe concentrations were chosen to be substantially below the predicted Kd values to 
assure equilibrium binding measurements. Measurements of fluorescence (Isample) were 
recorded for each sample. Average fluorescence (Imt) intensities of the background 
signal microtubules alone were calculated by averaging three sample intensities for 
each concentration of microtubules. Average fluorescence (If) intensities of the free 
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ligand were calculated by averaging three sample intensities of the Pacific Blue probe in 
GAB. Background-subtracted fluorescence (I) signals were calculated using the 
following equations:  
! =  !!"#$%& − !!" 
 
The change in fl. intensity for each sample was calculated by subtracting the average 
(n=6) fl. of the free ligand (If). The change in fl. intensity was plotted against the 
concentration of tubulin, and a one-site specific binding model (GraphPad Prism 6.0) 
was used for curve fitting to calculate a dissociation constant (Kd). 
 
Figure 3.14. Determination of extinction coefficients of 43–45 in PBS (pH 7.4) 
containing DMSO (10%) and triton X-100 (0.5%). 
 
3.9.3. Synthetic procedures and compound characterization data 
General procedure 3A: Synthesis of paclitaxel derivatives 47–49. Fmoc-amino acid 
derivatives (4 eq), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 
















43, ε415 = 24,300 M-1cm-1
44, ε415 = 23,300 M-1cm-1
45, ε415 = 24,100 M-1cm-1
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4 eq.), and 4-dimethylaminopyridine (DMAP, 0.5 eq) were stirred in anhydrous CH2Cl2 
at 22 °C for 15 min. 41 was added, and the reaction mixture was stirred for 16 h. The 
mixture was diluted with CH2Cl2 (75-175 mL) and washed with saturated aqueous 
NH4Cl (50-100 mL x 1), water (25-50 mL x 1) and satd. aqueous NaCl (25-50 mL x 1). 
The organic layer was collected, dried over anhydrous Na2SO4 and purified by column 
chromatography (silica, eluent: 97:3 CH2Cl2/MeOH).  
General procedure 3B: Synthesis of Paclitaxel derivatives 43 and 45. Tetra-N-
butylammonium fluoride in THF (TBAF, 1.0 M, 2 eq.) was added to a solution of 50 or 
52 (1 eq.) in THF (0.5 mL) and stirred at 22 °C for 90 min. The reaction was 
concentrated, the residue was dissolved in DMSO (1.5 mL), and the product purified by 
preparative RP-HPLC (Gradient: H2O:CH3CN (9:1) to (0:100) with added TFA (0.1%) 
over 20 min; elution time = 16-17 min). Pure fractions were collected, combined, and 









methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate (46). This 













solution of paclitaxel (41, 500 mg, 0.59 mmol) in anhydrous DMF (2.1 mL) at 22 °C were 
added imidazole (208 mg, 3.06 mmol) and tert-butyldimethylchlorosilane (542 mg, 3.61 
mmol). After stirring for 16 h, the mixture was diluted with CH2Cl2 (175 mL) and washed 
with saturated aqueous NH4Cl (100 mL x 1), water (50 mL x 1) and satd. aqueous NaCl 
(50 mL x 1). The organic layer was collected, dried over anhydrous Na2SO4 and 
concentrated. The residue was triturated with hexane to afford 46 as a white solid (536 
mg, 95%). 1H NMR (500 MHz, CDCl3) δ 8.18-8.10 (m, 2H), 7.74 (dt, J = 8.3, 1.4 Hz, 
2H), 7.64-7.45 (m, 4H), 7.45 - 7.36 (m, 4H), 7.32 (d, J = 7.3 Hz, 3H), 7.07 (d, J = 8.9 Hz, 
1H), 6.29 (s, 2H), 5.78-5.63 (m, 2H), 5.04-4.92 (m, 1H), 4.73-4.61 (m, 1H), 4.44 (dd, J = 
11.0, 6.6 Hz, 1H), 4.33 (d, J = 8.5 Hz, 1H), 4.22 (d, J = 8.5 Hz, 1H), 3.82 (d, J = 7.0 Hz, 
1H), 2.57 (d, J = 1.0 Hz, 3H), 2.40 (dd, J = 15.3, 9.5 Hz, 1H), 2.23 (t, J = 0.9 Hz, 3H), 
2.19-2.06 (m, 1H), 1.90 (t, J = 1.4 Hz, 3H), 1.69 (s, 3H), 1.24 (s, 3H), 1.13 (s, 3H), 0.80 
(t, J = 0.9 Hz, 9H), –0.02- –0.08 (m, 3H), –0.29 (d, J = 1.2 Hz, 3H); 13C NMR (126 MHz, 
CDCl3) δ 203.9, 171.49, 171.45, 170.3, 167.2, 167.0, 142.6, 138.4, 134.2, 133.8, 133.0, 
132.0, 130.4, 129.2, 128.9, 128.89, 128.86, 128.1, 127.1, 126.6, 84.6, 81.3, 79.3, 76.6, 
75.67, 75.3, 75.2, 72.3, 71.5, 58.7, 55.8, 45.6, 43.4, 35.9, 35.7, 26.9, 25.7, 23.2, 22.5, 











b]oxete-6,12b(2aH)-diyl diacetate (48). Following general procedure 3A, Fmoc-βAla-
OH (643 mg, 2.06 mmol) and 46 (500 mg, 0.52 mmol) yielded 48 (440 mg, 68%) as a 
white solid. 1H NMR (500 MHz, CDCl3) δ 8.17-8.11 (m, 2H), 7.79-7.73 (m, 4H), 7.68-
7.57 (m, 3H), 7.57-7.26 (m, 15H), 7.08 (d, J = 8.9 Hz, 1H), 6.31 (s, 1H), 5.89-5.59 (m, 
3H), 4.98 (dd, J = 9.6, 2.0 Hz, 1H), 4.68 (d, J = 2.2 Hz, 1H), 4.47-4.29 (m, 3H), 4.29-
4.15 (m, 2H), 3.99 (d, J = 6.8 Hz, 1H), 3.62-3.37 (m, 2H), 2.59 (s, 3H), 2.53 (dd, J = 4.9, 
2.3 Hz, 1H), 2.44 (dd, J = 15.2, 9.4 Hz, 1H), 2.21-2.12 (m, 2H), 2.10 (s, 3H), 1.99 (d, J = 
1.6 Hz, 3H), 1.84 (s, 3H), 1.73 (d, J = 4.8 Hz, 1H), 1.23 (s, 3H), 1.18 (s, 3H) 0.80 (s, 
9H), –0.03 (s, 3H), –0.30 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 202.4, 171.6, 171.5, 
170.1, 169.8, 167.1, 156.6, 144.20, 144.18, 141.4, 141.3, 138.4, 134.2, 133.9, 132.7, 
132.0, 130.4, 129.1, 129.0, 128.9, 128.1, 127.81, 127.75, 127.2, 127.1, 126.5, 125.3, 
125.2, 120.11, 120.05, 84.0, 81.0, 78.8, 76.5, 75.5, 75.2, 74.6, 71.7, 71.4, 66.7, 56.2, 
55.8, 47.4, 47.4, 46.8, 43.4, 36.2, 35.8, 34.4, 33.6, 26.5, 25.7, 23.2, 21.6, 20.9, 18.3, 























7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate (51). To a 
solution of 20% piperidine in DMF (2 mL) was added 48 (100 mg, 0.079 mmol) at 22 °C. 
The mixture was stirred for 10 min and concentrated. The intermediate was taken on 
without further purification. To a solution of the Fmoc-deprotected-48 in DMF (2 mL) 
was added Pacific Blue-NHS ester (15, 32 mg, 0.094 mmol) and DIEA (69 µL, 0.397 
mmol). After stirring for 16 h, the reaction mixture was concentrated and purified by 
column chromatography (silica, eluent: 290:9:1 CH2Cl2/MeOH/AcOH) to yield compound 
51 (80 mg, 80%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.94 (t, J = 6.0 Hz, 1H), 
8.71 (d, J = 1.3 Hz, 1H), 8.18-8.06 (m, 2H), 7.82-7.71 (m, 2H), 7.62-7.55 (m, 1H), 7.55-
7.28 (m, 10H), 7.19-7.08 (m, 2H), 6.27 (d, J = 17.6 Hz, 2H), 5.83-5.60 (m, 3H), 5.05-
4.95 (m, 1H), 4.68 (d, J = 2.1 Hz, 1H), 4.35 (d, J = 8.5 Hz, 1H), 4.21 (d, J = 8.3 Hz, 1H), 
3.98 (d, J = 6.8 Hz, 1H), 3.83 - 3.61 (m, 2H), 2.70-2.60 (m, 3H), 2.59 (s, 3H), 2.42 (dd, J 
= 15.3, 9.4 Hz, 1H), 2.20-2.15 (m, 1H), 2.15 (s, 3H), 1.98 (d, J = 1.5 Hz, 3H), 1.92 (ddd, 
J = 14.2, 10.9, 2.1 Hz, 1H), 1.83 (s, 3H), 1.76 (s, 1H), 1.22 (s, 3H), 1.16 (s, 3H), 0.80 (s, 





















170.1, 169.3, 167.5, 167.0, 161.5, 159.9, 149.1 (dd, J = 243.7, 3.9 Hz), 147.5, 141.1, 
139.7 (d, J = 258.4 Hz), 139.7 (d, J = 8.9 Hz), 138.2, 138.2 (d, J = 6.4 Hz), 134.1, 133.9, 
132.7, 132.1, 130.3, 129.1, 128.94, 128.88, 128.1, 127.2, 126.5, 116.8, 110.3 (d, J = 8.9 
Hz), 109.8 (dd, J = 20.1, 3.4 Hz), 84.2, 81.1, 78.8, 76.6, 75.4, 75.2, 74.6, 71.8, 71.5, 
56.1, 55.9, 47.0, 43.5, 35.7, 35.4, 34.1, 33.4, 26.5, 25.7, 23.1, 21.5, 20.9, 18.3, 14.8, 









PB, 44). To a solution of 51 (50 mg, 0.040 mmol) in anhydrous THF (1 mL) at 22 °C 
was added a solution of TBAF in THF (1.0 M, 84 µL, 0.084 mmol). After stirring for 90 
min, the mixture was concentrated and purified by column chromatography (silica, 
1:9:290 AcOH/MeOH/DCM) to afford 44 as a yellow solid (44 mg, 97%). 1H NMR (500 
MHz, CDCl3) δ 9.03 (t, J = 6.0 Hz, 1H), 8.76 (s, 1H), 8.10 (d, J = 7.1 Hz, 2H), 7.77 (d, J 
= 7.1 Hz, 2H), 7.62 (ddt, J = 8.7, 7.0, 1.3 Hz, 1H), 7.55-7.27 (m, 10H), 7.21 (dd, J = 9.1, 





















(d, J = 6.9 Hz, 1H), 5.61 (dd, J = 10.5, 7.1 Hz, 1H), 4.95 (dd, J = 9.3, 1.8 Hz, 1H), 4.81 
(d, J = 2.6 Hz, 1H), 4.32 (d, J = 8.5 Hz, 1H), 4.19 (d, J = 8.3 Hz, 1H), 3.91 (d, J = 6.6 
Hz, 1H), 3.77 (dq, J = 12.6, 6.2 Hz, 1H), 3.65 (dq, J = 13.0, 5.9 Hz, 1H), 2.75-2.66 (m, 
1H), 2.66-2.50 (m, 2H) 2.37 (s, 3H), 2.35-2.27 (m, 1H)  2.11 (m, 1H), 1.94-1.80 (m, 2H), 
1.86-1.76 (m, 6H), 1.25 (s, 3H), 1.20 (s, 3H), 1.15 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
201.8, 172.4, 171.2, 170.5, 169.1, 167.4, 166.8, 161.6, 159.7, 149.0 (d, J = 242.9 Hz), 
147.5, 140.6 (d, J = 8.3 Hz), 140.5, 139.6, 139.0 (dd, J = 249.5, 4.9 Hz), 137.8, 133.8, 
133.5, 132.8, 132.0, 130.1, 129.0, 128.9, 128.7, 128.3, 127.13 127.08, 116.5, 110.2 (d, 
J = 8.8 Hz), 109.9 (d, J = 20.4 Hz), 84.0, 81.0, 78.5, 76.5, 75.4, 74.2, 73.3, 72.0, 71.8, 
56.1, 55.1, 47.1, 43.2, 36.7, 35.5, 35.2, 33.7, 33.3, 29.7, 26.5, 22.6, 20.7, 14.6, 10.9; 







methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate (47). Following 
general procedure 3A, Fmoc-Gly-OH (119 mg, 0.4 mmol) and 46 (97 mg, 0.1 mmol) 















Hz, 2H), 7.84-7.74 (m, 4H), 7.71-7.61 (m, 3H), 7.60-7.30 (m, 15H), 7.11 (d, J = 8.9 Hz, 
1H), 6.29 (t, J = 9.2 Hz, 1H), 6.23 (s, 1H), 5.84-5.68 (m, 3H), 5.54 (dd, J = 7.4, 4.7 Hz, 
1H), 5.07-4.97 (m, 1H), 4.70 (d, J = 2.1 Hz, 1H), 4.48-4.35 (m, 3H), 4.30 (t, J = 7.4 Hz, 
1H), 4.23 (d, J = 8.5 Hz, 1H), 4.17-4.08 (m, 1H), 3.99 (d, J = 7.0 Hz, 1H), 3.91-3.81 (m, 
1H), 2.60 (s, 3H), 2.45 (dd, J = 15.6, 9.1 Hz, 1H), 2.22 (s, 3H), 2.18 (d, J = 3.0 Hz, 1H), 
2.00 (s, 3H), 1.96-1.89 (m, 1H), 1.85 (s, 3H), 1.28 (s, 3H), 1.25 (s, 3H), 1.19 (s, 3H), 
0.83 (s, 9H), –0.01 (s, 3H), –0.27 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 202.0, 171.6, 
170.1, 170.1, 169.8, 167.2, 167.0, 156.9, 144.2, 144.0, 141.40, 141.38, 141.4, 138.3, 
134.2, 133.9, 132.5, 132.0, 130.4, 129.1, 129.0, 128.94, 128.91, 128.2, 127.79, 127.78, 
127.2, 127.1, 126.5, 125.47, 125.46, 125.4, 120.1, 84.0, 81.1, 78.70, 76.5, 75.8, 75.2, 
74.5, 72.1, 71.5, 67.4, 56.2, 55.8, 47.3, 47.0, 43.5, 43.2, 35.7, 33.44, 33.40, 29.8, 26.5, 
25.7, 23.1, 21.5, 21.1, 18.3, 14.8, 11.0, –5.1, –5.7; HRMS (ESI+) m/z 1269.4939 






methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate (50). To a 




















The mixture was stirred for 10 min and concentrated. The intermediate was taken on 
without further purification. To a solution of the Fmoc-deprotected-47 in DMF (0.5 mL) 
was added Pacific Blue-NHS ester (15, 5 mg, 0.015 mmol) and DIEA (6 µL, 0.034 
mmol). After stirring for 16 h, the reaction was concentrated under vacuum, and the 
crude product was dissolved in DMSO (2 mL) and purified by preparative reverse phase 
HPLC (gradient: 90/10 H2O/MeCN to 100% MeCN over 20 min with 0.1% TFA added; 
retention time = 19 min) to yield compound 50 (12 mg, 85%) as a yellow solid. HRMS 






b]oxete-6,12b(2aH)-diyl diacetate (Taxol-Gly-PB, 43). Following general procedure 
3B, 50 (10 mg, 0.008 mmol) yielded compound 43 (6 mg, 67%) as a yellow solid. 1H 
NMR (500 MHz, CDCl3) δ 9.09 (t, J = 5.9 Hz, 1H), 8.79 (d, J = 1.3 Hz, 1H), 8.16-8.07 
(m, 2H), 7.82-7.75 (m, 2H), 7.68-7.60 (m, 1H), 7.56-7.34 (m, 10H), 7.23 (dd, J = 9.2, 1.9 
Hz, 1H), 7.12 (d, J = 8.9 Hz, 1H), 6.19 (s, 1H), 6.17 (s, 1H), 5.82 (dd, J = 9.0, 2.5 Hz, 
1H), 5.69-5.61 (m, 2H), 5.00-4.94 (m, 1H), 4.82 (d, J = 2.6 Hz, 1H), 4.40-4.28 (m, 2H), 




















2H), 2.27 (s, 3H), 1.92 (ddd, J = 14.5, 10.6, 2.0 Hz, 1H), 1.82 (s, 3H), 1.80 (s, 3H), 1.24 
(s, 3H), 1.17 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 201.6, 172.5, 170.5, 170.0, 169.0, 
167.3, 167.0, 161.9, 159.6, 148.5 (d, J = 245.1 Hz), 147.8, 140.9, 140.8, 138.0, 135.3, 
134.0, 133.7, 132.9, 132.2, 130.4-130.1 (m), 129.2-129.1 (m), 129.1, 128.9, 128.9, 
128.5, 127.7-126.6 (m), 117.0, 110.7 (d, J = 9.3 Hz), 110.0 (d, J = 22.2 Hz), 84.0, 81.1, 
78.6, 76.5, 75.7, 74.3, 73.3, 72.6, 72.3, 56.2, 55.0, 47.2, 43.4, 42.1, 35.6, 33.4, 26.7, 








methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate (49). Following 
general procedure 3A, 4-(Fmoc-amino)butyric acid (130 mg, 0.4 mmol) and 46 (97 mg, 
0.1 mmol) yielded 49 (100 mg, 79%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 
8.16-8.11 (m, 2H), 7.79-7.73 (m, 4H), 7.63-7.58 (m, 3H), 7.56-7.29 (m, 15H), 7.09 (d, J 
= 8.8 Hz, 1H), 6.26 (dd, J = 9.0, 1.8 Hz, 1H), 6.24 (s, 1H), 5.84-5.65 (m, 3H), 5.59 (dd, J 















(m, 1H), 4.25-4.16 (m, 2H), 3.96 (d, J = 7.0 Hz, 1H), 3.41-3.12 (m, 2H), 2.58 (s, 3H), 
2.51-2.36 (m, 2H), 2.34-2.08 (m, 2H), 2.06 (s, 3H), 1.96 (d, J = 1.4 Hz, 3H), 1.83 (s, 3H), 
1.22 (s, 3H), 1.16 (s, 3H), 0.80 (s, 9H), –0.04 (s, 3H), –0.31 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 201.8, 172.3, 171.5, 170.2, 169.9, 167.1, 166.9, 156.5, 144.1, 141.32, 141.31, 
141.30, 141.1, 138.2, 134.1, 133.8, 132.4, 131.9, 130.2, 129.0, 128.81, 128.78, 128.0, 
127.9, 127.64, 127.61, 127.2, 127.1, 127.03, 127.00, 126.4, 125.4, 125.03, 125.02, 
119.95, 84.0 , 81.0, 78.6, 76.4, 75.5, 75.1, 74.5, 71.5, 71.3, 66.2, 56.0, 55.7, 47.4, 46.8, 
46.7, 46.5, 43.4, 39.3, 35.6, 33.4, 32.9, 29.9, 26.4, 25.5, 23.7, 23.0, 21.4, 20.7, 18.1, 







methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate (52). To a 
solution of 20% piperidine in DMF (1 mL) was added 49 (30 mg, 0.024 mmol) at 22 °C. 
The mixture was stirred for 10 min and concentrated. The intermediate was taken on 
without further purification. To a solution of the Fmoc-deprotected-49 in DMF (1 mL) 





















mmol). After stirring for 16 h, the reaction was concentrated under vacuum, and the 
crude product was dissolved in DMSO (2 mL) and purified by preparative reverse phase 
HPLC (gradient: 90/10 H2O/MeCN to 100% MeCN over 20 min with 0.1% TFA added; 
retention time = 19 min) to yield compound 52 (26 mg, 87%) as a yellow solid. HRMS 






b]oxete-6,12b(2aH)-diyl diacetate (Taxol-GABA-PB, 45). Following general 
procedure 3B, 52 (16 mg, 0.013 mmol) yielded compound 45 (13 mg, 86%) as a yellow 
solid. 1H NMR (500 MHz, CDCl3) δ 8.81 (t, J = 6.0 Hz, 1H), 8.73 (d, J = 1.5 Hz, 1H), 
8.11-8.05 (m, 2H), 7.80-7.73 (m, 2H), 7.63-7.56 (m, 1H), 7.53-7.28 (m, 11H), 7.16 (dd, J 
= 9.4, 2.0 Hz, 1H), 6.19 (s, 1H), 6.18-6.13 (m, 1H), 5.79 (dd, J = 9.0, 2.9 Hz, 1H), 5.65 
(d, J = 6.8 Hz, 1H), 5.54 (dd, J = 10.4, 7.2 Hz, 1H), 4.92 (dd, J = 9.6, 2.0 Hz, 1H), 4.81 
(d, J = 2.9 Hz, 1H), 4.30 (d, J = 8.5 Hz, 1H), 4.17 (d, J = 8.5 Hz, 1H), 3.89 (d, J = 6.7 
Hz, 1H), 3.53-3.39 (m, 2H), 2.64-2.50 (m, 1H), 2.46 (dt, J = 17.3, 7.2 Hz, 1H), 2.36 (s, 
3H), 2.31-2.26 (m, 3H), 2.17 (s, 3H), 2.00-1.84 (m, 2H), 1.81 (s, 3H), 1.79 (s, 3H), 1.36-





















172.5, 170.6, 169.4, 167.7, 166.9, 161.9, 160.2, 149.3 (dd, J = 244.4, 4.0 Hz), 147.9, 
140.8 (d, J = 9.5 Hz), 140.5, 140.1 – 139.9 (m), 139.2 (dd, J = 249.0, 5.9 Hz), 138.0, 
133.9, 133.6, 133.0, 132.2, 130.3, 129.14, 129.08, 128.85, 128.83, 128.4, 127.24, 
127.19, 116.4, 110.2 (d, J = 9.4 Hz), 110.0 (d, J = 20.1 Hz), 84.1, 81.1, 78.6, 76.6, 75.4, 
74.4, 73.4, 72.2, 71.6, 56.2, 55.3, 47.1, 43.3, 35.6, 33.5, 31.7, 31.3, 26.6, 24.1, 22.7, 








difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (53).  To a solution of  
piperidine in DMF (20%, 2 mL) was added 48 (10 mg, 0.010 mmol) at 22 °C. The 
mixture was stirred for 10 min and concentrated. The intermediate was taken on without 
further purification. To a solution of the Fmoc-deprotected intermediate in DMF (2 mL) 
was added Oregon Green-NHS ester (5 mg, 0.011) and DIEA (5 µL). After stirring for 16 
h, the reaction was concentrated under vacuum, and the crude product was dissolved in 























H2O/MeCN to 100% MeCN over 20 min with 0.1% TFA added; retention time = 18 min 
(488 nm)) to afford 53 as an orange solid (6 mg, 43%). HRMS (ESI+) m/z 1431.4731 






(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (Flutax-2, 42). 
Following general procedure 3B, 53 (4 mg, 0.0028 mmol) yielded compound 42 (3 mg, 
82%) as an orange solid. HRMS (ESI+) m/z 1319.4038 (M+H+, C71H65F2N2O21 requires 
1319.4048).  
 
Figure 3.15. Analytical HPLC profile of 42 after preparative HPLC. Retention time = 17 
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Targeted drug delivery is an area of study with great importance for cancer 
therapeutics both for limiting off-target effects (toxicity), as well as enhancing 
accumulation of the therapeutic at the target site. These types of drug delivery systems 
range from small molecules to polymeric nanoparticles, and numerous successful 
candidates have progressed to the clinic.1-4 Many targeted delivery systems utilize a 
specific mechanism of cellular internalization, receptor mediated endocytosis (RME), to 
efficiently transport the drug into the cells of interest. Nature utilizes RME for cellular 
entry of large molecular complexes that cannot passively diffuse or be pumped across 
the cellular membrane.5 As an example of this process, the mechanism of RME of low-
density lipoprotein (LDL) is shown in Figure 4.1. In this mechanism, LDL first binds to 
the LDL receptor on cell surfaces. Clathrin-coated pits on the plasma membrane 
containing receptor-ligand complexes pinch off to form vesicles in the cytosol. These 
vesicles fuse with acidic sorting endosomes. The decrease in pH facilitates the 
dissociation of receptors from ligands, and the receptor is recycled back to the cell 
membrane via the endocytic-recycling compartment. Sorting endosomes containing free 
LDL mature into late endosomes that fuse with lysosomes. Hydrolytic lysosomal 





Figure 4.1. Receptor-mediated endocytosis of low-density lipoprotein (LDL). 
 
Previous work in the Peterson group has focused on using cholesterol mimics as 
models for the development of targeted drug delivery systems.6-8 These cholesterol 
mimics can bind plasma membranes, accumulate in early endosomes, and undergo 
RME, similar to the trafficking of many natural cell surface receptors.9-12 By taking 
advantage of the trafficking of the cholesterol mimics, fluorescent cargo has been 
delivered to the endosomes of numerous cell types.13 These cholesterol mimics have 
been shown to recycle between early endosomes and the plasma membrane, and they 
generally do not traffic to lysosomes for degradation.6 However, in most cases, drugs 
must be efficiently delivered into the cytosol to reach the target site and manifest 
therapeutic effects. To combat this problem, the Peterson group developed a peptide 
linked to a mimic of cholesterol that selectively disrupts early/recycling endosomes 
(Figure 4.2, panel B).8 This peptide is a derivative of a previously published14 
membrane-lytic dodecapeptide termed PC-4. Early studies by our group showed that 
























fluorescent cargo into the cytoplasm of the cell. This cargo is derived from the polar 
fluorophore fluorescein, which upon release, is trapped in the cytosol of cells (Figure 
4.2, panel A). The proposed mechanism for the release was cleavage of the disulfide by 
reduced glutathione (GSH), which would enter the endosome following disruption of 




Figure 4.2. A: Proposed mechanism of release of fluorescent probe 54 upon disruption 
of early endosomes. B: Structure of the cholesterylamine-PC4 endosome disruptor (55), 
a fluorescent disulfide N-alkyl-3β-cholesterylamine (54) and the products of cleavage 
(56, 57). C: Confocal fluorescence and DIC micrographs8 of Jurkat lymphocytes treated 
for 12 h with (i) 54 (2.5 µM) and (ii) 54 (2.5 µM) + 55 (2 µM).  
 
Following our previously published8 studies of endosome disruption, the 
Peterson group has worked to improve the efficacy and reduce the toxicity of endosome 
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disruptive peptides, as well as examine their mechanism of action. Additionally, other 
targeted delivery systems have been explored utilizing improved endosome disruptive 
peptides. During his dissertation research, Dr. David Hymel characterized the delivery 
of endosome disruptors, fluorescent cargo, and toxins conjugated to antibodies, and this 
research continues to be actively pursued in the Peterson group.  
Antibody-drug conjugates (ADCs) are widely used in cancer chemotherapy, with 
over 55 currently in clinical trials.15 ADCs achieve antigen-specific delivery of potent 
cytotoxic agents to tumor cells that overexpress specific cell surface receptors.16-18 They 
have a complex structure that generally comprises three main parts: a small molecule 
drug (payload), an antibody, and a cleavable or non-cleavable linker.15 ADCs typically 
employ cytotoxic agents that are extremely potent and could otherwise not be used in 
an untargeted manner. The potency is critical, as only 1-2% of the administered ADC 
dose will reach a tumor cell, and therefore the intracellular levels of the drug will be 
low.19 The ideal antibody targets an antigen that is highly expressed across the tumor, 
with limited shedding and normal tissue expression, and is internalized via RME.20 
ADCs typically incorporate either non-cleavable linkers such as thioethers that require 
proteolytic degradation of the antibody, or cleavable linkers such as dipeptides, 
disulfides, or acid-labile hydrazones.15, 21 In recent years, second generation ADCs have 
emerged which focus on optimizing the stability of the linker in the bloodstream to 
ensure efficient and selective delivery of the cytotoxin to the target cell.22 
The redox potential of endosomes has been previously reported to vary from 
oxidizing (–240 mV, compared with a much more reducing value of –318 mV for 
mitochondria)23  to reducing,24, 25 but how these values relate to the release profiles of 
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structurally diverse disulfide conjugates that traffic through endosomes in a soluble or 
membrane-bound manner remains unclear. Endocytic disulfide cleavage could occur 
via enzymatic reduction (e.g. via soluble and membrane-bound glutathione-S-
transferases26), cell surface sulfhydryls,25, 27 and cleavage by small redox molecules 
(e.g. glutathione, cysteine). One extensively studied targeted delivery system involves 
folate conjugates that bind folate receptors, and therapeutics using this system have 
advanced to clinical trials for the treatment of cancer. Many of the conjugates 
developed, including EC145 (Figure 4.3, panel A), a current clinical candidate, 
incorporate a disulfide bond for release of a cytotoxic drug following internalization to 
target cancer cells via RME.28 Studying an analogous disulfide-linked system, Low and 
coworkers at Purdue Univ. developed a FRET-based assay using folate-linked 
BODIPY-FL and tetraethyl rhodamine (Figure 4.3, panel B) and found that after 
endocytosis, reduction of a disulfide occurred with a half time of 6 h in cell culture24 and 
4 h in mouse kidney tissue,29 providing evidence that the endosomes the folate receptor 
traffics through are reducing. However, in contradistinction, Austin et. al. at Genentech 
found that the disulfide bond linked to an anti-HER2 antibody was stable in breast 





Figure 4.3. Structures of the folate receptor-targeted disulfide-containing agents 
vintafolide (EC145) and a FRET reporter.24  
 
To gain a greater understanding of the stability of disulfides in endocytic 
compartments accessed by cholesterol mimics and targeting antibodies, we are 
investigating the cellular properties of disulfide-linked molecular probes comprising the 
novel FRET pair Pacific Blue and Pennsylvania Green. We initially reasoned that the 
low intrinsic affinity of these anionic fluorophores for cellular membranes might be well 
suited for non-perturbative studies of processes involving dynamic membrane trafficking 
in living cells. However, we later learned that the high hydrophobicity of Pennsylvania 
Green has disadvantages for studies of these types of probes, and additional FRET 
probes derived from the spectrally similar Oregon Green were investigated. In this 
Chapter, we report the synthesis of molecular probes derived from Pacific Blue, 
Pennsylvania Green, and Oregon Green, the efficiency of FRET between these anionic 
fluorophores, and their in vitro and cellular properties related to disulfide bond cleavage.  
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4.2. Characterization of Pacific Blue and Pennsylvania Green as a FRET pair 
In addition to using Pacific Blue (PB) as a FRET acceptor for tryptophan (Chapter 
2), we sought to investigate PB as a potential FRET donor to create new tools for 
chemical biology. As a complementary partner, Pennsylvania Green was of interest as a 
potential FRET acceptor. This hydrophobic derivative of fluorescein exhibits high 
photostability and is insensitive to changes in pH in a wide range of biological 
microenvironments, similar to Pacific Blue.30, 31 Pennsylvania Green is also 
advantageous because the Peterson group has developed an efficient multigram 
synthesis of 4-Carboxy-Pennsylvania Green (PG, 58).32 The extent of spectral overlap 
J(λ), measured as the area under the overlapping sections of the emission spectra of 
the donor (PB) and the absorbance spectra of the acceptor (PG), was determined. As 
highlighted in grey (Figure 4.4, J(λ)), the substantial spectral overlap indicates these two 
fluorophores could be a complementary FRET pair. The calculated Förster distance for 
this FRET pair is 47.4 Å, similar to other previously reported blue-green FRET pairs.33, 34 
 
 
Figure 4.4. Absorbance (Abs., solid lines) and emission (Em., dotted lines) spectra of 
PB (5, blue lines) and PG (58, green lines) in PBS (pH 7.4). The spectral overlap 
integral (J(λ)) critical for FRET is shaded grey. 
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 To characterize the FRET efficiency of the PB-PG FRET pair, we first synthesized 
a simple FRET probe (59, Figure 4.5) that links the two fluorophores through a disulfide 
bond that can be cleaved by reduction. As illustrated in Figure 4.5 (panel A), before the 
addition of a reductant, the disulfide bond should be intact, and the two fluorophores in 
close proximity to one another. Consequently, when excited at 400 nm, energy transfer 
from PB to PG should occur, and fluorescent photons should be emitted at > 520 nm. 
However, after the addition of a reductant such as dithiothreitol (DTT) or glutathione 
(GSH), the disulfide bond should be cleaved. Following cleavage, the two fluorophores 
would diffuse away from one another in solution, preventing energy transfer between 
the fluorophores. When the disulfide is reduced, excitation at 400 nm would then reveal 
only fluorescence from PB, emitting maximally at ~460 nm.  
 To calculate the FRET efficiency, a large excess of DTT (25 mM) was added to 
the fluorescent probe, followed by excitation of PB at 400 nm to trigger FRET 
(measured at 530 nm). The emission from PB (measured at 455 nm) and FRET 
(measured at 530 nm) was followed over time. As the cleavage reaction progressed, the 
PB signal increased, while the FRET signal decreased (Figure 4.5, panel D). Curve 
fitting was used to calculate a half-life of 14.3 ± 0.2 min in PBS (1% triton-X 100, Figure 
4.5, panel E). The FRET efficiency, calculated as E = 1 – Ida/Id,33 where Ida and Id are the 
intensity of PB (λmax = 455 nm) in the presence and absence of the acceptor, 
respectively, equals 0.97, indicating that for this system, when PB and PG are in close 
proximity, 97% of the PB signal is suppressed through energy transfer to PG. To ensure 
the changes in fluorescence emission was due to separation of the fluorophore via 
disulfide cleavage, and not from changes in the environment with the addition of DTT, 
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an amide control (60, Figure 4.5, panel B) was synthesized. This derivative does not 
change the distance between the fluorophores appreciably, but does incorporate a non-
labile amide bond in the place of the disulfide bond of 60. The amide FRET probe 60 
was subjected to the same reductive conditions as 59, and no changes were observed 
upon addition of DTT, suggesting that the significant changes in the fluorescence 
spectra after the addition of DTT are due to the cleavage of the disulfide bond and 
subsequent increase in the distance between the two fluorophores. Consequently, PB 
and PG were shown to be an efficient new FRET pair.  
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Figure 4.5. A: Structures of the Pacific Blue-Pennsylvania Green FRET probe 59 and 
products of cleavage by DTT. B: Structure of the amide control 60. C: Emission spectra 
of 60 (25 nM) alone (dashed black line) and with the addition of DTT (25 mM) for 75 min 
(solid red line). Panels D and E show the spectroscopic properties of 59 over a 75 
minute period following the addition of DTT (25 mM) in PBS (1% triton-X 100, pH=7.4). 
D: Emission spectra (λex = 400 nm) over a 75 minute period. Spectra was collected at 
time = 0, 1, 4, 8, 13, 20, 30, and 75 min. The PB emission signal (λmax = 455 nm) grew 
in intensity over time, while the PG emission signal (λmax = 530 nm) decreased as the 
disulfide bond was cleaved over time. E: Cleavage kinetics of the increase in PB 
emission signal (λmax = 455 nm) over time after the addition of DTT. The half-time of 




4.3. Stability of the disulfide of a cholesteryl carbamate delivery system in vitro  
 We hypothesized that the efficient PB-PG FRET pair could prove useful in 
studying the stability of disulfide bonds trafficked to endosomes via cholesterol mimics. 
Based on recent studies in the Peterson group on the use of cholesteryl carbamates to 
trigger cellular uptake of endosome disruptors and cargo, we chose this membrane 
anchor as a simple cellular targeting agent. Additionally, some cholesteryl carbamates 
have been shown to traffic through endocytic pathways, and require binding to HDL or 
LDL for internalization.35 Cholesteryl carbamate conjugates have been used 
successfully in siRNA delivery,35-37 DNA transfection, and other cellular targeting 
applications.38 In our laboratory, Hymel et. al. discovered that the incorporation of two 
anionic glutamic acid residues near a cholesteryl carbamate can improve the normally 
slow lipoprotein-mediated cellular uptake of these compounds and increased the overall 
efficacy of uptake of cholesteryl carbamates compared to other mimics of cholesterol 
that were studied.13 To probe the stability of disulfides for use as delivery systems, we 
designed FRET probes that link PB and PG through a disulfide-containing amino acid.  
Building on other published studies,39 we hypothesized that a bulky group near 
the disulfide bond might hinder its cleavage. Additionally, an anionic group might repulse 
negatively charged reducing agents such as glutathione. To test this hypothesis, we 
designed two cholesteryl linked-FRET probes, 61 and 62 (Figure 4.6). Compared to 61, 
an extra βAla group (Figure 4.6, panel A, colored red) between the disulfide bond and 
Lysine-PG was added to 62, lengthening the distance between the cleavage site and 
the large anionic fluorophore. Using an optimized cholesteryl carbamate anchor,13 we 
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synthesized the two disulfide-linked FRET probes utilizing solid phase synthesis, as 
shown in Figure 4.12.  
To study the difference in disulfide bond stability, DTT was added to the 
fluorescent probes, followed by excitation of PB at 400 nm to trigger FRET. The 
fluorescence of PB (measured at 460 nm) was followed over time. As the cleavage 
reaction progressed, the PB signal increased, while the FRET signal (measured at 530 
nm) decreased (Figure 4.6, panel B). Curve fitting was used to calculate a half life of 74 
± 5 min for 61 and 42 ± 2 min for 62 (Figure 4.6, panel C). This study provides evidence 
that a large hydrophobic group (Pennsylvania Green) near the disulfide bond can slow 
the cleavage reaction in this cholesteryl carbamate delivery system and should enable 
the design of cargo that can be more readily released upon disruption of endosomes. 
Unfortunately, in related studies, Pacific Blue did not show a favorable release profile by 
confocal microscopy upon disulfide cleavage and endosome disruption, so these probes 
were not pursued for further study in cellular systems. As an alternative, the more polar 
fluorophore Oregon Green was used as a releasable fluorophore for cellular assays 
because it is much more similar in polarity to 5-carboxyfluorescein, which we previously 
demonstrated as a cargo that efficiently escapes from endosomes upon disruption8  as 
shown in Figure 4.2. 
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Figure 4.6. A: Structures of PG-PB cholesteryl carbamate FRET probes 61 and 62. B: 
Emission spectra of 61 (50 nM) alone (solid line) and with the addition of β-
mercaptoethanol (300 mM, β-ME) for 3 h (dashed line). C: Cleavage kinetics of the 
increase in PB emission signal (λmax = 460 nm) over time after the addition of DTT (100 
mM) to 61 or 62 (20 nM). The half life and rate constant were determined using 
GraphPad Prism software. All experiments were run in PBS pH 7.4 containing 0.5% 
triton X-100.  
 
 
4.4. Examination of the stability of disulfides linked to cholesteryl carbamates in 
living Jurkat cells 
 
To study a related but more polar delivery system in living Jurkat cells, a new 
FRET pair was employed: Pacific Blue-Oregon Green. Oregon Green (OG) is a 
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fluorinated derivative of fluorescein with a relatively low pKa of 4.7, making it useful for 
biological studies at a wide range of pH values, including acidic endosomes.40 We 
reasoned that its higher polarity compared to Pennsylvania Green might prevent it from 
inserting into membranes, which could provide better properties for cellular assays of 
disulfide cleavage. Moreover, based on the spectral properties of Flutax-2 described in 
Chapter 3, a high degree of spectral overlap is observed between the absorbance of 
OG and the emission of PB, indicating they could also be a complementary FRET pair 
(Figure 3.4). To study this new FRET system, we synthesized two PB-OG FRET probes 
(63 and 64, Figure 4.7, panel A) utilizing solid phase synthesis, as shown in Figure 4.14.  
As described in Section 4.2, the FRET efficiency and cleavage kinetics of the disulfide 
FRET probe 63 were calculated by tracking the PB signal (measured at 460 nm) over 
time after addition of DTT (10 mM). Curve fitting was used to calculate a half life of 20 ± 
1 min in PBS pH 7.4 with 0.5% triton X-100 and 1% DMSO (Figure 4.7, panel C). The 
FRET efficiency, calculated as E = 1 – Ida/Id,33 where Ida and Id are the intensity of PB 
(λmax = 460 nm) in the presence and absence of the acceptor, respectively, equals 0.89 




Figure 4.7. A: Structures of PB-OG cholesteryl carbamate FRET probes 63 and 64. B: 
Emission spectra of 63 and 64 (50 nM) alone (63, blue dotted line; 64, black dashed 
line) and with the addition of DTT (10 mM) for 2 h (63, blue solid line; 64, red solid line). 
C: Kinetics of the increase in PB emission signal (λmax = 460 nm) over time after the 
addition of DTT (10 mM) to 63 (50 nM). The half-time for cleavage of the disulfide was 
calculated using GraphPad Prism software. All experiments were run in PBS pH 7.4 
containing 0.5% triton X-100 and 1% DMSO. 
 
 
  To test the cellular uptake and disulfide cleavage kinetics in living cells, confocal 
laser scanning microscopy and flow cytometry were used to analyze subcellular 
distribution and fluorescence intensity. For the cellular studies, compounds 63 and 64 
were synthesized using unnatural D-amino acids to limit potential changes in 
fluorescence emission that might arise from proteolytic cleavage after endocytosis.41 
Jurkat lymphocytes were treated with compounds 63 and 64 at 10 µM, and the 
fluorescence intensities of three channels (flow cytometry- Blue: Ex. 405 nm, Em. 
448/50 nm; FRET: Ex. 405 nm, Em. 525/30 nm; Green: Ex. 488 nm, Em. 525/30 nm; 
confocal microscopy- Blue: Ex. 405 nm, Em. 425-475 nm; FRET: Ex. 405 nm, Em. 520-
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600 nm; Green: Ex. 488 nm, Em. 500-600 nm) were tracked over time. In comparison to 
the amide control 64 (Figure 4.8, panel C), cells stained with 63 (Figure 4.8, panel B) 
showed significant increases in the blue channel and decreases in the FRET channel 
after a 28 h incubation. This suggested that the amide bond of 64 was non-labile over 
this time period and the energy transfer from Pacific Blue to Oregon Green occurred 
efficiently at each time point. For the amide probe 64, the FRET ratio, calculated as the 
intensities of Blue/FRET and detected by flow cytometry, did not increase. Conversely, 
over a time period of 28 h, the FRET ratio of cells treated with 63 increased significantly 
(Figure 4.8, panel D). Curve fitting was used to calculate a half-life of 4 ± 1 h. From these 
experiments, we were able to determine that the disulfide bond of 63 is fairly reactive during 
the process of endocytosis even without the addition of an endosome disruptive peptide. 
We conclude that the Pacific Blue-Oregon Green FRET pair is excellent for cellular studies 
by confocal microscopy and flow cytometry. Future studies will involve the addition of an 
endosome disruptive peptide to investigate the effect it would have on disulfide cleavage 
kinetics in living cells. Additional studies will involve the synthesis and biological evaluation 
of cholesteryl carbamate FRET probes that include the PB-OG FRET pair and differing 
linkers near the disulfide bond to determine if changes found in vitro track changes in 
disulfide bond cleavage rates realized in living cells. These studies should assist in 
enhancing the properties of related delivery systems currently under development in the 




Figure 4.8. Measurement of the stability of the disulfide of 63 in Jurkat cells. A: 
Schematic representation of disulfide cleavage on cell surface and in endosomal 
compartments over time. B and C: Confocal laser scanning and DIC micrographs of 
living Jurkat cells treated with 63 (10 µM, panel B) or 64 (10 µM, panel C) for 28 h. At 28 
h, treatment with 63 shows significantly less fluorescence in the FRET channel (Ex. 405 
nm, Em. 515-600 nm, 2nd column, colored purple) in comparison to the PB channel (Ex. 
405 nm, Em. 425-475 nm, 2nd column, colored cyan). Conversely, at 28 h, treatment 
with 64, which has a stable amide bond, shows little fluorescence in the PB channel, 
and significant fluorescence in the FRET channel, indicating the molecule is still intact. 
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D: Kinetics of cleavage calculated based on the increase in the FRET ratio over time 
after addition of 63 (10 µM) to living Jurkat cells, as measured by flow cytometry. The 
half-life was determined using GraphPad Prism software. FRET ratio = PB (Ex. 405 nm, 
450 emission channel) / FRET (Ex. 405 nm, 530 emission channel).  
 
4.5. Studies of the stability of disulfides conjugated to antibodies 
 
 The Peterson group is investigating the release of antibody-conjugated 
cytotoxins upon addition of endosome disruptive peptides. Similar to our studies of 
cholesteryl carbamates, we wished to determine the release profile of disulfide-linked 
antibody conjugates in the presence and absence of endosome disrupting peptides. To 
accomplish this goal, we worked with Dr. Chamani Perera of the KU Molecular Probes 
Core to prepare the Pacific Blue-Pennsylvania Green FRET pair molecules 65–69 
(Figure 4.9) using solid phase synthesis and solution phase amide bond-coupling 
reactions as shown in Figure 4.18. These compounds include an NHS ester that is 
designed to react with lysine residues of antibodies.  
 For these studies, we used Herceptin (trastuzamab, Genentech), an FDA-
approved therapy that is used clinically to treat breast cancer patients.42 Herceptin is a 
humanized IgG that targets the human epidermal growth factor receptor 2 (HER2). 
Kelsey Knewtson, a graduate student in the Peterson group, conjugated compounds 
65–69 to Herceptin using a standard protein labeling protocol to produce 70–74 (Figure 
4.9), and conducted the bioassays described below.  




Figure 4.9. Structures of the FRET-NHS esters (65–69) and the conjugates of the anti-
HER2 antibody Herceptin (70–74).  
 
 Similar to the cholesteryl carbamate FRET probes, we first evaluated the release 
profile in vitro of compounds 70 and 71. In the first set of experiments, we investigated 
the effect of the anionic glutamic residue on the right hand side of the disulfide bond. 
We hypothesized that the anionic group could repulse negatively charged reducing 
agents such as glutathione (GSH) and may block disulfide cleavage through steric and 
electronic effects. In comparison to 71, the anionic glutamic acid residue was replaced 
with a glycine residue in 70. To study the difference in stability of the disulfide bond, 
excess GSH was added to the fluorescent antibodies, followed by excitation of PB at 
400 nm to trigger FRET. The fluorescence of PB (measured at 455 nm) was followed 
over time. As the cleavage reaction progressed, the PB signal increased (Figure 4.10, 
panel A). Curve fitting was used to calculate a half life of 47 ± 1 min for 70 and 84 ± 1 min 
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for 71, consistent with the idea that the proximal glutamate can retard approach by 
reducing agent. 
Similarly, we studied the release profile of conjugates 72–75 that also had 
increasing number of glutamic acid residues surrounding the disulfide linkage. Again, 
we tracked increases in the fluorescence of PB (measured at 455 nm) over a 3 h period 
(Figure 4.10, panel B). We found a ~2-fold increase in stability with each additional 
glutamic acid. This study provides evidence that a glutamic acid near the disulfide bond 
has a significant effect on the cleavage reaction of FRET probes conjugated to an 
antibody. These results are consistent with previous studies39 of the effect of negatively 
charged substituents on cleavage of simple disulfides.  
 Finally, we evaluated the release profile of conjugate 70 in living SkBr3 cells, as 
this conjugate has the fastest in vitro cleavage rate. SkBr3 cells, which endogenously 
overexpress HER2 on the cell surface, were treated with 70 (5 µM). By confocal laser 
scanning microscopy (Blue: Ex. 405 nm, Em. 415-500 nm; Green: Ex. 488 nm, Em. 
500-600 nm), we were able to observe time-dependent increases in the Blue / Green 
ratio, indicating cleavage of the disulfide bond. The maximum Blue / Green ratio that we 
could obtain in this cellular system was ~3, as determined by SkBr3 cells co-treated with 
DTT and 70 (data not shown). This indicates that at 27 h (Figure 4.10, panel C), the 
cleavage could only be estimated to be ~ 50% complete, and consequently the half-life 
could not be accurately determined, but it is likely to be > 20 h. Future studies include 
evaluation of conjugates 71–74 to determine if there are correlations between the in 
vitro and cellular release profiles and evaluation of release profiles in the presence and 




Figure 4.10. In vitro kinetics of cleavage of disulfides by following the increase in PB 
emission (λmax = 455 nm) over time after the addition of GSH (5 mM) to 70 (DOL = 1.3) 
and 71 (DOL = 1.0)  (100 nM, panel A) and 72 (50 nM, DOL = 2.3, panel B), 73 (50 nM, 
DOL = 1.0, panel B), and 74 (25 nM, DOL = 1.0, panel B) in PBS pH 7.4. The half-lives 
were determined using GraphPad Prism software. C: Kinetics of cleavage of the 
disulfide of 70 (5 µM, DOL = 1.3) based on the increase in FRET ratio over time after 
addition to living SkBr3 cells, as measured by confocal laser scanning microscopy. 
Blue/Green ratio = PB (Ex. 405 nm, Em. 415-500 nm) / Green (Ex. 488 nm, Em. 500-
600 nm). Concentrations were based on [Herceptin]. 
 
4.6. Conclusions and future directions 
 We characterized Pacific Blue and Pennsylvania Green as a new FRET pair. 
These fluorophores compliment one another in pH insensitivity and have large spectra 
overlap, ideal for FRET. We can make multi-gram quantities of each of these 
fluorophores readily, allowing for the preparation of a wide variety of PB-PG FRET 
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probes. Through organic synthesis and in vitro characterization of a simple FRET 
system, we found this pair to have a high FRET efficiency equal to 0.97, indicating that 
these dyes should be widely applicable to the study of biological processes.  
 We used this FRET pair as well as another related FRET pair (Pacific Blue-
Oregon Green) to study the release profile of two model drug delivery systems. We 
found that the addition of steric hindrance and/or anionic groups near the disulfide bond 
decreases the cleavage rate, both in the cholesteryl carbamate anchored system, and 
the Herceptin-conjugates. Through cellular studies of endocytosis, we found that the 
disulfide stability within a molecule that traffics via a cholesteryl carbamate anchor has a 
half life of ~ 4 h in living Jurkat lymphocytes, whereas the disulfide half life of a molecule 
delivered using Herceptin in SkBr3 cells is much longer. Future studies will investigate 
the release profile of molecules trafficking via cholesterol mimics and antibodies alike, 
both in the presence and absence of an endosome disruptive peptide to help elucidate 
the mechanisms of release for these targeted delivery systems. To further explore why 
the observed disulfide cleavage kinetics between antibody conjugates and cholesteryl 
carbamate derivatives are so different, we will investigate whether the much more 
hydrophobic Pennsylvania Green fluorophore used in the antibody studies might limit 
cleavage of disulfides compared to the much more hydrophilic Oregon Green 
fluorophore that is likely to be more solvent accessible. To carry out these experiments, 
we have synthesized compounds 75–76 (Figure 4.11), and in the future we will evaluate 
the cleavage kinetics of the antibody conjugates 77–78 (Figure 4.11) in vitro and in 
SkBr3 cells. Another hypothesis that might be fruitful to investigate would be whether 
membrane-bound glutathione-S-transferase enzymes of endosomes might preferentially 
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cleave disulfides that are proximal to membranes such as those present in the 
cholesteryl carbamates described here.  
 
Figure 4.11. Structures of Pacific Blue-Oregon Green FRET-NHS esters (75–76) and 




4.7.1. General experimental section 
Chemicals were purchased from Sigma Aldrich, Acros Organics, Alfa Aesar, Oakwood 
Chemical, or Chem-Impex International. 1H NMR and 13C NMR were acquired on an 
Avance AVIII 500 MHz instrument. For 1H and 13C, chemical shifts (δ) are reported in 
ppm referenced to CDCl3 (7.26 ppm for 1H and 77.2 ppm for 13C) or DMSO-d6 (2.50 
ppm for 1H, 39.5 ppm for 13C). 1H coupling constants (JHH, Hz) and 13C coupling 
constants (JCF, Hz) are reported as: chemical shift, multiplicity (s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet, dt = doublet of triplets, dd = doublet of doublets, ddd 
= doublet of doublet of doublets, td = triplet of doublets, qd = quartet of doublets), 
coupling constant, and integration. High Resolution Mass Spectra (HRMS) were 
obtained at the Mass Spectrometry Laboratory at the University of Kansas on a 
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aluminum-backed (0.20 mm) silica plates (60 F-254), and flash chromatography used 
ICN silica gel (200-400 mesh). TLC plates were visualized with a UV lamp. Preparative 
HPLC was performed with an Agilent 1200 instrument equipped with a Hamilton PRP-1 
reverse phase column (250 mm length, 21.2 mm ID, 7 µm particle size) with detection 
by absorbance at 215, 254, 370, and 490 nm. All non-aqueous reactions were carried 
out using flame- or oven-dried glassware under an atmosphere of dry argon or nitrogen. 
N,N-dimethylformamide (DMF) was purified via filtration through two columns of 
activated basic alumina under an atmosphere of Ar using a solvent purification system 
from Pure Process Technology (GlassContour). Other commercial reagents were used 
as received. Absorbance spectra were obtained using semimicro (1.4 mL) UV quartz 
cuvette (Sigma-Aldrich, Z27667-7) on an Agilent 8452A diode array spectrometer. 
Fluorescence spectra were acquired using a SUPRASIL ultra-micro quartz cuvette 
(PerkinElmer, B0631079) on a Perkin-Elmer LS55 Fluorescence Spectrometer (10 nm 
excitation slit width).  
 
4.7.2. Biological protocol and analysis 
Cell culture: SkBr3 cells (ATCC #HTB-30) were cultured in DMEM/Ham’s F-12 medium 
(Sigma 8437). Jurkat lymphocytes (human acute leukemia, ATCC #TIB-152) were 
cultured in RPMI-1640 medium (Sigma R8758). All media was supplemented with fetal 
bovine serum (FBS, 10%), penicillin (100 units/mL), and streptomycin (100 µg/mL) and 




Analysis of cleavage kinetics of simple and cholesteryl carbamate FRET probes 
by fluorescence spectroscopy 
FRET probes were diluted with PBS with 0.5% triton X-100 and 1% DMSO (pH 7.4, 37 
°C) to provide 1 mL of the desired concentration.  Dithiothreitol (DTT) or β-
mercaptoethanol (β-ME) was added from a 1 mM aqueous stock to the final desired 
concentration. The solution were immediately transferred to a quartz cuvette equipped 
with a stir bar (PerkinElmer). The cuvette was immediately placed in a PerkinElmer LS 
55 Fluorescence Spectrometer equipped with a Biokinetics Accessory for analysis. The 
cuvette holder was heated to 37 °C and stirring was set to fast. Full emission spectra 
(Ex. 400 nm, 10 nm slit width) were taken at various time intervals (dependent on the 
probe, listed in each figure). The increase in fluorescence at 455 or 460 nm was 
followed over time as an indicator of the cleavage of the disulfide bond. The half-time 
(t1/2) for cleavage of the disulfide was calculated using GraphPad Prism software. 
 
Confocal microscopy of OG-PB cholesteryl carbamate conjugates 
Jurkat lymphocytes (350,000 cells/mL) were treated with 10 µM of the disulfide and 
amide FRET probes and were incubated at 37 °C for 27 h. Cells were centrifuged at 
2000 x g for 2 min and the media was replaced to remove excess fluorophore not taken 
up by the cells. Fluorescent probes were excited with either a 405 nm (Pacific Blue) or 
488 nm (Pennsylvania Green) solid-state laser and emitted photons were collected from 
425-475 nm to image the PB signal (405 nm laser), 520-600 nm to image the FRET 
signal (405 nm laser), and 500-600 nm to image the OG signal (488 nm laser). Laser 
power and PMT gain settings were kept identical for all images acquired within a given 
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experiment to allow accurate comparisons of cellular fluorescence. 
 
Cleavage kinetics of OG-PB cholesteryl carbamate conjugates analyzed by flow 
cytometry 
Jurkat lymphocytes (350,000 cells/mL) were treated with 10 µM of the disulfide and 
amide FRET probes and were incubated at 37 °C for various time points. Cells were 
centrifuged at 2000 x g for 2 min and the media was replaced to remove excess 
fluorophore not taken up by the cells. FACS analysis was preformed on a Millipore 
Guava Flow Cytometer equipped with 405 and 488 nm lasers. 10,000 cells were 
counted for each sample. Data was collected under a Pacific Blue filter (448/50 nm) and 
Green filter (525/30 nm). FACS data was analyzed by gating cell populations based on 
untreated cells. Kinetics of cleavage were calculated based on the increase in the FRET 
ratio over time. FRET ratio = PB (Ex. 405 nm, 450 emission channel) / FRET (Ex. 405 
nm, 530 emission channel). The half-life was determined using GraphPad Prism 
software.  
 
Procedure for labeling Herceptin 
Lyophilized Herceptin was reconstituted in sterile PBS (pH 7.4) and the protein 
concentration was determined by absorbance at 280 nm (ε E1% = 13.7 L g-1 cm-1). To 
remove stabilizing agents and salts, Sephadex G-25 resin (Superfine, Sigma) was 
suspended in PBS (pH 7.4). The resulting slurry (950 µL) was added to a minispin 
column (USA Scientific) and centrifuged at 16,000 x G for 20 s to remove the buffer and 
pack the resin. The solution containing Herceptin was loaded onto the packed resin of 
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the spin column (50-70 µL per column) and centrifuged at 16,000 x G for 30 s to 
separate the protein from the small molecules retained by the resin. The absorbance at 
280 nm was used to determine the resulting concentration, which was then adjusted to 
100 µM. The FRET probes were dissolved in DMSO to give 10 mM stocks, as verified 
by absorbance. Aqueous sodium bicarbonate (final concentration = 100 mM, pH 8) was 
added to the Herceptin solution, followed by the FRET probe (10 eq. from DMSO stock). 
Reaction of the NHS ester was allowed to proceed at 37 °C for 30 min. To purify the 
conjugate, the solution was passed twice through a Sephadex G-25 resin mini-column, 
as described above (50 – 70 µL per column). The absorbance at 280 nm and 425 nm 
(Pacific Blue, ε = 29,500 M-1cm-1) of the eluent was used to determine the concentration 
and degree of protein labeling (DOL = 1–3). 
 
Confocal microscopy of Herceptin conjugates: SkBr3 breast cancer cells were 
plated (200,000 cells/mL, 300 µL/well) into µ-Slide 8 Well (ibiTreat, Ibidi) and incubated 
overnight. Cells were then washed two times with media and treated with 5 µM 
Herceptin-FRET probe conjugate in media for the indicated time. Cells were then 
washed twice with media and imaged using an inverted Leica TCS SPE confocal laser-
scanning microscope fitted with a Leica 63x oil-immersion objective. Fluorescent probes 
were excited with either a 405 nm (Pacific Blue) or 488 nm (Pennsylvania Green) solid-
state laser and emitted photons were collected from 415-500 nm or 500-600 nm, 
respectively. Laser power and PMT gain settings were kept identical for all images 
acquired within a given experiment to allow accurate comparisons of cellular 
fluorescence. 4 fields of cells were imaged for each time point, and 4 endosomes were 
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manually selected from each field as regions of interest (ROIs). The mean fluorescence 
intensity of each ROI was recorded for both fluorophores being studied and averaged. 
Dithiothreitol (DTT, Sigma) was added to treated cells as a control for full cleavage of 
the disulfide bond. To this end, SkBr3 cells plated in µ-Slide 8 well as described above 
were treated with 5 µM of the Herceptin-FRET probe conjugate for the indicated time. 
Cells were then washed twice with media, and treated with plain media or media with 1 
mM DTT for 30 min. After this incubation, cells were imaged as above. For analysis, the 
ratio of mean fluorescence intensity for 405 nm/488 nm excitation for each ROI was 
averaged. 
 
Analysis of kinetics of Herceptin-FRET probe conjugates by fluorescence 
spectroscopy 
Herceptin-FRET probe conjugates were diluted with PBS (pH 7.4, 37 °C) to provide 600 
µL of the desired concentration. Glutathione (reduced, Acros Organics) was added from 
a 100 mM aqueous stock solution to a final concentration of 5 mM. The solution was 
immediately transferred to a quartz cuvette equipped with a stir bar (PerkinElmer). The 
cuvette was immediately placed in a PerkinElmer LS 55 Fluorescence Spectrometer 
equipped with a Biokinetics Accessory for analysis. The cuvette holder was heated to 
37 °C and stirring was set to fast. Readings were taken every 30 s (0.1 s integration) 
using the Time Drive application with an excitation of 405 nm, emission of 455 nm, 10 
nm slit widths and the lamp turned off between readings. The increase in fluorescence 
at 455 nm was followed over time as an indicator of the cleavage of the disulfide bond.  
For, fluorescence spectra that were acquired using the Scan Application, 600 µL of the 
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Herceptin-FRET probe conjugate was placed in a quartz cuvette (PerkinElmer). 
Fluorescence scans of Pacific Blue were performed with excitation at 405 nm and 
emission from 425-700 nm. For Pennsylvania Green, excitation of 490 nm and emission 
from 510-700 nm were used. All slit widths were 10 nm. All measurements were 
background subtracted using a spectrum obtained from a quartz cuvette containing 
PBS. Scans were performed at t=0 and t=final of the kinetic studies. 
 
4.7.3. Synthetic procedures and compound characterization data 
General procedure 4A. Compounds 61–62 were constructed using SPPS with 2-
chlorotrityl resin with L-amino acids. The procedure for coupling as described in Section 
2.10.3 (general procedure 2D) was followed. After completing all the steps of coupling 
reactions, the peptide was cleaved from the resin by treatment with a mixture of 
DCM/TFE/acetic acid (7:2:1) with shaking for 2 h. The resin was removed by filtration 
and washed with DCM (2 mL x 3). The filtrates were combined and concentrated under 
vacuum. The crude peptide, HBTU (1.2 eq.), HOBt (1.2 eq.) and DIEA (5 eq.) were 
added to DMF (0.5 mL). Separately, 35 (2 eq.) was treated with a solution of 
trifluoroacetic acid (TFA) / CH2Cl2 (0.5 mL, 50:50) for 1 h. The mixture was concentrated 
under vacuum and washed with CH2Cl2 (2 mL) and ether (2 mL x 2) to remove excess 
TFA. Following deprotection, the amine was dissolved in DMF (0.5 mL) and added to 
the activated acid solution. The reaction was stirred at 22 °C for 16 h. The vessel was 
placed on high vacuum for 2 h to remove DMF followed by purification by preparative 
RP-HPLC (Gradient: H2O:CH3CN (9:1) to (0:100) with added TFA (0.1%) over 20 min; 
elution time = 17-20 min). Pure fractions were collected, combined, and solvent was 
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removed by lyophilization.  
General procedure 4B. Compounds 84–85 (Figure 4.15) were constructed using SPPS 
with 2-chlorotrityl resin with D-amino acids. The procedure for coupling as described in 
Section 2.10.3 (general procedure 2D) was followed. After completing all the steps of 
coupling reactions, the peptide was cleaved from the resin by treatment with a mixture 
of DCM/TFE/acetic acid (7:2:1) with shaking for 2 h. The resin was removed by filtration 
and washed with DCM (2 mL x 3). The filtrates were combined and concentrated under 
vacuum. The crude peptide, N-Boc-ethylenediamine (4 eq.), HATU (3.8 eq.), DIEA (5 
eq.) were added to DMF (1 mL). The reaction was stirred at 22 °C for 16 h. The vessel 
was placed on high vacuum for 2 h to remove DMF. The crude product was then treated 
with a solution of trifluoroacetic acid (TFA) / CH2Cl2 (0.5 mL, 50:50) for 1 h. The mixture 
was concentrated and purified by preparative RP-HPLC (Gradient: H2O:CH3CN (9:1) to 
(0:100) with added TFA (0.1%) over 20 min; elution time = 17-20 min). Pure fractions 
were collected, combined, and solvent was removed by lyophilization.  
General procedure 4C. To a solution of peptides 84–85 (Figure 4.15, 1.5 eq.) and 
DIEA (5 eq.) in DMF (0.5 mL), Oregon Green Carboxylic Acid succinimidyl ester 
(Thermo Fisher O6149, OG-NHS, 1 eq.) was added. The reaction was stirred at 22 °C 
for 16 h. The vessel was placed on high vacuum for 2 h to remove DMF. The crude 
product was then treated with a solution of trifluoroacetic acid (TFA) / CH2Cl2 (0.5 mL, 
50:50) for 1 h. The mixture was concentrated and purified by preparative RP-HPLC 
(Gradient: H2O:CH3CN (9:1) to (0:100) with added TFA (0.1%) over 20 min; elution time 
= 17-20 min). Pure fractions were collected, combined, and solvent was removed by 
lyophilization.  
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General procedure 4D. Compounds 65–69 were constructed using SPPS with 2-
chlorotrityl resin with L-amino acids. The procedure for coupling as described in Section 
2.10.3 (general procedure 2D) was followed. After completing all the steps of coupling 
reactions, with the N-terminal Fmoc intact, the peptide was cleaved from the resin by 
treatment with a mixture of DCM/TFE/acetic acid (7:2:1) with shaking for 2 h. The resin 
was removed by filtration and washed with DCM (2 mL x 3). The filtrates were combined 
and concentrated under vacuum. The crude peptide, HATU (3.8 eq.), and DIEA (5 eq.) 
were added to DMF (1 mL). Separately, 79 (2 eq.) was treated with a solution of 
trifluoroacetic acid (TFA) / CH2Cl2 (0.5 mL, 50:50) for 30 min. The mixture was 
concentrated under vacuum and washed with CH2Cl2 (2 mL) and ether (2 mL x 2) to 
remove excess TFA. Following deprotection, the amine was dissolved in DMF (0.5 mL) 
and added to the activated acid solution.  The reaction was stirred at 22 °C for 16 h. The 
vessel was placed on high vacuum for 2 h to remove DMF. The crude product was then 
treated with 20% piperidine (1 mL) for 20 min followed by concentration under vacuum. 
The peptide was then treated with a solution of trifluoroacetic acid (TFA) / CH2Cl2 (0.5 
mL, 50:50) for 1 h. The mixture was concentrated under high vacuum and treated with 
disuccinimidyl glutarate (10 eq.) in DMF (1 mL) in the presence of DIEA for 3 h. The 
resulting solution was concentrated and purified by preparative RP-HPLC (Gradient: 
H2O:CH3CN (9:1) to (0:100) with added TFA (0.1%) over 20 min; elution time = 9-11 







methylbenzamido)ethyl)carbamate (79). To a solution of 4-Carboxy Pennsylvania 
Green succinimidyl ester (95 mg, 0.2 mmol), prepared as previously reported,31 in DMF 
(1 mL) was added DIEA (125 µL, 0.5 mmol) and N-Boc-ethylenediamine (47 µL, 0.3 
mmol). The reaction mixture was stirred at 22 °C for 4 h. The vessel was placed on high 
vacuum for 2 h to remove DMF followed by purification by column chromatography on 
silica gel (eluent: DCM/MeOH (10:1)) to afford 79 (100 mg, 96%) as an orange solid.1H 
NMR (500 MHz, DMSO-d6) δ 8.62 (t, J = 5.7 Hz, 1H), 7.96 (d, J = 2.0 Hz, 1H), 7.88 (dd, 
J = 7.8, 1.7 Hz, 1H), 7.39 (d, J = 7.9 Hz, 1H), 6.94 (t, J = 5.8 Hz, 1H), 6.61 (d, J = 10.9 
Hz, 2H), 3.34 (q, J = 6.3 Hz, 2H), 3.14 (q, J = 6.3 Hz, 2H), 2.08 (s, 3H), 1.38 (s, 9H); 13C 
NMR (126 MHz, DMSO-d6) δ 172.5, 166.3, 156.2, 149.8 (d, J = 6.1 Hz), 136.4, 136.2, 
134.7, 130.0, 129.5, 125.6, 105.6, 78.2, 41.8, 40.5, 28.7, 21.5, 19.6; HRMS (ESI-) m/z 




yl)-3-methylbenzamido)ethyl)amino)-3-oxopropyl)disulfanyl)ethyl)carbamate, (80).  



















mg, 0.08 mmol) and DIEA (40 µL, 0.16 mmol) were stirred in anhydrous DMF at 0 °C for 
25 minutes. Separately, 79 (31 mg, 0.059 mmol) was treated with a solution of 
trifluoroacetic acid (TFA) / CH2Cl2 (2 mL, 30:70) for 20 min. The mixture was 
concentrated under vacuum and washed with CH2Cl2 (5 mL) and ether (5 mL x 2) to 
remove excess TFA. Following deprotection, the amine was dissolved in DMF (0.5 mL) 
and added to the activated acid solution. The reaction was stirred at 22 °C for 16 h. The 
vessel was placed on high vacuum for 2 h to remove DMF followed by purification by 
column chromatography on silica gel (gradient: DCM:MeOH (100:1) to (16:1)) to afford 
80 (47 mg, 98%) as an orange solid. 1H NMR (500 MHz, DMSO-d6) δ 8.66 (t, J = 5.7 
Hz, 1H), 8.12 (t, J = 5.8 Hz, 1H), 7.96 (d, J = 1.7 Hz, 1H), 7.88 (dd, J = 7.8, 2.1 Hz, 3H), 
7.67 (d, J = 7.5 Hz, 2H), 7.50 (t, J = 5.7 Hz, 1H), 7.45 – 7.36 (m, 3H), 7.31 (td, J = 7.5, 
1.2 Hz, 2H), 6.61 (d, J = 11.0 Hz, 2H), 4.29 (d, J = 6.9 Hz, 2H), 4.20 (t, J = 6.9 Hz, 1H), 
3.37 (q, J = 6.4 Hz, 4H), 3.27 (ddd, J = 7.2, 4.6, 1.8 Hz, 4H), 2.91 (t, J = 7.2 Hz, 2H), 
2.76 (t, J = 6.8 Hz, 2H), 2.07 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 170.8, 166.3, 
156.5, 149.8, 144.3, 141.2, 136.4, 136.1, 134.8, 130.0, 129.5, 128.0, 127.5, 125.6, 
120.6, 105.6, 65.8, 47.2, 38.8, 37.8, 35.6, 34.3, 19.6; HRMS (ESI-) m/z 808.1935 (M-
























hydroxy-2-oxo-2H-chromene-3-carboxamide (59).  5 (8 mg, 0.033 mmol), HATU (11 
mg, 0.031 mmol) and DIEA (25 µL, 0.11 mmol) were stirred in anhydrous DMF (1 mL) at 
22 °C for 15 minutes. Separately, 80 (18 mg, 0.022 mmol) was treated with a solution of 
piperidine in DMF (20%, 0.7 mL) for 45 min to remove the Fmoc protecting group. The 
mixture was concentrated under high vacuum and washed with DMF (1 mL x 2) to 
remove excess piperidine. Following deprotection, the amine was dissolved in DMF (1 
mL) and added to the activated acid solution. The reaction was stirred at 22 °C for 16 h. 
The vessel was placed on high vacuum for 2 h to remove DMF followed by purification 
by preparative RP-HPLC (Gradient: H2O:CH3CN (9:1) to (0:100) with added TFA (0.1%) 
over 20 min; elution time = 15 min). Pure fractions were collected, combined, and 
solvent was removed by lyophilization to yield 59 (16 mg, 89%). 1H NMR (500 MHz, 
MeOD) δ 8.71 (d, J = 1.4 Hz, 1H), 7.96 (dt, J = 1.7, 0.8 Hz, 1H), 7.94-7.89 (m, 2H), 
7.50-7.39 (m, 2H), 6.77 (d, J = 10.8 Hz, 2H), 3.86 (d, J = 5.5 Hz, 1H), 3.72 (t, J = 6.5 Hz, 
2H), 3.64–3.57 (m, 2H), 3.52 (dd, J = 6.8, 4.7 Hz, 2H), 3.00 (t, J = 6.9 Hz, 2H), 2.93 (t, J 
= 6.5 Hz, 2H), 2.68 (t, J = 6.9 Hz, 2H), 2.14 (s, 3H); 13C NMR (126 MHz, MeOD-d4) δ 
174.3, 169.6, 163.6, 161.4, 156.0 (d, J = 3.7 Hz), 153.7, 150.9 (dd, J = 242.6, 4.4 Hz), 
149.1, 143.6, 142.4, 142.3, 142.2, 140.49 (d, J = 240.6 Hz), 138.0, 137.4, 136.3, 130.9, 
130.5, 129.8, 128.9, 126.5, 125.9, 121.7, 116.7, 115.9, 115.8, 112.9, 112.7, 111.3 (dd, J 
= 21.2, 3.1 Hz), 111.0 (d, J = 10.4 Hz), 106.27, 106.25, 41.0, 39.9, 39.6, 38.1, 36.4, 






methylbenzamido)ethyl)amino)-3-oxopropyl)carbamate (81). Fmoc-β-alanine-OH 
(131 mg, 0.42 mmol), HATU (160 mg, 0.42 mmol) and DIEA (225 µL, 1.3 mmol) were 
stirred in anhydrous DMF (3.5 mL) at 0 °C for 30 minutes. Separately, 79 (170 mg, 0.32 
mmol) was treated with a solution of trifluoroacetic acid (TFA) / CH2Cl2 (6.5 mL, 30:70) 
for 40 min. The mixture was concentrated under vacuum and washed with CH2Cl2 (5 
mL) and ether (5 mL x 2) to remove excess TFA. Following deprotection, the amine was 
dissolved in DMF (3.5 mL) and added to the activated acid solution. The reaction was 
stirred at 22 °C for 16 h. The vessel was placed on high vacuum for 2 h to remove DMF. 
The mixture was treated with ethyl acetate (100 mL) and water (100 mL). The mixture 
was extracted with ethyl acetate, and the organic layer was washed with sat. aqueous 
NaCl (2 x 100 mL). The organic layer was dried, filtered, concentrated under reduced 
pressure, and purified by column chromatography on silica gel (gradient: 
hexanes:EtOAc (1:0) to (7:3)) to afford 81 (180 mg, 78%) as an orange solid. 1H NMR 
(500 MHz, DMSO-d6) δ 8.68 (t, J = 5.6 Hz, 1H), 8.06 (t, J = 5.8 Hz, 1H), 8.00-7.94 (m, 
1H), 7.93-7.83 (m, 3H), 7.68 (d, J = 7.5 Hz, 2H), 7.46-7.28 (m, 6H), 6.61 (d, J = 11.0 Hz, 
2H), 4.27 (d, J = 6.7 Hz, 2H), 4.20 (t, J = 6.9 Hz, 1H), 3.37 (q, J = 6.3 Hz, 2H), 3.24 (dq, 
J = 17.2, 6.4 Hz, 4H), 2.29 (t, J = 7.2 Hz, 2H), 2.07 (s, 3H); 13C NMR (126 MHz, DMSO-











127.1, 125.2, 125.1, 120.1, 105.2, 65.3, 46.7, 40.1, 38.3, 37.1, 35.8, 19.1; HRMS (ESI-) 





(82).Fmoc-β-alanine-OH (80 mg, 0.25 mmol), HATU (95 mg, 0.25 mmol) and DIEA (130 
µL, 0.78 mmol) were stirred in anhydrous DMF (2.5 mL) at 0 °C for 30 min. Separately, 
81 (140 mg, 0.20 mmol) was treated with a solution of piperidine in DMF (20%, 2 mL) 
for 45 min to remove the Fmoc protecting group. The mixture was concentrated under 
high vacuum and washed with DMF (2 mL x 2) to remove excess piperidine. Following 
deprotection, the amine was dissolved in DMF (2.5 mL) and added to the activated acid 
solution. The reaction was stirred at 22 °C for 4 h. The vessel was placed on high 
vacuum for 2 h to remove DMF. The mixture was treated with ethyl acetate (100 mL) 
and water (100 mL). The mixture was extracted with ethyl acetate, and the organic layer 
was washed with sat. aqueous NaCl (2 x 100 mL). The organic layer was dried, filtered, 
concentrated under reduced pressure, and purified by column chromatography on silica 
gel (gradient: hexanes:EtOAc (1:0) to (7:3)) to afford 82 (100 mg, 68%) as an orange 
solid. 1H NMR (500 MHz, DMSO-d6) δ 8.68 (t, J = 5.7 Hz, 1H), 8.05 (t, J = 5.8 Hz, 1H), 
7.94 (dd, J = 12.5, 3.7 Hz, 2H), 7.9146 – 7.8311 (m, 3H), 7.66 (d, J = 7.5 Hz, 2H), 7.39 













(d, J = 6.7 Hz, 2H), 4.18 (t, J = 6.9 Hz, 1H), 3.39 – 3.33 (m, 2H), 3.26 (q, J = 6.5 Hz, 
4H), 3.18 (q, J = 6.8 Hz, 2H), 2.24 (q, J = 7.6 Hz, 4H), 2.07 (s, 3H). 13C NMR (126 MHz, 
DMSO-d6) δ 171.2, 170.7, 166.3, 156.5, 149.8 (d, J = 6.3 Hz), 144.3, 141.1, 136.4, 
136.1, 134.8, 130.0, 129.5, 128.1, 127.5, 125.61, 125.55, 111.7 (d, J = 13.5 Hz), 105.6, 
65.8, 47.1, 40.5, 38.8, 37.5, 36.1, 36.0, 35.8, 19.6; HRMS (ESI-) m/z 787.2560 (M-H+), 





hydroxy-2-oxo-2H-chromene-3-carboxamide (60). 5 (8 mg, 0.033 mmol), HATU (11 
mg, 0.031 mmol) and DIEA (20 µL, 0.11 mmol) were stirred in anhydrous DMF (1 mL) at 
22 °C for 15 minutes. Separately, 82 (17 mg, 0.022 mmol) was treated with a solution of 
20% piperidine in DMF (0.7 mL) for 45 min to remove the Fmoc protecting group. The 
mixture was concentrated under high vacuum and washed with DMF (1 mL x 2) to 
remove excess piperidine. Following deprotection, the amine was dissolved in DMF (1 
mL) and added to the activated acid solution. The reaction was stirred at 22 °C for 16 h. 
The vessel was placed on high vacuum for 2 h to remove DMF followed by purification 
by preparative RP-HPLC (Gradient: H2O:CH3CN (9:1) to (0:100) with added TFA (0.1%) 























solvent was removed by lyophilization to yield 60 (15 mg, 90%). 1H NMR (500 MHz, 
D2O) δ 8.68 (d, J = 1.4 Hz, 1H), 7.92 (d, J = 1.8 Hz, 1H), 7.91-7.85 (m, 1H), 7.46-7.33 
(m, 2H), 6.86 (d, J = 6.9 Hz, 2H), 6.76-6.68 (m, 2H), 3.62 (t, J = 6.4 Hz, 2H), 3.52 (dd, J 
= 6.7, 4.8 Hz, 2H), 3.48-3.39 (m, 4H), 2.46 (t, J = 6.4 Hz, 2H), 2.39 (t, J = 6.6 Hz, 2H), 
2.10 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 174.4, 173.8, 169.6, 165.5, 163.5, 161.4, 
154.9 (d, J = 294.9 Hz), 154.3 (d, J = 251.6 Hz), 150.9 (d, J = 3.2 Hz), 150.8 (d, J = 
242.8 Hz), 148.9, 142.3, 142.2, 142.2, 140.5 (d, J = 240.9 Hz), 138.0, 137.4, 136.3, 
132.0, 131.0 (d, J = 8.2 Hz), 130.8, 130.5, 126.4, 116.9, 115.9, 115.8, 112.9, 112.7, 
111.3 (dd, J = 21.4, 2.9 Hz), 111.0 (d, J = 9.8 Hz), 106.28, 106.25, 40.9, 40.2, 37.21, 
37.19, 37.1, 36.3, 19.7; HRMS (ESI-) m/z 789.1829 (M-H+), C39H29F4N4O10 requires 
789.1820). 
 
Figure 4.12. Reagents and conditions: a) 35, TFA (30%) in DCM; b) HBTU, HOBt, 
DIEA, DMF; c) TFA (30%) in DCM. PG = 4-Carboxy Pennsylvania Green, PB = Pacific 























































xanthen-9-yl)-3-methylbenzoyl)-L-lysine (83, PG-Lys). To a solution of Fmoc-L-
Lysine-OH (280 mg, 0.58 mmol) and DIEA (400 µL, 2.9 mmol) in DMF (2 mL) was 
added Pennsylvania Green NHS ester (1.25 g, 3.69 mmol), prepared as previously 
reported.31 The reaction mixture was stirred at 22 °C overnight. The reaction mixture 
was added dropwise to cold aq. HCl (1 N, 200 mL). The precipitate formed was filtered, 
washed with cold aq. HCl (1 N, 25 mL), and dried in vacuum to give 83 as an orange 
solid (340 mg, 80%). 1H NMR (500 MHz, DMSO-d6) δ 8.64 (t, J = 5.7 Hz, 1H), 7.96 (d, J 
= 1.7 Hz, 1H), 7.88 (d, J = 7.7 Hz, 3H), 7.73 (dd, J = 7.5, 2.4 Hz, 2H), 7.46-7.27 (m, 6H), 
6.89-6.72 (m, 2H), 6.60 (d, J = 11.0 Hz, 2H), 4.29 (d, J = 8.3 Hz, 2H), 4.24 (q, J = 7.5, 
6.7 Hz, 1H), 3.96 (ddd, J = 9.8, 8.0, 4.6 Hz, 1H), 3.32 (q, J = 6.8 Hz, 2H), 2.07 (s, 3H), 
1.74-1.35 (m, 6H); 13C NMR (126 MHz, DMSO-d6) δ 174.5, 166.1, 156.6 (d, J = 3.0 Hz), 
149.8 (t, J = 6.0 Hz), 144.3, 144.2, 141.2 (d, J = 2.3 Hz), 136.4 (d, J = 10.5 Hz), 134.7, 
130.0, 129.5, 128.1, 127.5, 125.8, 125.5, 120.6, 113.9, 111.6 (d, J = 21.6 Hz), 105.6 (d, 
J = 4.3 Hz), 66.1, 54.3, 47.1, 30.9, 29.17, 23.7, 19.6; HRMS (ESI-) m/z 731.2218 (M-




















(61). Following general procedure 4A, 3-((((cholester-3-yl)oxy)carbonyl) 
amino)propanoic acid,43 PG-Lys (83), Fmoc-protected 3-((2-
aminoethyl)disulfanyl)propanoic acid,8 Fmoc-β-ala-OH, and Fmoc-L-Glu-OH were used 
with 2-chlorotrityl resin (1.22 mmol/g) to synthesize a peptide. The crude peptide (30 
mg, 0.02 mmol) and 35 (11 mg, 0.03 mmol) yielded 61 (10 mg, 30%). LRMS (ESI-) m/z 





































Figure 4.13. Analytical HPLC profile of 61 after preparative HPLC. Retention time = 









(62). Following general procedure 4A, 3-((((cholester-3-yl)oxy)carbonyl) 
amino)propanoic acid43, PG-Lys (83), Fmoc-protected 3-((2-
aminoethyl)disulfanyl)propanoic acid,8 Fmoc-βAla-OH, and Fmoc-L-Glu-OH were with 
H-β-ala-2-chlorotrityl resin (0.74 mmol/g) to synthesize a peptide. The crude peptide (6 




















































mg, 0.004 mmol) and 35 (3 mg, 0.008 mmol) yielded 62 (4 mg, 58%). LRMS (ESI-) m/z 
1821.8 (M-H+ C91H113F4N10O21S2 requires 1821.7). 
 
Figure 4.14. Analytical HPLC profile of 62 after preparative HPLC. Retention time = 19 
min monitored by UV absorbance at 254 nm. Purity >90% by HPLC. 
 
 
Figure 4.15. Reagents and conditions: d) N-Boc-ethylenediamine, HATU, DIEA, DMF; 
e) 30% TFA in DCM; f) DIEA, DMF; OG = Oregon Green, PB = Pacific Blue.  
 
 















































































































84, X,Y = S
85, X = CO, Y = NH
63, X,Y = S














chromene-3-carbonyl)-D-lysine (86, PB-D-Lys). 5 (175 mg, 0.72 mmol), HATU (300 
mg, 0.8 mmol) and DIEA (700 µL, 3.62 mmol) were stirred in anhydrous DMF (4 mL) at 
22 °C for 30 minutes. Separately, Fmoc-D-Lys-OH (400 mg, 0.85 mmol) was treated 
with trifluoroacetic acid (TFA) / CH2Cl2 (5 mL, 30:70) for 20 min. The mixture was 
concentrated under vacuum and washed with CH2Cl2 (5 mL) and ether (5 mL x 2) to 
remove excess TFA. Following deprotection, the amine was dissolved in DMF (2 mL) 
and added to the activated acid solution. The reaction was stirred at 22 °C for 16 h. The 
vessel was placed on high vacuum for 2 h to remove DMF followed by purification by 
column chromatography on silica gel (eluent: DCM:acetone:acetic acid (83:15:2) to 
afford 86 (400 mg, 94%) as a light yellow solid. 1H NMR (500 MHz, DMSO) δ 8.76 (d, J 
= 1.4 Hz, 1H), 8.61 (t, J = 5.8 Hz, 1H), 7.87 (dd, J = 7.6, 3.4 Hz, 2H), 7.76 – 7.69 (m, 
3H), 7.67 (d, J = 8.1 Hz, 1H), 7.40 (tdd, J = 7.5, 4.0, 1.1 Hz, 2H), 7.32 (qd, J = 7.4, 1.2 
Hz, 2H), 4.34 – 4.27 (m, 1H), 4.23 – 4.18 (m, 2H), 3.94 (ddd, J = 9.9, 8.0, 4.5 Hz, 1H), 
3.32 (qd, J = 6.9, 2.8 Hz, 2H), 1.84 – 1.30 (m, 6H). 13C NMR (126 MHz, DMSO) δ 
174.4, 161.4, 160.0, 156.6, 149.2 (dd, J = 240.6, 4.7 Hz), 147.5, 144.2 (d, J = 9.2 Hz), 
141.1 (d, J = 4.7 Hz), 140.9 (d, J = 8.4 Hz), 140.3 (d, J = 5.9 Hz), 139.2 (dd, J = 244.9, 
6.6 Hz), 128.1, 128.0, 125.8, 125.7, 120.54, 120.50, 116.9, 110.9 (dd, J = 20.9, 3.0 Hz), 
110.0 (d, J = 10.1 Hz), 66.1, 54.1, 47.1, 30.9, 29.0, 23.6; HRMS (ESI-) m/z 591.1556 









dithia-3,11,15,18,21-pentaazahexacosan-26-oic acid (84). Following general 
procedure 4B, 3-((((cholester-3-yl)oxy)carbonyl) amino)propanoic acid,43 PB-D-Lys (80), 
Fmoc-protected 3-((2-aminoethyl)disulfanyl)propanoic acid,8 Fmoc-βAla-OH, and Fmoc-
D-Glu-OH were used with 2-chlorotrityl resin (1.22 mmol/g) to produce a peptide. The 
crude peptide (30 mg, 0.02 mmol) and N-Boc-ethylenediamine (13 mg, 0.08 mmol) 













































2-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid, (63). Following 
general procedure 4C, OG-NHS (1 mg, 0.002 mmol) and 84 (4.5 mg, 0.003 mmol) 
yielded compound 63 (3 mg, 81%) as a yellow solid. LRMS (ESI-) m/z 1851.5 (M-H+ 
C91H111F4N10O23S2 requires 1851.7). 
 
Figure 4.16. Analytical HPLC profile of 63 after preparative HPLC. Retention time = 19 






























































3,7,11,15,18,21-hexaazahexacosan-26-oic acid (85). Following general procedure 4B, 
3-((((cholester-3-yl)oxy)carbonyl) amino)propanoic acid43, PB-D-Lys (86), Fmoc-β-ala-
OH, and Fmoc-D-Glu-OH were used with 2-chlorotrityl resin (1.22 mmol/g) to produce a 
peptide. The crude peptide (30 mg, 0.02 mmol) and N-Boc-ethylenediamine (13 mg, 
























































































difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (64). Following general 
procedure 4C, OG-NHS (1.5 mg, 0.003 mmol) and 85 (6 mg, 0.004 mmol) yielded 
compound 64 (3 mg, 53 %) as a yellow solid. LRMS (ESI-) m/z 1832.0 (M-H+, 
C92H112F4N11O24 requires 1830.8). 
 
 
Figure 4.17. Analytical HPLC profile of 64 after preparative HPLC. Retention time = 
18.5 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
 
















Figure 4.18. Reagents and conditions: g) 79, 30% TFA in DCM; h) HATU, DIEA, DMF; 
j) i. 30% TFA in DCM, ii. DIEA, DMF. Schematic shown for 66, but applies to 65–69 





chromene-3-carbonyl)-L-lysine (PB-L-Lys, 87). To a solution of Fmoc-L-Lys-OH (1.76 
g, 4.78 mmol) and DIEA (3.3 mL, 18.45 mmol) in DMF (20 mL) was added Pacific Blue 
NHS ester (15, 1.25 g, 3.69 mmol). The reaction mixture was stirred at 22 °C overnight. 
The reaction mixture was added dropwise to cold aq. HCl (1 N, 200 mL). The precipitate 
formed was filtered, washed with cold aq. HCl (1 N, 25 mL), and dried under vacuum to 
give 87 as a yellow solid (2.14 g, 98%). 1H NMR (500 MHz, DMSO-d6) δ 8.76 (d, J = 1.4 
Hz, 1H), 8.61 (t, J = 5.8 Hz, 1H), 7.86 (dd, J = 7.5, 3.4 Hz, 2H), 7.74-7.64 (m, 3H), 7.39 
















































































































(ddd, J = 10.0, 8.1, 4.5 Hz, 1H), 3.31 (qd, J = 6.9, 2.9 Hz, 2H), 1.89-1.24 (m, 6H). 13C 
NMR (126 MHz, DMSO-d6) δ 174.0, 161.0, 159.6, 156.2, 148.8 (d, J = 239.9 Hz), 147.1 
(d, J = 3.7 Hz), 143.8, 143.8, 140.7, 140.7, 140.5 (d, J = 8.5 Hz), 140.0 (dd, J = 5.1, 2.4 
Hz), 138.7 (dd, J = 245.3, 6.5 Hz), 127.6, 127.6, 127.1, 127.1, 127.1, 127.0, 125.3, 
125.3, 120.1, 120.1, 116.4, 110.5 (dd, J = 21.2, 2.4 Hz), 109.6 (d, J = 10.2 Hz), 65.6, 








hexaazaoctacosan-28-oate (65). Following general procedure 4D, PB-L-Lys (87), 
Fmoc-protected 3-((2-aminoethyl)disulfanyl)propanoic acid,8 and Fmoc-βAla-OH were 
used with 2-chlorotrityl resin (1.22 mmol/g, 0.025 mmol) to produce 65 (4 mg, 13%). 




































Figure 4.19. Analytical HPLC profile of 65 after preparative HPLC. Retention time = 






16,17-dithia-2,9,13,21-tetraazapentacosan-25-oic acid (66). Following general 
procedure 4D, PB-L-Lys (87), Fmoc-protected 3-((2-aminoethyl)disulfanyl)propanoic 
acid,8 Fmoc-βAla-OH, and Fmoc-L-Glu-OH were used with 2-chlorotrityl resin (1.22 
mmol/g, 0.025 mmol) to produce 66 (4 mg, 12%). LRMS (ESI-) m/z 1349.5 (M-H+, 
C61H61F4N8O19S2 requires 1349.3). 


















































Figure 4.20. Analytical HPLC profile of 66 after preparative HPLC. Retention time = 10 







hexaazaheptacosan-27-oate (67). Following general procedure 4D, PB-L-Lys (87), 
Fmoc-protected 3-((2-aminoethyl)disulfanyl)propanoic acid,8 Fmoc-Gly-OH, and Fmoc-
βAla-OH were used with 2-chlorotrityl resin (1.22 mmol/g, 0.025 mmol) to produce 67 (3 
mg, 10%). LRMS (ESI-) m/z 1263.6 (M-H+, C57H55F4N8O17S2 requires 1263.3). 















































Figure 4.21. Analytical HPLC profile of 67 after preparative HPLC. Retention time = 11 






dithia-2,5,8,16-tetraazahenicosan-21-oic acid (68). Following general procedure 4D, 
PB-L-Lys (87), Fmoc-protected 3-((2-aminoethyl)disulfanyl)propanoic acid,8 Fmoc-L-
Glu-OH, and Fmoc-βAla-OH were used with 2-chlorotrityl resin (1.22 mmol/g, 0.025 
mmol) to produce 68 (2 mg, 6%). LRMS (ESI-) m/z 1335.5 (M-H+, C60H59F4N8O19S2 
requires 1335.3). 

















































Figure 4.22. Analytical HPLC profile of 68 after preparative HPLC. Retention time = 







1,8,11,19-tetraoxo-15,16-dithia-2,9,12,20-tetraazatetracosan-24-oic acid (69). 
Following general procedure 4D, PB-L-Lys (87), Fmoc-protected 3-((2-
aminoethyl)disulfanyl)propanoic acid,8 and Fmoc-L-Glu-OH were used with 2-chlorotrityl 
resin (1.22 mmol/g, 0.025 mmol) to produce 69 (4 mg, 11%). LRMS (ESI-) m/z 1407.5 
(M-H+, C63H63F4N8O21S2 requires 1407.3). 


















































Figure 4.23. Analytical HPLC profile of 69 after preparative HPLC. Retention time = 10 
min monitored by UV absorbance at 254 nm. Purity >90% by HPLC. 
 
 
Figure 4.24. Reagents and conditions: k) OG-NHS ester, DIEA, DMF; l) 20% piperidine 






























































































75, X = Y = S
76, X = CO, Y = NH
89, X = Y = S
91, X = CO, Y = NH
88, X = Y = S
































pentaazahexacosan-7-yl)carbamate (88). Compound 88 was constructed using SPPS 
with 1,2-diaminoethane trityl resin (0.89 mmol/g, 0.05 mmol, 56 mg) with L-amino acids. 
The procedure for coupling as described in Section 2.10.3 (general procedure 2D) was 
followed. After completing all the steps of coupling reactions, the peptide was cleaved 
from the resin by treatment with a mixture of DCM/TFA (1:9) with shaking for 2 h. The 
resin was removed by filtration and washed with DCM (2 mL x 3). The filtrates were 
combined and concentrated under vacuum, followed by purification by preparative RP-
HPLC (Gradient: H2O:CH3CN (9:1) to (0:100) with added TFA (0.1%) over 20 min; 
elution time = 11 min). Pure fractions were collected, combined, and solvent was 
removed by lyophilization to yield 88 (6 mg, 13%). LRMS (ESI-) m/z 924.3 (M-H+ 




difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (89). To a solution of 
peptide 88 (5 mg, 0.0054 mmol) and DIEA (5 eq.) in DMF (0.5 mL), Oregon Green 






























mmol) was added. The reaction was stirred at 22 °C for 16 h. The vessel was placed on 
high vacuum for 2 h to remove DMF. The crude product was then treated with a solution 
of 20% piperidine in DMF (300 µL) for 20 min. The mixture was concentrated and 
purified by preparative RP-HPLC (Gradient: H2O:CH3CN (9:1) to (0:100) with added 
TFA (0.1%) over 20 min; elution time = 9–10 min). Pure fractions were collected, 
combined, and solvent was removed by lyophilization to yield 89 (5.6 mg, 94%). LRMS 





yl)carbamoyl)benzoic acid (75). Peptide 89 (3.2 mg, 0.003 mmol) and disuccinimidyl 
glutarate (10 mg, 0.03 mmol) were dissolved in DMF (0.75 mL) with DIEA (2.5 µL, 0.015 
mmol).  The reaction was stirred at 22 °C for 16 h. The vessel was placed on high 
vacuum for 1 h to remove DMF. The reaction was concentrated and purified by 
preparative RP-HPLC (Gradient: H2O:CH3CN (9:1) to (0:100) with added TFA (0.1%) 
over 20 min; elution time = 8.5 min). Pure fractions were collected, combined, and 
solvent was removed by lyophilization to yield 75 (3 mg, 78%). LRMS (ESI-) m/z 1307.4 




































Figure 4.25. Analytical HPLC profile of 75 after preparative HPLC. Retention time = 15 





yl)carbamate (90). Compound 90 was constructed using SPPS with 1,2-diaminoethane 
trityl resin (0.89 mmol/g, 0.05 mmol, 56 mg) with L-amino acids. The procedure for 
coupling as described in Section 2.10.3 (general procedure 2D) was followed. After 
completing all the steps of coupling reactions, the peptide was cleaved from the resin by 
treatment with a mixture of DCM/TFA (1:9) with shaking for 2 h. The resin was removed 
by filtration and washed with DCM (2 mL x 3). The filtrates were combined and 
concentrated under vacuum, followed by purification by preparative RP-HPLC 
(Gradient: H2O:CH3CN (9:1) to (0:100) with added TFA (0.1%) over 20 min; elution time 
= 10 min min). Pure fractions were collected, combined, and solvent was removed by 









































hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (91). To a solution of peptide 90 (4 mg, 
0.0044 mmol) and DIEA (5 eq.) in DMF (0.5 mL), Oregon Green Carboxylic Acid 
succinimidyl ester (Thermo Fisher O6149, OG-NHS, 2.3 mg, 0.0044 mmol) was added. 
The reaction was stirred at 22 °C for 16 h. The vessel was placed on high vacuum for 2 
h to remove DMF. The crude product was then treated with a solution of 20% piperidine 
in DMF (300 µL) for 20 min. The mixture was concentrated and purified by preparative 
RP-HPLC (Gradient: H2O:CH3CN (9:1) to (0:100) with added TFA (0.1%) over 20 min; 
elution time = 9 min). Pure fractions were collected, combined, and solvent was 
removed by lyophilization to yield 91 (4.5 mg, 95%). LRMS (ESI-) m/z 1065.5 (M-H+ 


































yl)carbamoyl)benzoic acid (76). Peptide 91 (2 mg, 0.0019 mmol) and disuccinimidyl 
glutarate (6 mg, 0.019 mmol) were dissolved in DMF (0.5 mL) with DIEA (2 µL, 0.009 
mmol).  The reaction was stirred at 22 °C for 16 h. The vessel was placed on high 
vacuum for 1 h to remove DMF. The reaction was concentrated and purified by 
preparative RP-HPLC (Gradient: H2O:CH3CN (9:1) to (0:100) with added TFA (0.1%) 
over 20 min; elution time = 8 min). Pure fractions were collected, combined, and solvent 
was removed by lyophilization to yield 76 (1.5 mg, 64%). LRMS (ESI-) m/z 1286.4 (M-
H+ C88H108F4N9O20S2 requires 1286.4). 
 
Figure 4.26. Analytical HPLC profile of 76 after preparative HPLC. Retention time = 
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 Development of Fluorescence-based Assays of Inhibitors of BfrB 
 
5.1. Introduction 
Pseudomonas aeruginosa is an opportunistic Gram-negative bacterium that 
infects both plants and animals. It is a leading cause of nosocomial infections, defined 
as those acquired under medical care, and accounts for 10% of all hospital-acquired 
infections.1 This bacterium adapts to its surroundings, including surfaces within 
hospitals and clinics, making it particularly dangerous in these settings.2 P. aeruginosa 
primarily affects patients with compromised immune systems, such as those with 
neutropenia, AIDS, severe burns, and cystic fibrosis.3 
Cystic fibrosis (CF) is congenital, inherited disease characterized by mutations in 
the gene encoding cystic fibrosis transmembrane conductance regulator (CFTR), a 
cAMP-regulated chloride channel.2 Approximately 80% of adult patients with cystic 
fibrosis are chronically infected with P. aeruginosa, and these lung infections are 
typically associated with morbidity.4, 5 Although recent advances have improved the 
treatment of lung infections in CF,4, 6 biofilms and drug resistance continue to hinder 
treatment strategies. Because P. aeruginosa is highly dependent on iron-dependent 
processes for infectivity and biofilm formation,7, 8 a better understanding of iron uptake 
in this bacterium could be critical for the discovery of new treatments.  
Iron is an essential cofactor in DNA synthesis, respiration, and nitrogen fixation, 
as it is able to participate in one-electron transfer reactions that catalyze enzymatic 
processes.9, 10 Proper regulation of iron homeostasis is critical in nature, since Fe2+ can 
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react with O2 and H2O2 to form insoluble Fe3+, reactive hydroxyl radicals, and 
superoxide via the Haber-Weiss reaction.11 To avoid the formation of these reactive 
oxygen species, cells tightly regulate iron acquisition and storage through the use of 
iron storage proteins and siderophores.12 Iron storage proteins, such as ferritins (Ftn), 
bacterioferritins (Bfr), and DNA binding proteins (Dps), store iron intracellularly and are 
particularly crucial for survival of bacteria under iron depletion conditions.  
Bacterioferritins are unique to bacteria and their major functions are to oxidize 
reactive Fe2+ to Fe3+, store the mineral, and release it when needed.13 Bfrs are 
assembled into a polymeric spherical structure consisting of 24 subunits with an outer 
diameter of 120 Å and an inner diameter of 80 Å. The hollow core can store up to 3500 
iron atoms.14, 15 Two subunits are paired to form a dimer with heme, and therefore 12 
heme molecules are present in each 24-mer protein.16 Bfrs contain a ferroxidase center 
that converts Fe2+ to Fe3+. This oxidation step is followed by translocation to the interior 
cavity, where it is mineralized for storage. Utilizing electrons originating from NADPH, 
the iron atoms are then reduced and released to the cytosol, a process facilitated by a 
ferrodoxin reductase and bacterioferritin-associated ferrodoxin (Bfd).17, 18 In P. 
aeruginosa (Pa), Pa-Bfd binds to Pa-BfrB (Kd = 3 µM) and facilitates iron mobilization by 
heme-mediated electron transfer.19 Rivera and coworkers found that this protein-protein 
interaction consists of a highly complementary interface with a network of hotspots 
defined by leucines, glutamic acids, and a tyrosine that are conserved across a number 




5.2. A new strategy to overcome multidrug resistance in P. aeruginosa 
  P. aeruginosa is considered a ‘superbug’ due to its high propensity to acquire 
multidrug resistance.  The low permeability of its outer membrane, as well as secondary 
adaptive resistance mechanisms such as increased efflux and enzymatic antibiotic 
modifications, enable it to be resistant to a wide range of antibiotics from β-lactams to 
fluoroquinolones.21 Drug resistance is increasing,1 and therefore new strategies must be 
developed to fight this bacterium. As described in Section 5.1, iron is an essential 
nutrient, but can be toxic if improperly regulated. This vulnerability could possibly be 
exploited through inhibition of the bacterial BfrB:Bfd interaction. Since BfrB is unique to 
bacteria and archaea,22 disruption of this protein-protein interaction could present a 
novel, specific way to treat patients infected with P. aeruginosa. 
 To investigate this antibacterial approach, Dr. Huili Yao and Dr. Mario Rivera at 
the University of Kansas Dept. of Chemistry conducted an iterative fragment based drug 
discovery (FBDD) screen. In FBDD, a relatively small library of low molecular weight 
compounds that are generally polar and soluble is often screened by NMR against a 
protein target. When possible, this method provides an attractive alternative to more 
traditional high-throughput screening of large libraries of drug-like molecules. The 
fragments used in FBDD typically bind proteins with low affinity (mM) and are later 
combined with other fragments to generate leads for a drug discovery campaign.23 For 
the initial screen against BfrB, the Rivera group used saturation transfer difference 
nuclear magnetic resonance spectroscopy (STD-NMR). STD-NMR is an attractive 
method for FDBB because it focuses on the signal of the ligand, so processing of 
additional NMR information of the receptor is unnecessary.24 A fragment training set 
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was screened to find molecules (hits) that bound at the BfrB:Bfd binding site. These hits 
were then tested for binding to BfrB by two orthogonal assays, SPR and X-ray 
crystallography. By SPR, FC996 (Figure 5.1) was found to bind BfrB with a Kd of 1.3 
mM, and a high-resolution X-ray co-crystal structure further confirmed that this small 
molecule bound BfrB occurred in a cleft where Bfd normally associates. 
 
 
Figure 5.1. Structure of FC996 (4-hydroxyphthalimide), the initial hit found by the Rivera 
group via a FBDD screen. The phthalimide ring is numbered to clarify the differential 
substitution patterns of analogues that were later investigated.  
 
  
After the initial hit was identified, more than 100 second generation compounds 
were designed to take advantage of additional interactions at the Bfd:BfrB binding 
interface. Docking to BfrB using Autodock vina25 were performed on each of the 
derivatives, and those that showed promising docking scores were synthesized and 
investigated for binding and inhibition of iron release. Initial binding studies were 
performed using SPR, but this format was limited by solubility, as a high concentration 
of DMSO needed to solubilize these compounds altered the results of the assay and 
complicated the interpretation of the results.  
 This chapter will describe a new assay that we developed that uses fluorescence 
polarization to quantify the binding affinities of the derivatives of FC996 to BfrB. I will 












that hindered the development of the assay. I will additionally describe the degradation 
of a lead compound that led to the discovery of new interactions in the binding pocket, 
and discuss potential future directions for this project.  
 
5.3. Toward a new fluorescence polarization assay for BfrB:Bfd inhibitors 
 Docking and X-ray crystallography studies of BfrB revealed that substitution of 
potentially inhibitory phthalimides at the 3-position could be more favorable than 
substitution at the 4-position, as is observed in FC996. Based on these studies, 
compound 92 (Figure 5.2, panel A) was designed and synthesized as a lead compound 
capable of dose-dependent inhibition of iron release in a functional assay performed in 
the Rivera group. To examine the photophysical properties of 92, we obtained excitation 
and fluorescence emission spectra of 92 (Figure 5.2, panel B). This compound has an 
excitation λmax at ~400 nm, and an emission λmax at 530 nm. Although a high 
concentration of this ligand was needed due to low brightness, compound 92 showed a 
3-fold increase in fluorescence polarization when glycerol was added to buffer, 
indicating that as the mobility of the compound was restricted (due to the increase in 




Figure 5.2. A: Structure of inhibitor 92, a second generation derivative of FC996. B: The 
excitation spectrum (λem = 530 nm, solid line) and emission spectrum (λex = 380 nm 
dotted line) of 92 (10 µM) in KPi (100 mM, pH 7.6), containing TCEP (1 mM) are shown. 
 
 Spectroscopic studies revealed that the 12-heme molecules of the holo-BfrB 
protein fluoresce, and this intrinsic fluorescence was found to interfere with the signal 
from the fluorescent ligand. To overcome this complication, we used Apo-BfrB for 
fluorescence polarization assays. To confirm that studies using Apo-BfrB were valid, Dr. 
Huili Yao and Dr. Mario Rivera measured the binding affinity of Bfd to Apo-BfrB and 
holo-BfrB and found identical Kd values of 3 µM. Since the BfrB-Bfd interface is at the 
surface of the protein, the absence of heme, which is buried within the 24-mer protein, 
should not have a large effect on these binding interactions. To investigate the affinity of 
92 binding to BfrB, Apo-BfrB was titrated into a fixed concentration of the fluorescent 
ligand for 1 h, followed by excitation at 380 nm and analysis of fluorescence polarization 
at λem = 565 nm.  Curve fitting was initially used to calculate a direct binding Kd value of 
~ 50 µM, but this number was found to fluctuate unpredictably under these conditions. 
To investigate these fluctuations, we monitored the fluorescence of 92 over time and 
discovered large changes in its spectral properties in buffer (Figure 5.3, panels A and B). 
The λmax for absorption shifted from 415 nm to 380 nm after 90 min in buffer, and the 
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fluorescence intensity of the compound increased significantly over time. To explain 
these results, we proposed that 92 degrades to 3-aminophthalimide in buffer over time 
(Figure 5.3, panel C), and this hypothesis was confirmed by subsequent NMR 
spectroscopy studies. However, since the docking results with this compound were 
promising, and we desired to determine the binding affinity of BfrB for 92, we minimized 
the incubation time to maintain 92 in buffer for only a total of 10 minutes, which 
decreased the effects of degradation. Under these conditions, ApoBfrb was titrated into 
a fixed concentration of 92 for 5 min, followed by excitation at 380 nm, and changes in 
polarization at λem = 565 nm were detected.  This modified approach allowed calculation 






Figure 5.3. Spectral evidence of degradation of compound 92 in KPi buffer (100 mM). 
Absorbance (panel A) and emission (panel B) spectra of 92 over a 90-minute period. As 
92 is incubated in buffer, it degrades to form 3-aminophthalmide (panel C). The 
absorbance is slightly decreased and blue-shifted, while the emission is significantly 
increased. D: Quantification of the affinity (Kd) of Apo-BfrB for probe 92 (5 µM) in KPi 
(100 mM, pH 7.6) containing TCEP (1 mM) by FP. The probe was briefly incubated in 
buffer for 5 min and with protein for 5 min to minimize degradation. Values were 
corrected to account for fluorescence enhancement upon binding. [Apo-BfrB] was 
based on a dimer (two subunits). Dissociation constants (Kd) were calculated using a 




Figure 5.4. X-ray crystal structure of Pa-BfrB20 (PDB 3IS7) with models of 3-
aminophthalimide bound in two different poses generated with Autodock vina.  
 
Stability testing of other derivatives revealed that the phenol at the 4 position of 
the southern ring (Figure 5.3, panel C, atom highlighted in red) was destabilizing the 
linkage between the two ring systems. Additionally, docking studies showed that in 
some poses 3-aminophthalimide was rotated by 180° and could interact with a different 
set of amino acids at the BfrB:Bfd binding interface (Figure 5.4). This could explain the 
large differences in affinity between 3-aminophthalimide (~50 µM, measured by FP, 
data not shown) and FC996 (1.3 mM, measured by SPR by Rivera group) for BfrB. 
From these two observations, compound 93 was designed to remove the 4-phenol on 
the southern ring and incorporate an amine at the 6-position of the phthalimide. To 
generate an equilibrium binding curve, Apo-Bfrb was titrated into a fixed concentration 
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of this fluorescent ligand for 1 h, followed by excitation at 405 nm and detection of 
changes in polarization at λem = 530 nm.  Curve fitting was used to calculate a direct 
binding Kd value 4 ± 1 µM (Figure 5.5), indicating that any activity that was lost from 
removal of the 4-phenol on the southern ring was regained through additional 
interactions of the 6-amino group on the phthalimide ring system.  
  
Figure 5.5. A: Structure of the third generation inhibitor 93. B: Quantification of the 
affinity (Kd) of Apo-BfrB for probe 93 (1 µM) in 100 mM KPi (pH 7.6) with TCEP (1 mM) 
by FP. Values were corrected to account for fluorescence enhancement upon binding. 
[ApoBfrB] was based on monomeric protein. Dissociation constants (Kd) were 
calculated using a one-site binding model in GraphPad Prism. 
 
5.4. Conclusions and future directions 
 The laboratory of Prof. Mario Rivera designed inhibitors of the BfrB:Bfd protein-
protein interaction based on a hit that they found through a FBDD screen using STD-
NMR. To test the affinity of these compounds, we collaborated with the Rivera 
laboratory to develop a new fluorescence polarization assay. One promising compound, 
92, was found to bind 1,000-fold more tightly than the original hit, but suffered from 
instability. It was determined that the product of degradation was 3-aminophthalimide, 
which binds more tightly to ApoBfrB than other phthalimides studied. Docking studies 
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with 3-aminophthalimide revealed there could be two binding modes for this compound. 
Based on this information, a new compound, 93, was developed to take advantage of 
both binding modes, and proved to be comparable in affinity to the unstable lead 
compound 92.  
 Future studies of more highly fluorescent analogues are needed to improve the 
utility of this assay for drug screening applications. High concentrations of the 
fluorescent ligand are required to detect the low fluorescence of 93, and these high 
concentrations approach the Kd values of some of the highest affinity compounds 
identified to date, making this assay unsuitable for quantification of new inhibitors that 
might have affinities of less than one micromolar. If the fluorophore was substantially 
brighter, the concentration of the probe could be substantially decreased and 
competition assays could be used to discover more potent ligands. The BfrB:Bfd 
protein-protein interaction offers a promising target for antimicrobial inhibition of 
Pseudomonas aeruginosa and could help to overcome challenges arising from 
multidrug resistance observed with this superbug. Better inhibitors, as well as assays to 
screen these inhibitors more readily, need to be developed for this goal to be realized.  
 
5.5. Experimental 
Apo-BfrB was expressed and purified as described previously.15, 19 Absorbance spectra 
and measurements of molar extinction coefficients (ε) were generated using semimicro 
(1.4 mL) UV quartz cuvettes (Sigma-Aldrich, Z27667-7) on an Agilent 8452A diode 
array spectrometer. All optical spectroscopy and protein binding assays were conducted 
in 100 mM KPi (pH 7.6) with TCEP (1 mM) unless otherwise noted. All fluorescence 
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spectra were acquired using a SUPRASIL ultra-micro quartz cuvette (PerkinElmer, 
B0631079) on a Perkin-Elmer LS55 Fluorescence Spectrometer (10 nm excitation slit 
width).   
 
Determination of Kd values of 92 by fluorescence polarization (FP) 
Different concentrations of Apo-BfrB, chosen to span a range of at least 20% to 80% 
complexation, were incubated with fixed concentrations of 92 (5 µM) in 100 mM KPi (pH 
7.6) with TCEP (1 mM) at room temperature with shaking for 5 min. The probe was in 
buffer for a maximum of 5 minutes prior to incubation with protein to minimize 
degradation. These fixed probe concentrations were chosen to be below the predicted 
Kd values to assure equilibrium binding measurements. Measurements of fluorescence 
intensity and fluorescence polarization (I380 and P, λex= 380 λem= 565 nm) were recorded 
for each sample.  The change in polarization for each sample was calculated by 
subtracting the average (n=3) polarization of the free ligand (Pf). This change was 
plotted against the concentration of SA, and the maximum polarization of the fully bound 
complex was estimated (Bmax) based on a one-site specific binding model (GraphPad 
Prism 6.0). This polarization of the complex (Pb) was used in the following equation to 





Background-subtracted fluorescence (I) signals were calculated as follows:  
! =  !!"# − !!"#$ 
where IBfrB is the background fluorescence intensity of the protein alone at each 
concentration measured, excited under the same conditions as the protein with 92.  In 
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order to correct for fluorescence enhancement or quenching, a fluorescence 
enhancement factor (Q) was calculated using the following equation, where I and I0 are 
the fluorescence intensity (λex= 380 nm, λem= 565 nm) of the sample and free ligand, 
respectively: 
! =  ! − !!!!
 
To incorporate fluorescence enhancement/quenching into the measurements, the 





To calculate the dissociation constant (Kd), the corrected fraction bound was plotted 
against the concentration of Apo-BfrB (dimer concentration), and a one site- specific 
binding equation of GraphPad Prism 6.0 was used for curve fitting. Note: for compound 
93, the same procedure was followed, but the concentration of the ligand was 
decreased to 1 µM, and excitation and emission wavelengths were as follows: λex= 405 
and λem= 530 nm. 
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Figure 6.1. 1H NMR (500 MHz, DMSO-d6) spectrum of 5. 	
 



























































Figure 6.5. 13C NMR (126 MHz, DMSO-d6) spectrum of 11.  
 
 

















Figure 6.7. 1H NMR (500 MHz, DMSO-d6) spectrum of 15. 
 
	




























Figure 6.9. 19F NMR (376 MHz, DMSO-d6, decoupled) spectrum of 15. 
 
 

























Figure 6.11. 13C NMR (126 MHz, CDCl3) spectrum of 17.  
	
	






















Figure 6.13. 1H NMR (500 MHz, CDCl3) spectrum of 18.
	



































































Figure 6.17. 13C NMR (126 MHz, CDCl3) spectrum of 19. 
	
 

















Figure 6.19. 1H NMR (500 MHz, DMSO-d6) spectrum of 20. 	
 

































































Figure 6.21. 1H NMR (500 MHz, DMSO-d6) spectrum of 21. 	
 


















































































































































Figure 6.25. 1H NMR (500 MHz, DMSO-d6) spectrum of 23.  
 










































































Figure 6.27. 1H NMR (500 MHz, DMSO-d6) spectrum of 24.  
 





































































Figure 6.29. 1H NMR (500 MHz, DMSO-d6) spectrum of 25.  
 
 






































































Figure 6.31. 1H NMR (500 MHz, DMSO-d6) spectrum of 26.  
 



























































Figure 6.33. 1H NMR (500 MHz, CD3OD) spectrum of 28.  
 





























Figure 6.35. 1H NMR (500 MHz, CDCl3) spectrum of 29.  
 




































Figure 6.37. 1H NMR (500 MHz, CDCl3) spectrum of 30.  
 






































Figure 6.39. 1H NMR (500 MHz, DMSO-d6) spectrum of 34.  
 


























































Figure 6.41. 1H NMR (500 MHz, DMSO-d6) spectrum of 35. 
 







































Figure 6.43. 1H NMR (500 MHz, DMSO-d6) spectrum of 36. 
 
 














































Figure 6.45. 1H NMR (500 MHz, DMSO-d6) spectrum of 37.  
 













































Figure 6.47. 1H NMR (500 MHz, CDCl3) spectrum of 38.  
 








































Figure 6.49. 1H NMR (500 MHz, CDCl3) spectrum of 39.  
 









































Figure 6.51. 1H NMR (500 MHz, DMSO-d6) spectrum of 40.  
 
 











































Figure 6.53. 1H NMR (500 MHz, CDCl3) spectrum of 43. 
 
 











































































































Figure 6.55. 1H NMR (500 MHz, CDCl3) spectrum of 44.  
 
 














































































































Figure 6.57. 1H NMR (500 MHz, CDCl3) spectrum of 45.  
 

















































































































Figure 6.59. 1H NMR (500 MHz, CDCl3) spectrum of 46. 
 
 






























































































Figure 6.61. 1H NMR (500 MHz, CDCl3) spectrum of 47. 
 
 





















































































































Figure 6.63. 1H NMR (500 MHz, CDCl3) spectrum of 48. 
 
 















































































































Figure 6.65. 1H NMR (500 MHz, CDCl3) spectrum of 49.  
 
 














































































































































































































































Figure 6.69. 1H NMR (500 MHz, MeOD) spectrum of 59.  
 





































































Figure 6.71. 1H NMR (500 MHz, MeOD) spectrum of 60.  
 


































































Figure 6.73. 1H NMR (500 MHz, DMSO-d6) spectrum of 79.  
 
 
















































Figure 6.75. 1H NMR (500 MHz, DMSO-d6) spectrum of 80.  
 




































































Figure 6.77. 1H NMR (500 MHz, DMSO-d6) spectrum of 81.  
 


























































Figure 6.79. 1H NMR (500 MHz, DMSO-d6) spectrum of 82.  
 





































































Figure 6.81. 1H NMR (500 MHz, DMSO-d6) spectrum of 83.  
 





























































Figure 6.83. 1H NMR (500 MHz, DMSO-d6) spectrum of 86.  
 

























































Figure 6.85. 1H NMR (500 MHz, DMSO-d6) spectrum of 87.  
 



















































List of cell lines used in this research 
Cell 
Line 







































List of plasmids 








SA-mRFP CMV Mammalian S Athavankar 
(Peterson 
group) 
pHaMDR-EGFP MDR1-EGFP n/a Mammalian M. Gottesman 
(NCI) 
	
 
	
